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Human Protein Disulphide Isomerase (hPDI) is an important protein folding catalyst involved 
in the reduction, oxidation and isomerisation of disulphide bonds, a major rate-limiting step in 
the formation of many proteins. hPDI also exhibits molecular chaperone activity, selectively 
binding small, unfolded peptides and a large range of mis-folded protein intermediates. hPDI is 
the founding member of a family of 21 structurally related proteins, and consists of domain 
subunits a and D¶ (which are catalytically active) and b and E¶ (which are not). b domain is 
thought to confer structural stability to the protein, and E¶ contains the primary ligand binding 
site. There is also an x-linker region, and a C-terminal acidic tail c, in the complete domain 
structure DEE¶[D¶F.  
Despite a recently solved crystal structure of hPDI DEE¶[D¶ (4EKZ.pdb) and over 50 years of 
research, we still have limited knowledge of how hPDI works, and more specifically how it 
interacts with ligands. Obtaining more detailed information is of significant importance; not 
only is hPDI associated with several human disease states, but it shows great potential as a 
therapeutic treatment, and is also used industrially to improve recombinant protein yields in 
mammalian and bacterial cell expression systems. Nonetheless, physiological ligand specificity 
of hPDI is still poorly understood.  
This study focuses on characterising the ligand binding ability and specificity of hPDI using a 
model binding peptide, ǻ-somatostatin ǻ-som), and two recombinantly expressed fragments 
of hPDI: E¶[, the smallest monomeric fragment of hPDI capable of ligand binding, and DEE¶[, 
a larger fragment previously uncharacterised by NMR. Backbone and side-chain resonance 
assignments were carried out, and allowed hPDI binding affinity to be quantified using both 
protein-observed and ligand-observed NMR methods. Peptide affinity was in agreement with 
the previously estimated 0.1-1 mM affinity, and was found to be independent of neighbouring 
domains and protein redox state. Fluorination of the peptide at key aromatic residues and 
subsequent Ala substitutions showed that the three Phe residues of the peptide all contributed 
in some part to hPDI binding, with substitution of the C-terminal Phe having the largest 
negative effect. Substitution of the three Phe residues to Ala abolished binding to hPDI, 
suggesting that unlike the family member PDIp (pancreas-specific Protein Disulphide 
Isomerase), hPDI ligand specificity may be mediated by Phe residues. 
Investigation of DEE¶[ redox potential by NMR supported recently published values of full-
length protein as determined by mass spectrometry, but also highlighted how the redox state of 
a domain becomes progressively more reducing upon addition of subsequent domains to the 
protein, further confirming cross-talk among the four domains of hPDI.   
Recombinant fluoroindole incorporation into DEE¶[ showed the incorporation rate was not as 
extensive as previously reported for E¶[fragment. Preliminary work showed the fluorine probe 
did not significantly alter ligand binding affinity, but in contrast reported a markedly more 
reducing redox potential, suggesting care must be taken to consider the potential impact 














1.1 Protein Folding in the ER   
The endoplasmic reticulum (ER) is a cellular compartment present in all eukaryotes, where 
a large number of membrane and secretory proteins obtain their correct three-dimensional 
structure by post-translational modification (Sitia and Braakman, 2003). One of these 
modifications is the formation of disulphide bonds, which are made by the oxidation of 
two side chain cysteine thiols to form a covalent sulphur-sulphur bond.  
The ER is a naturally oxidising environment that promotes the formation of disulphides. 
These bonds can help stabilise the native tertiary structure of a protein, and it is estimated 
that 16% of all human proteins contain disulphide bonds (Wang et al., 2014). Many 
proteins contain several cysteine residues that need to form the correct intramolecular 
disulphide bond pairs before the protein can reach its native or active state. Often, 
molecular chaperones and protein folding catalysts play a role in aiding protein folding by 
increasing the speed at which a protein folds into its correct native state, so that the event 
happens on a feasible time scale for secretion.  
Molecular chaperones are a class of proteins present in most cellular compartments of the 
eukaryotic cell, and as such are ranked as some of the most abundant cellular proteins 





Defining roles common for all molecular chaperones are as follows:-  
- The chaperone will exhibit little substrate specificity 
- It will recognise some common elements present in unfolded substrates (e.g. an 
exposed hydrophobic surface) 
- The chaperone will only bind to a mis-folded substrate (and not native protein).  
The most abundant ER chaperone is binding immunoglobulin protein (BiP), which uses 
energy generated from the hydrolysis of ATP to prevent aggregation of proteins in the ER 
(Hendershot et al., 1988). This thesis is involved in the study of human Protein Disulphide 
Isomerase (hPDI), another highly abundant ER resident protein and a multifunctional 
enzyme that possesses the ability to act as both a protein folding catalyst and molecular 
chaperone. Protein folding catalysts are enzymes that work in a similar manner to 
molecular chaperones, but are able to catalyse specific reactions. In the case of hPDI this is 
the reduction, oxidation and isomerisation of disulphide bonds, a crucial step in the correct 
folding of many proteins.  
Despite a large suite of ER resident protein folding catalysts and molecular chaperones, it 
is still quite common for unfolded proteins to build up in the ER. These newly synthesised 
(unfolded) or mis-folded proteins are prone to aggregation, owing to their exposed 
hydrophobic regions and high concentrations. The role of a molecular chaperone is to aid 
in the prevention of this aggregation. If the ER lumen comes under oxidative stress due to 
an accumulation of mis-folded protein, the unfolded protein response (UPR) is activated to 
try and counteract the cellular stress (Walter and Ron, 2011). The UPR attempts to restore 
normal cellular activity by:- 
- Targeting unfolded or mis-folded proteins for proteasomal degradation 
- Up-regulating signalling pathways that lead to increased expression of foldases and 
molecular chaperones 
- Reducing cellular translation rates 
Prolonged activation of the UPR will ultimately lead to apoptosis of the cell, and chronic 
activation of the UPR is implicated in many different disease states including metabolic 
diseases (atherosclerosis, obesity, insulin resistance, fatty liver), renal disease, cancer and 





1.2 An Overview of hPDI  
Protein Disulphide Isomerase (PDI) was the first protein folding catalyst to be discovered 
some 50 years ago, isolated and characterised by two groups independently whilst they 
ZHUHERWKSHUIRUPLQJVWXGLHVRQ51DVH&KULVWLDQ$QILQVHQ¶VJURXSSXULILHG WKHHQ]\PH
from microsomes of rat liver homogenate samples (Goldberger et al., 1963), and Brun 
6WUDXE¶VJURXSFROOHFWHGH[WUDFWVFRQWDLQLQJ3',SURWHLQIURPSLJHRQDQGFKLFNHQpancreas 
(Venetianer and Straub, 1963).  
The protein was located primarily within the ER of cells, where it was found to play a 
crucial role: PDI is capable of facilitating the formation of correctly folded and functional 
proteins for secretion out of the cell, by acting as a catalyst for the oxidation, reduction and 
isomerisation of native disulphide bonds, a rate limiting step in the formation of many 
proteins. PDI also exhibits molecular chaperone activity, selectively binding small, 
unfolded peptides and a large range of mis-folded protein intermediates (Hatahet and 
Ruddock, 2007). As the first and founding member, PDI now lends its name to a family of 
over 20 structurally related proteins.  
Human PDI (hPDI) is a 491 amino acid, 57 kDa multi-domain protein found within the 
lumen of the ER at concentrations estimated to be ~0.8% of total cell protein, making it the 
most abundant member of its family (Freedman et al., 1994). In addition to its roles as an 
R[LGRUHGXFWDVH DQG FKDSHURQH K3', IRUPV WKH ȕ VXEXQLW RI SURO\O-4-hydroxylase, an 
enzyme involved in the synthesis of collagens (Pihlajaniemi, Helaakoski et al. 1987), and 
is also a subunit of microsomal triglyceride transfer protein, an enzyme involved in the 
assembly of lipoproteins (Wetterau et al., 1990). hPDI also binds and stabilises the major 
histocompatibility complex class I peptide loading complex (Lee et al., 2009). In addition 
to the ER, hPDI is also found at the cell surface, where it is thought to have a mediatory 
role of the adhesion, secretion and aggregation of platelets (Essex and Li, 1999), and 
facilitates fusion of the HIV virus with the cell membrane (Barbouche et al., 2003). 
In humans, PDI is up-regulated in several disease states that occur due to protein 
aggregation or incorrect folding, most notably the neurodegenerative diseasHV$O]KHLPHU¶V
3DUNLQVRQ¶V +XQWLQJWRQ¶V and Motor Neurone Disease, where the accumulation of non-
functional or incorrectly folded proteins leads to a loss of normal brain function (Andreu et 





progression of several types of cancer (Xu et al., 2014), and that other members of the PDI 
family play a direct role in the resistance of certain cancers to chemotherapeutics (Tufo et 
al., 2014). 
1.2.1 hPDI Structure 
PDI is the archetypal member of a family of 21 structurally related proteins that are part of 
the thioredoxin superfamily, as they all contain at least one thioredoxin-like domain. 
Thioredoxins are a class of redox proteins present in all organisms, that contain a 
distinctive architectural fold named after the reductase Thioredoxin A (Martin, 1995). The 
fold in hPDI is characterised E\  FHQWUDO ȕ-VKHHW VWUDQGV IODQNHG E\  Į-helices, in a 
ȕĮȕĮȕĮȕȕĮ formation (see Figure 1.1) (Kemmink et al., 1997).  
PDI family members are thought to have all originally derived from a two thioredoxin-
like-domain ancestor that has since evolved into the current family members by means of 
multiple gene duplication or deletion events. This theory is supported by homology of the 
ligand binding site of one domain of hPDI to the two catalytically active redox sites of 




Figure 1.1: Crystal structure of oxidised thioredoxin (1ERU.pdb) Alpha helices are shown in blue, and 
beta sheets in red. The two active site cysteines are shown as ball and stick figures and the sulphur atoms are 






Full length hPDI consists of four thioredoxin-like domains, defined by Alanen et al. in 
2003 (Alanen et al., 2003) 7KH WZR µD¶ GRPDLQV a and D¶, are catalytically active and 
contain a conserved CXXC active site motif, wKLOVWWKHWZRµE¶domains, b and E¶, are non-
catalytic, and therefore lack the conserved cysteine residues. There is also a short 19 amino 
acid x-linker region between the E¶ and D¶ domains, and a C-terminal acidic tail region c, 




Figure 1.2: Domain architecture of hPDI (a) and amino acid sequence of hPDI (b). The domains are 
coloured purple (a), yellow (b), orange (E¶) and red (D¶). The x-linker is coloured blue, the c-terminal tail is 







The catalytic a and D¶ GRPDLQV DUH UHVSRQVLEOH IRU K3',¶V DFWLRQ DV DQ R[LGDVH RU
reductase, whilst the E¶ domain is reported to be the primary substrate binding site for 
peptide ligands and mis-folded proteins (Klappa et al., 1998). Whilst isolated catalytic 
domains of hPDI can work as red/ox catalysts, the binding site of the E¶ domain is essential 
for the protein to carry out isomerase activity, with the minimum isomerase fragment 
identified as E¶[D¶(Wang et al., 2012). The b domain has additional hydrophobic patches 
that increase the size of the substrate binding cleft, and is thought to play a structural role 
DVDSK\VLFDOµVSDFHU¶EHWZHHQWKHWZRFDWDO\WLFGRPDLQV(Kozlov et al., 2010). In addition, 
the b domain is also thought to help aid in protein solubility, on account of its overall 
hydrophilic nature (Kober et al., 2013).  
Whilst individual domain structures of hPDI have been solved over the last 20 years by a 
combination of x-ray crystallography and NMR spectroscopy, it was only during the 
period of this thesis that the first crystal structures of near full-length reduced and oxidised 
hPDI DEE¶[D¶ were published by the Wang group (see Figure 1.3), with the same group 
also publishing a crystal structure of the EE¶[D¶ hPDI fragment the year prior (Wang et al., 
2012), (Wang et al., 2013). 
Whilst these structures lack the c-terminal tail extension of hPDI (a region high in acidic 
residues that encodes WKH SURWHLQ¶V KDEL ER-retention motif), other functional 
significances of the tail have not been reported, and its removal helped crystallisation of 
the protein (Wang et al., 2012). NMR spectra of full length hPDI protein also benefit from 
removal of the c-terminal tail, which appears to be unstructured and adds significantly to 
the hydrodynamic volume of the protein in solution (unpublished observations). 
In the oxidised state of hPDI, the four domains all appear within the same plane, where as 
in the reduced structure the D¶ domain rotates out of plane ~45϶, around the x-linker and 
away from the substrate binding site of E¶ domain. The distance between active sites 
increases from 27.6 in the reduced state to 40.3 in the oxidised state, with the cleft 
between the domains doubling in size (see Figure 1.3) (Wang et al., 2013). Thus, 
chaperone activity of hPDI is controlled in a redox-dependent manner: as hPDI becomes 
oxidised, it adopts a more open conformation and is able to accommodate larger substrates 










Figure 1.3: Crystal structures of (A) reduced (4EKZ.pdb) and (B) oxidised (4EL1.pdb) K3',DEE¶[D¶
as published by Wang et al. (2013). The domains are coloured purple (a), yellow (b), orange (E¶) and red 
(D¶). The x-linker is coloured blue and the redox active cysteines are shown in green. The distances between 





Both reduced and oxidised structures of hPDI DEE¶[D¶ show the four domains to be 
arranged in a horseshoe shape, where the EE¶ fragment forms the base and the catalytic 
domains form the two ends, a similar conformation as observed for yeast PDI (yPDI). 
Figure 1.4 shows an overlay of hPDI and yPDI structures for comparison.  
 
 
Figure 1.4: Overlaid crystal structures of yPDI (2B5E.pdb) and hPDI DEE¶[D¶ (.=SGE The 
domains of hPDI are coloured as Figures 1.2 and 1.3, with yPDI coloured cyan. Note that the c region in the 
yPDI structure forms a helical conformation- this region is absent from the hPDI structure, but is thought to 
be unstructured. 
 
Historically, crystallization of hPDI protein had been hindered by the proteins intrinsic 
inter-domain flexibility (Hatahet and Ruddock, 2009). Until the Wang group published 
DEE¶[D¶ structures, the two structures of yPDI were routinely used to model hPDI, despite 
hPDI and yPDI only sharing 31% sequence identity (Wang et al., 2015). In yPDI, the EE¶ 
base is fairly rigid, with the catalytic a domains being much more flexible. 
Superimposition of the hPDI structures onto yPDI show a domain rotation of ~20¡ of E¶
relative to b domain, suggesting that EE¶ is more flexible than yPDI, behaving more like 
the hPDI family member ERp27 (composing a EE¶ structure) (Amin et al., 2013). In 





al., 2008), it is the D¶ domain of hPDI that is more flexible. This is thought to be due to the 
plasticity of the x-linker region between the E¶ and D¶ domains (Wang et al., 2010). 
More recently, the oxidised and reduced hPDI crystal structures have been used to simulate 
how the protein may behave in solution. It is imagined that the crystal structures of hPDI 
were more indicative of ligand bound structures than that of free protein, as both the 
oxidised and reduced resolved structures show the E¶ substrate binding site partly occupied 
by another hPDI molecule (Wang et al., 2013). Molecular dynamic simulations showed the 
protein adopts a much more compact structure, stabilised by additional salt bridges 
between a and b domains, a and E¶ (which was an unexpected observation as the a and E¶ 
domains are ~45 away from each other in the crystal structures) and E¶ and the x-linker. 
Many of these interactions were confirmed in vitro by site-directed mutagenesis studies 
(Yang et al., 2014). 
  1.2.2 Ligand Binding  
In 1998 the E¶ domain of hPDI was identified as the domain responsible for primary 
binding of ligand peptides and non-native proteins (Klappa et al., 1998; Pirneskoski et al., 
2004). A crystal structure of (I272A) E¶[was published by Nguyen et al. in 2008 (Nguyen 
et al., 2008), and the substrate binding site was subsequently mapped using NMR 
spectroscopy (Byrne et al., 2009).  
Unlike the catalytic domains, E¶ has no specific conserved binding motif. The E¶domain 
does contain two cysteine residues, but they are hidden deep within the protein, too far 
apart for a disulphide bond to form and inaccessible to thiol-modification reagents such as 
iodoacetamide (unpublished observation). Instead, the domain contains a large multivalent 
hydrophobic binding pocket that binds ligands primarily via hydrophobic interactions 
(Byrne et al., 2009; Denisov et al., 2009). The site was found to consist mainly of residues 
IURP WKH FRUH ȕ-VKHHW DQG Į-helices 1 and 3 (see Figure 1.5), including residues 228Ala, 








Figure 1.5: Crystal structure of the hPDI ligand binding domain E¶[ I272A mutant (3BJ5.pdb). I272A 
E¶[ LVD µFDSSLQJ¶PXWDQW ZKHUH WKH x-linker (in blue) caps the hydrophobic ligand binding site of the E¶ 
domain (in cyan). Residues mapped by Byrne et al. (2009) as composing the ligand binding site are coloured 
red. 
As an individual domain, E¶ is able to bind a range of different peptides, including 
somatostatin and mastoparan. This binding is driven by reversible hydrophobic 
interactions, and was shown to be independent of the presence of disulphide bonds or 
cysteine residues (Klappa et al., 1997).  Hence, the historic gold-standard peptide used to 
study hPDI ligand binding is ¨-VRPDWRVWDWLQ ¨-som), a double Cys-to-Ser form of the 
peptide hormone somatostatin (AG(CїS)KNFFWKTFTS(CїS), which lacks the WT 
3Cys-14Cys disulphide bond. This 14-mer is employed extensively within this thesis to 
study the ligand binding specificity of hPDI.  
In 2000, work was published that identified mutations made in the D¶ domain of full length 
hPDI protein that indirectly affected peptide binding of the E¶ domain, but it was suspected 
the mutations caused destabilisation of the D¶ domain, such that it behaved like a 
disordered structure and bound the ligand binding site in E¶ (Klappa et al., 2000). It is 
anticipated that the peptide ligand binding affinity of E¶ domain is independent of 
neighbouring domains, however other domains of PDI have been shown to contribute to 
the substrate binding of larger peptides and proteins, with the D¶ domain having been 





1997). The binding site in E¶ is also crucial for re-oxidation of the protein to occur by 
EroĮsee 1.2.4). More recently, small hydrophobic patches on the surface of domains a, 
b and D¶ have been identified as regions likely assisting the hydrophobic binding of larger 
mis-folded proteins by hPDI (Wang et al., 2013a), (Wang et al., 2015). Having large, low-
affinity binding site(s) like this allows PDI to weakly bind to unstructured or mis-folded 
protein intermediates, and then release the correctly folded protein once the correct 
conformation is reached. An unfolded protein will display several hydrophobic residues on 
its surface, facilitating binding to the hydrophobic sites on PDI. As the protein adopts its 
correct conformation, fewer hydrophobic patches will be exposed, so PDI will lose its 
affinity to the now correctly folded substrate. 
Studies of the E¶[ fragment of hPDI by NMR spectroscopy and intrinsic fluorescence have 
shown the x-linker LV LQ FRQIRUPDWLRQDO H[FKDQJH H[LVWLQJ DV HLWKHU D µFDSSHG¶ RU
µXQFDSSHG¶ FRQIRUPDWLRQ (Wallis et al., 2009)  ,Q WKH µFDSSHG¶ IRUP WKHx-linker binds 
across the hydrophobic ligand binding site of the E¶ domain, whereas in the uncapped form 
the x-linker is free in solution (Nguyen et al., 2008).  Monomeric E¶[ can be isolated from 
dimeric species by gel filtration, but the protein slowly uncaps and dimerises upon 
prolonged storage (Curtis-Marof et al., 2014). Capping helps to explain why purified hPDI  
E¶ and EE¶ fragments exist in exclusively dimeric states; removal of the x-linker region 
promotes dimerization of the protein at its hydrophobic binding site (Wallis et al., 2009). 




Figure 1.6: Alternative conformations of the x-linker region in E¶[ (taken from Byrne et al. 2009). 
When E¶[ is in solution LWFDQH[LVW LQD µFDSSHG¶PRQRPHULF µXQFDSSHG¶KRPR-dimeric equilibrium, with 
both states stabilising the protein by occlusion of the hydrophobic binding site. In the presence of ligand, the 
SURWHLQDGRSWVDQµXQFDSSHG¶PRQRPHULFIRUPDVWKHOLJDQGRFFupies the substrate binding site, and the x-





The observation of capping lead to the theory that the x-linker region may work to 
modulate the ligand binding site of hPDI, with exposure of the hydrophobic site allowing 
the protein to bind ligands (Byrne et al., 2009). A similar capping event had been observed 
in the PDI family member ERp44, which is capped by its C-terminal tail (Wang et al., 
2008). Whilst this phenomena is observed in fragments of PDI that end immediately after 
the x-linkerµFDSSLQJ¶KDVQRWEHHQFRQFOXVLYHO\SURYHQLQIXOOOHQJWKK3',.    
The peptide binding specificity of hPDI has not been extensively studied, and there is scant 
recent work published on this functional role of hPDI. Early work showed that other 
SHSWLGHVFDQFRPSHWHZLWK¨-som to bind hPDI, but these peptides have few residues in 
FRPPRQZLWK¨-som (for example the sequence of mastoparan is INLKALAALAKKIL), 
suggesting there is no specific binding motif recognition (Ruddock et al., 2000). More 
detailed work has been carried out to ascertain the specificity of PDIp (a pancreatic 
specific PDI family member), where it has been shown that a single Tyr or Trp residue is 
sufficient for binding recognition. Mutation of these residues to Phe abolishes recognition 
by PDIp (Ruddock et al., 2000), and subsequently the binding motif of ligands was 
identified as an hydroxyaryl group (Klappa et al., 2001). This simple recognition motif 
opened up a wide range of potential non-physiological ligands for PDIp, including 
[HQRELRWLFVDQGRHVWURJHQVPDNLQJ3',SDPXFKPRUHµGUXJJDEOH¶WDUJHWWKDQK3',1R
such recognition motif has been identified for hPDI, and it is anticipated that substrate 
recognition by hPDI may be much more complex.  
1.2.3 Catalytic Activity  
Depending on its redox state, hPDI is able to catalyse the reduction, oxidation or 
isomerisation of disulphide bonds, on account of its two CGHC motif redox active sites 
(the CXXC motif is conserved among most catalytic domains of the thioredoxin and PDI 
families). During substrate oxidation, the disulphide of a PDI active site is reduced to the 
dithiol state, after which PDI is subsequently re-oxidised (see 1.2.4). Similarly, disulphide 
reduction is catalysed by the transfer of reducing equivalents from PDI to the oxidised 
substrate (Wilkinson and Gilbert, 2004).  
7KHUH DUH WZR SRWHQWLDO PHWKRGV RI GLVXOSKLGH µLVRPHULVDWLRQ¶ HLWKHU VHYHUDO F\FOHV RI
reduction and oxidation will occur until the correct native conformation is reached, or true 





structure, with no net change to the catalysts redox state (unlike reduction and oxidation 
reactions) (Hatahet and Ruddock, 2009). This occurs in hPDI because the N-terminal 
active site cysteine of PDI is maintained primarily in a thiolate S- state by virtue of its low 
pKa  (pKa of N-terminal Cys in the a domain is 4.8 +/- 0.1, compared to a typical cysteine 
residue pKa of ~8.3) (Karala et al., 2010). The abnormally low PKa is brought about by the 
residues structural location (at the N-WHUPLQXVRIDQĮ-helix, which has a permanent dipole 
associated with it) and stabilisation of the ionised state by the histidine imidazole group 
within the CGHC motif (Darby and Creighton, 1995), (Kortemme and Creighton, 1995). In 
contrast, the C-terminal cysteines of the hPDI catalytic sites have somewhat limited 
solvent exposure, and exist with a higher than average pKa (pKa of C-terminal Cys in the a 
domain is ~8.6 (Lappi et al., 2004), (Karala et al., 2010)). This high pKa would ordinarily 
limit the re-oxidation of hPDI in vivo, however an arginine residue conserved in a domain 
of hPDI and other PDI family members is able to move in and out of the active site, 
sufficiently lowering the pKa of the C-terminal cysteine, enabling re-oxidation of hPDI 
(Lappi et al., 2004), (Karala et al., 2010). Disulphide reduction, oxidation and 











Figure 1.7: PDI-catalysed disulphide bond formation (taken from Wang et al. 2015). Oxidised PDI can 
oxidise reduced substrates to form native (a) or non-native (b) disulphide-bonded protein, which leaves PDI 
in its reduced form.  Reduced PDI can subsequently be re-oxidised by reduction of native disulphides (e), 
mis-folded substrates (d) or a variety of different oxidising agents (not shown). Non-native disulphides can 
be remedied either by cycles of reduction and subsequent re-oxidation, or by isomerisation with PDI by 
direct intra-molecular disulphide shuffling (c). Note only one redox catalytic site has been shown for clarity.         
 
:KLOVW3',UHVHDUFKLVFRPPRQO\FDUULHGRXWRQGLIIHUHQWIUDJPHQWFRQVWUXFWVRI3',LWLV
LPSRUWDQW WR UHPHPEHU WKDW WKH IXQFWLRQDO DELOLW\ RI WKH FRQVWUXFW LV GHSHQGHQW RQ WKH
FRPSRVLWLRQRIGRPDLQVDomains can work independently in vitro (for example, a simple 
oxidation reaction requires only a single catalytic domain (Pirneskoski et al., 2004), but for 
LVRPHULVDWLRQ UHDFWLRQV WKH PLQLPXP UHGR[ IUDJPHQW LV E¶[D¶ :DQJ HW DO 
0D[LPXPLVRPHULVDWLRQHIILFLHQF\RUPore complex isomerisation reactions WKDWLQYROYH
VXEVWDQWLDOFKDQJHVLQVWUXFWXUHWRWKHVXEVWUDWHrequire all domains of hPDI (Darby et al., 
1998), findings that indicate hPDI domains work synergistically (Freedman et al., 2002). 
In full length protein, the a domain of hPDI is thought to primarily act as an  isomerase and 
the D¶ domain primarily as an oxidase, due to the preferential oxidation of a¶ domain. This 
is despite the two active sites sharing highly similar reduction potentials (Chambers et al., 





The recent molecular modelling simulations by Wang et al. also show the a and D¶ redox 
catalytic sites may come within 5.4 of one another- close enough to exchange 
disulphides. This work was supported by mutagenesis, and the group were able to identify 
a 36Cys-380Cys disulphide-bonded form of their C38A/C383A mutant, suggesting 
disulphide exchange can occur among the active sites of full length hPDI (Yang et al., 
2014).  
1.2.4 Re-R[LGDWLRQRI3',E\(URĮ 
After oxidation of a PDI substrate, PDI is left either in a mixed disulphide state or as a 
fully reduced protein. In vitro PDI can be selectively reduced or oxidised by either 
dithiothreitol (DTT) or oxidised glutathione (GSSG). It can also be re-oxidised by GSSG 
in vivo, or additionally by hydrogen peroxide or other ER oxidoreductins, peroxiredoxins 
or peroxidases (Ruddock, 2012). However, the largest contributor to PDI re-oxidation in 
vivo LVWKH(5R[LGRUHGXFWLQIDPLO\PHPEHU(URĮDSURWHLQH[SUHVVHGFRQVWLWXWLYHO\E\
most cells (Tavender and Bulleid, 2010) 7KH IDPLO\ PHPEHU (URȕ FDQ DOVR UH-oxidise 
hPDI, but this protein is expressed by a smaller subset of cells (Pagani et al., 2000).  
3',LVWKHSUHIHUUHGVXEVWUDWHRIWKHIODYLQGHSHQGHQW(URĮDQGWKLVLQWHUDFWLRQKDVEHHQ
shown to be highly specific to PDI, for instance, ERp57, a PDI family member which 
VKDUHVWKHVDPHGRPDLQVWUXFWXUHDV3',LVQRWDEOHWRUHGXFH(URĮ(Inaba et al., 2010). 
The transfer of disulphides occurs through contacts between the PDI redox active sites and 










Figure 1.8: Proposed model of hPDI re-R[LGDWLRQE\(URĮ(taken from Wang et al. 2009). This figure 
demonstrates that the minimal binding fragment for re-R[LGDWLRQE\(URĮLVE¶[D¶'XHWR(URĮELQGLQJDW
the E¶ substrate binding site, the 94Cys-99&\VUHGR[SDLURI(URĮIDFHWKHUHGR[DFWLYHVLWHRIWKHD¶ domain 
of hPDI.    
 
$ȕ-KDLUSLQORRSRI(URĮELQGVWRK3',DWWKHE¶ substrate binding site, which due to the 
overall binding orientation means its electron shuttle loop is within close proximity of the 
D¶ DFWLYHVLWHRIK3',WKXV(URĮSUHIHUHQWLDOO\R[LGLVHVWKHD¶ domain. This preferential 
oxidation was proven by the domain swap mutant D¶EE¶[DF, which was oxidised at its a 
domain (Wang et al., 2009). 
7KH(URĮDFWLYHVLWHLVWKHQUH-R[LGLVHGE\GLVXOSKLGHH[FKDQJHZLWKLWVµLQQHU¶DFWLYHVLWH
disulphides (Tavender and Bulleid 2010) and the electrons are ultimately passed to 
molecular oxygen to form hydrogen peroxide (H2O2).  
The ability of several enzymes to re-oxidise PDI suggests a complex network of disulphide 
bond formation in mammalian cells, and recently a new model of disulphide bond 
formation in the ER has been proposed. The Inaba group have shown that the 
peroxiredoxin Prx4, (which first reduces H2O2 to form water), preferentially oxidises P5 
and ERp46 (two other PDI family members), which go on to mediate rapid, albeit error-
prone, disulphide bond formation of newly synthesised proteins, in a reaction independent 
of molecular oxygen (Sato et al., 2013),WLVWKHQSURSRVHGWKDW3',R[LGLVHGE\(URĮ





DQR[\JHQGHSHQGHQWPDQQHU(URĮLVR[LGLVHGE\PROHFXODU22). The idea is presented in 
Figure 1.9.  
 
 
Figure 1.9: Proposed model of mammalian oxidative protein folding (taken from Okumura et al. 2015). 
This figure suggests that P5 and Erp46 rapidly form error-prone disulphides in nascent proteins, with PDI 
playing a later role in slower but more efficient disulphide isomerisation.  
 
This theory is supported by the observation that the presence of these components in vitro 
accelerates the overall rate of both reactions (thus showing the two systems could work 
synergistically (Sato et al., 2013),(Kojima et al., 2014)), and the proposal is also supported 
by observations made in vivo (Koritzinsky et al., 2013). This idea may in part also help to 
explain the seeming redundancy of so many PDI family members, if certain family 
members are found to carry out distinct roles in the cell (Okumura et al., 2015).  
1.2.5 Chaperone Activity 
In addition to its activity as a sulfhydryl protein folding catalyst, hPDI has been shown to 
exhibit activity as a molecular chaperone, by aiding in protein folding and preventing 





must display some chaperone activity before it is able to function as an isomerase, 
promoting peptide chain folding by bringing together distant cysteines prior to native bond 
formation. The idea was first proposed in 1993 by Wang and Tsou (Wang and Tsou 1993), 
and after strong support from experimental data the idea is now widely accepted.  
Instead of interaction with the redox active domains, PDI can bind non-cysteine containing 
unfolded substrates primarily at its E¶ domain. PDI chaperone activity can therefore be 
abolished by the binding of a small peptide ligand at the E¶ substrate binding site (Quan et 
al., 1995). Binding of larger mis-folded substrates also occurs throughout the entire 
hydrophobic cleft of hPDI, and it has been shown that the oxidised (open) conformation of 
hPDI exhibits greater chaperone activity than its reduced (closed) protein form (Wang et 
al., 2012), (Yang et al., 2014). This seems logical- a more open conformation would allow 
the protein to bind larger misfolded protein intermediates.   
Measuring the molecular chaperone activity specifically of PDI is challenging, as many of 
3',¶V QDWLYH VXEVWUDWHV DOVR need to form disulphide bonds- hence it can be hard to 
differentiate between PDI functioning as a molecular chaperone, or as an oxidase or 
isomerase. PDI chaperone activity is traditionally assayed using D-glyceraldehyde-3-
phosphate-dehydrogenase (GAPDH)) (Cai et al., 1994), as GAPDH does not form any 
disulphide bonds, but hPDI can also prevent aggregation of lactate dehydrogenase, citrate 
synthase, rhodanese, or alcohol dehydrogenase (Watanabe et al., 2014), in an ATP 
independent manner (Cai et al., 1994).  
The ability of PDI to behave as a molecular chaperone in vitro is often measured by 
activity of the refolded substrate protein. This result may not be indicative of the role PDI 
plays in vivo- the substrate protein may not always be folded by PDI to completion, or PDI 
may be just one of many molecular chaperones working to assist the correct refolding of a 
substrate (Cai et al., 1994). Indeed GAPDH is a cytoplasmic enzyme, and Cai et al. 
acknowledge the ER-resident hPDI may not be involved in GAPDH biogenesis in vivo 
(Cai et al., 1994).     
Somewhat paradoxically, under certain conditions PDI has also been shown to behave as 
an anti-chaperone in vitro, forming large, insoluble complexes with lysozyme (Puig and 





of denatured lysozyme (that already has a tendency to self associate into aggregates) is 
lower than to be in excess (5-10 unfolded protein: 1 PDI), (see Figure 1.10). 
 
 
Figure 1.10: The chaperone/anti-chaperone behavior of PDI (taken from Gilbert, 1997). 
Increasing the concentration of PDI from low concentrations (left region), can first lead to a 
decrease in solubility of the substrate, by providing extra ways for the unfolded protein to cross-
link into larger aggregates (anti-chaperone behavior, shown by middle region). At higher 
concentrations this self-associated cross-linking is inhibited by PDI (chaperone behavior, right 
region). 
 
In this case, multivalent interactions with PDI can inadvertently work to promote larger 
aggregate formation (Gilbert, 1997). In vitro this type of aggregation is often irreversible, 
but in vivo, DTT-induced ER chaperone associated aggregates of misfolded proteins are 
correctly folded and released from the ER upon removal of DTT (Tatu et al. 1993). It is 
thought this could be a crucial preservation mechanism to retain unfolded proteins in the 
ER, and to protect these proteins from degradation when the when the cell is under stress, 
or when the stoichiometric chaperone capacity of PDI is exceeded (Gilbert, 1997).    
Finally, PDI has also been implicated in the degradation of some terminally misfolded 
proteins (Gillece et al., 1999), and more recently it has been proposed that this degradation 
is mediated by an interaction with signal peptide peptidase (SPP), where PDI bound to SPP 
works to unfold the misfolded protein into a dislocation competent state, for transport back 





required for the degradation of Major Histocompatibility Complex (MHC) Class I heavy 
chains (Lee et al., 2010).  
1.3 PDI Family Members 
PDI is the founding member of a group of 21 structurally related proteins, grouped on 
account of their thioredoxin-like domain structure. Like PDI, family members contain 
thiol-reactive sites that display red/ox/isomerase activity, and/or thiol-non-reactive 
thioredoxin-like domains that display chaperone-like activities, to facilitate ER protein 
folding (Kozlov et al., 2010). Figure 1.11 shows the current hPDI family members.   
 
Figure 1.11: Current human PDI family members (taken from Andreu et al. 2012). Catalytic 
thioredoxin-like domains a and D¶ are shown in blue, non-catalytic b domains in green, and E¶ substrate 
binding domains are shown in purple. The x-linker region is shown in orange, and transmembrane domains 





It is still not fully understood why there is such a large number of functionally similar 
enzymes present in the ER lumen. Whilst it has been shown in mammalian cell lines that 
knockout of PDI can be compensated for by ERp57 (Rutkevich et al., 2010), knockouts of 
PDI or ERp57 are both lethal at an embryonic stage (Ni and Lee, 2007), and mice deficient 
in ERp57 suffer from severe bone growth complications during puberty (Linz et al., 2015). 
Researchers suggest that each enzyme has its own substrate specificity, or that in vivo each 
enzyme catalyses a distinct redox reaction (Ellgaard and Ruddock, 2005), (Jessop et al., 
2009), (Rutkevich et al., 2010).!Whilst most catalytic PDI family members have been 
extensively studied, the functions of many of the redox-inactive family members are 
somewhat less well defined, with several enzymes still classed as having unknown 
functions.  
An overview of several PDI family members is now given, with particular focus given to 
family members that are homologous to PDI, or those that are also capable of binding 
peptide ligands.  
1.3.1 PDIp (PDIA2) 
PDIp is a homologue of PDI primarily secreted by acinar cells of the pancreas, with 
expression also observed in the human brain, bladder and stomach (Hatahet and Ruddock, 
2009), and in rat liver, kidney, lung, GI tract and reproductive organs (Conn et al., 2004), 
(Klappa et al., 1998). The protein has the same DEE¶[D¶c domain architecture as PDI and 
shares 45% sequence identity (Walker et al., 2013). There is no full length structure of 
PDIp currently available, but the protein is anticipated to share high structural similarity to 
PDI.   
PDIp displays both disulphide isomerase and chaperone activity; PDIp is able to bind 
scrambled RNAse but not native protein, as well as a range of peptides derived from 
pancreatic digesWLYHHQ]\PHVDQGǻ-som (Klappa et al., 1998) 
Unfortunately there is little published on the redox activity of PDIp. The protein is known 
to deviate from the conserved CGHC motif observed in PDI and has a CTHC redox active 
PRWLILQLW¶VD¶ domain, showing ~50% activity compared to PDI in a peptide oxidase assay 





Early ligand binding studies of PDIp suggested that a single Trp or Tyr residue in the 
peptide was sufficient to trigger peptide binding (Ruddock et al., 2000), with subsequent 
work showing the protein interacts specifically with a hydroxyaryl group (Klappa et al., 
2001). PDIp was also shown to bind the hormone oestradiol in a hydrophobic pocket 
between the b and E¶domains with an approximate Kd of 150 nM (Fu et al., 2011), (Fu et 
al., 2012). Proposed physiological roles of PDIp include the modulation of oestrogenic 
hormones (Fu et al., 2009) or vice versa (Klappa et al., 2001), and the isomerisation of 
incorrectly folded secretory proteins (for example zymogens) (Klappa et al., 1998). A loss 
of PDIp expression is also observed in pancreatic cancer, suggesting that PDIp could be 
used as an important biological marker.  
1.3.2 ERp 57 (PDIA3) 
ERp57 is a homologue of PDI, which shares the same domain structure but lacks a specific 
hydrophobic substrate binding site in its E¶ domain. Instead, the corresponding patch of 
ERp57 is negatively charged, and the protein is therefore unable to bind PDI model 
peptides or other larger substrates (Zapun et al., 1998). ERp57 interacts almost exclusively 
at this modified site with calnexin or calreticulin, two ER resident proteins (calnexin is 
found anchored into the ER membrane and calreticulin is resident in the ER lumen), that 
themselves interact specifically with glycoproteins (Oliver et al., 1997).  
Unlike other PDI family members, instead of binding its substrates directly ERp57 relies 
on the association of calnexin or calreticulin with glycoproteins to bring its substrates into 
close proximity of its a and a¶ active sites (Kozlov et al., 2006). Hence the main functional 
role of ERp57 is thought to be the isomerisation of non-native disulphide bonds in a 
specific subset of glycoproteins (Jessop et al. 2009).  
The calnexin/calreticulin cycle 
Calnexin and calreticulin are components of the protein quality control system in 
the ER, and work either to promote the correct folding of a secretory pathway 
protein, or alternatively to target misfolded proteins for degradation, and the 





Protein glycosylation is an extremely common post-translational modification that 
involves the covalent addition of sugar moieties, in this case a core oligosaccharide 
containing three glucose molecules, to particular residues in a nascent polypeptide 
chain. Glycosylation is used within the ER as a quality control mechanism, and to 
directly monitor the status of protein folding (for detailed reviews see (Ellgard and 
Helenius, 2003), (Caramelo and Parodi, 2008)). Successive hydrolysis of two of the 
three glucose molecules of the oligosaccharide by ER glucosidase I and II leaves a 
monoglucosylated glycoprotein that is able to interact with calnexin or reticulin- 
which in turn enables the folding glycoprotein to interact with ERp57 and undergo 
disulphide bond isomerisation. Upon removal of the final glucose molecule by ER 
glucosidase II, the protein is able to dissociate from the bound lectin. Correctly 
folded proteins are then directed to the Golgi- EXW QRW EHIRUH LW LV µFKHFNHG¶ E\
glycosyltransferase enzyme. If the protein displays a non-native structure or the 
enzyme identifies exposed hydrophobic patches, the protein is re-glycosylated with 
a single glucose molecule, and consequently re-enters the calnexin/calreticulin 
cycle until it adopts a correct structure.     
ERp57 also functions as a component of the MHC Class I loading complex, (where it 
forms a disulphide-linked complex with tapasin, and is thought to facilitate the correct 
formation of Class I molecules) (Radcliffe et al., 2002), and is also involved in the correct 
folding of influenza protein HA (Daniels et al., 2003). More recently, ERp57 has been 
VKRZQ FUXFLDO IRU WKH µXQFRDWLQJ¶ RI 6LPLDQ 9LUXV  E\ LVRPHULVDWLRQ RI LQWHU-chain 
disulphides of major capsid protein VPI (Schelhaas et al., 2007), a reaction that happens 
independently of calnexin or calreticulin. 
1.3.3 ERp27 (PDIA8) 
ERp27 is another ER resident protein expressed by the pancreas, kidney, spleen, bone 
marrow and lungs of vertebrates (Lash et al., 2000). It is homologous to the non-catalytic 
EE¶ domains of hPDI, and whilst currently classed as a protein with unknown function, it is 
known to be up-regulated in times of ER oxidative stress and the UPR (Kober et al., 2013). 
It consists of two thioredoxin folds, although neither contain a CXXC redox motif (Amin, 
Freedman, 2013), so the protein is not able to function as an oxido-reductase. The b 





ELQG ǻ-som at a hydrophobic site in its second domain, that is homologous to the E¶ 
substrate ligand binding site of hPDI, but in contrast to PDI, ERp27 does not contain a 
flexible x-linker after its homologous E¶ domain. !
In addition to disordered peptide binding, the protein has also been shown to interact with a 
model protein substrate exclusively in an unfolded state (Alanen et al., 2006b), (Kober et 
al., 2013) suggesting the protein acts as a molecular chaperone. ERp27 also binds ERp57 
at the same site ERp57 binds lectins (the C-terminus of its E¶ domain), a site distinct from 
its ligand binding site. With recent observations of an ERp27-ERp57 interaction, Kober et 
al. have proposed that in times of oxidative stress, the up-regulation of ERp27 allows the 
chaperone to recruit ERp57 to the global oxidative protein folding effort; binding of 
ERp27 presents ERp57 with a greatly increased pool of mis-folded substrates (ERp57 
would otherwise only interact with certain lectin bound glycoproteins) (Kober et al., 2013). 
1.3.4 PDILT (PDIA7) 
PDILT is another tissue specific (testis) ER resident glycoprotein that is homologous to 
PDI, however it is the only PDI family member under developmental control. It is induced 
during puberty, and plays a role in the quality control of the sperm membrane protein 
ADAM3. It has been implicated in cases of male mouse infertility (Tokuhiro et al. 2012), 
and further work aims to see if this relationship is also inferred in some cases of male 
human infertility.   
The protein lacks the catalytic cysteine residues of PDI, and therefore does not exhibit 
oxidoreductase activity in vitro. Instead of the CXXC motifs of PDI, PDILT displays a 
SKQS motif in a domain, and the single cysteine motif SKKC in D¶ domain. This motif is 
highly conserved in PDILT of other species, and also among bacterial thioredoxin proteins 
(van Lith et al., 2007). This lack of cysteines suggests the protein functions primarily as a 
molecular chaperone, aiding with the correct folding of spermatid-specific proteins.  
The recent crystal structure of PDILT E¶ domain shows the hydrophobic substrate binding 
pocket occupies a larger area that observed in PDI (Bastos-Aristizabal et al., 2014). The 
crystal structure shows the binding pocket to be occupied by Trp and Tyr side chain 
residues of another PDILT molecule, suggesting that E¶ preferentially binds exposed 





1.3.5 ERp44 (PDIA10)  
ERp44 is another PDI family member GLVFRYHUHG GXH WR LWV LQWHUDFWLRQ ZLWK (URĮ DQG
(URȕ ZLWK ZKLFK LW IRUPV PL[HG GLVXOSKLGHV ,W KDV a similar clover-shape arranged 
domain structure as PDI, with domain sequence DEE¶, and a CRFS catalytic motif in its a 
domain (Wang et al., 2008). ERp44 is upregulated in times of oxidative cellular stress, 
although the protein shows little activity as an oxidoreductase or isomerase, thought to be 
GXHLQSDUWWRWKHSURWHLQ¶VIOH[LEOHc-terminal tail. In solution the tail partly occludes the 
hydrophobic substrate binding pocket of E¶ domain, as well as an additional hydrophobic 
patch around the active site motif of a (Anelli et al., 2002). The c-tail is thought to regulate 
ERp44 activity in vivo, as removal of it improves protein activity five-fold (Wang et al., 
2008).  
 
1.4 Implication of hPDI in Disease States 
Whilst initially PDI and its family members were thought to play a protective role in the 
cell, owing to their up-regulation as part of the UPR (to reduce oxidative stress levels of 
the cell), more recent PDI publications describe how it may actually have a causal role in 
some disease states. Recently, Erp72 and ERp5 have been implicated in mediating drug 
resistance of metastatic lung cancer to cisplatin (Tufo et al., 2014), and there is an 
increasing number of publications linking post-translationally modified hPDI to the 
umbrella of neurodegenerative diseases (Jeon et al., 2014). In addition, PDI is implicated 
in the progression of other cancers (Xu et al., 2014), diabetes (Grek and Townsend, 2014) 
and cardiovascular disease (Ali Kahn et al., 2014), although the exact role PDI plays in 
these diseases is still to be determined.  
There is evidence suggesting that some viruses are able to take advantage of PDI¶s ability 
to carry out thiol-disulphide exchange, to either enter the cell, or a specific cellular 
compartment. Newcastle virus is able to gain entry into its host cell by large 
conformational changes of its F fusion protein (mediated by disulphide re-arrangement 
carried out by PDI) (Jain et al., 2008), and the toxic A1 subunit of a holotoxin secreted by 
Vibrio cholerae is displaced from the secretory pathway into the cytoplasm by PDI (Tsai et 





There is increasing evidence to suggest that hPDI can even escape the ER, and mediate 
thiol-disulphide exchange at the surface of the cell, to play a role in haemostasis (Jordan 
and Gibbins, 2006). While it has been difficult to prove that it is PDI itself, and not another 
PDI family member being recruited to the surface, recent work suggests that PDI is able to 
activate tissue factor, which itself controls the production of fibrin- a crucial factor in 
blood plasma that allows clotting to occur (Reinhardt et al., 2008). Cell surface PDI has 
also been shown to increase infectivity of Th2 (T helper 2) cells to HIV virus, by binding 
to and enhancing the activity of galectin-9, a secretory lectin (Bi et al., 2011).       
Detrimental roles of PDI may also be down to a loss of its normal protective function, or a 
toxic gain of function- for example, a common post translational modification of proteins 
is s-nitrosylation, a normal cellular mechanism analogous to phosphorylation, that controls 
a range of protein functions by the addition of a nitroso (NO) group to a reactive thiol 
group (Stamler et al., 2001). However, such a modification to hPDI is an aberrant, 
irreversible reaction that inhibits the normal protein activity, reducing both chaperone and 
isomerase activity (Uehara et al., 2006). This topic has been particularly well reviewed 
recently by Parakh et al., (2015), and makes clear that these newly emerging deleterious 
roles of hPDI require further investigation. Either way, PDI shows promise as a biomarker 
for diagnosis or prognosis of many disease states, as well a potential therapeutic treatment 
and drug target (Andreu et al., 2012).  
 
1.5 An Introduction to Biomolecular NMR 
Since publication of the first solution structure solved by NMR in 1985 (that of BPTI by 
(Chazin et al., 1985)), biomolecular NMR has proved an invaluable tool in the field of 
protein and protein-ligand complex structure determination. NMR has many advantages 
over other techniques like x-ray crystallography or cryo-EM, particularly for the study of a 
conformationally active enzyme like PDI. First, proteins do not always readily crystalize, 
RU PD\ QRW IRUP WKH µFRUUHFW¶ W\SH RI FU\VWDO IRU DGHTXDWH GLIIUDFWLRQ VWUXFWXUH 
determination of PDI has historically been hindered by poor crystal formation). Although 
the field of cryo-EM has rapidly advanced to a stage where data can now be of a 
comparative resolution to these two methods, it is still better suited to the study of larger 






images of the protein in particular conformations, that may not be indicative of how the 
protein behaves in solution. NMR is particularly well-suited to study dynamic events such 
as ligand binding or a change in redox state, and as such is employed throughout this 
thesis.  
An NMR spectrometer is very powerful in detecting the subtle changes of the local 
chemical environment a given NMR-active nuclei may experience. It is a technique made 
possible by a quantum property that is intrinsic to some nuclei, known as nuclear spin 
angular momentum, or simply µQXFOHDUVSLQ¶&HUWDLQLVRWRSHVRIHOHPHQWVKDYHDQRQ-zero 
spin, a property that means the placement of such nuclei into a static magnetic field will 
cause the nuclei to interact with the field to induce a magnetic moment.  The magnetic 
moment aligns either with or against the magnetic field, and resonates at a frequency 
related to the field strength of the applied magnet. For example, within a 14.1 Tesla 
magnet, 1H nuclei resonate with a frequency of approximately 600 MHz, and 15N nuclei 
with a frequency of 60.9 MHz. These resonance frequencies are usually quoted as a 
µFKHPLFDO VKLIW¶ LQSDUWVSHr million (ppm), a unit that was derived to be independent of 
field strength, allowing the direct comparison of data collected using different 
spectrometers. 
Nuclei that are typically studied by NMR are either naturally abundant isotopes (e.g. 1H 
and 19F have natural abundances of 99.99% and 100% respectively) or proteins can be 
artificially enriched with stable NMR-active nuclei by supplementing the growth media 
with 13C and/or 15N sources (natural abundance of these isotopes is otherwise only 1.11% 
and 0.36% respectively). The unique chemical shifts of 1H, 15N, 13C and 19F nuclei have 
been used within this thesis for both the assignment and subsequent ligand binding/redox 
studies of both hPDI protein fragments and the ǻ-som peptide ligand. Further theory 









1.6 Project Aims 
This work aims to further characterise the ligand binding ability and specificity of hPDI to 
LWV PRGHO ELQGLQJ SHSWLGH ǻ-som. Early binding work carried out by Klappa et al. 
suggested the binding event relied upon hydrophobic interactions, and recently published 
work located the primary binding site of hPDI to a hydrophobic patch of the E¶ domain 
(Byrne et al., 2009). Since publication of Klappa et al¶V original work (Klappa et al., 
1997) OLWWOH KDV EHHQ UHSRUWHG RI K3',¶V SHSWLGH VSHFLILFLW\ 2EWDLQLQJ PRUH GHWDLOHG
information is of significant importance; hPDI is associated with several human disease 
states, but its physiological ligand specificity is still poorly understood.  
The aims of this thesis were: 
1. Recombinant expression, purification and isotopic labelling of the model binding 
SHSWLGHǻ-somatostatin, and the hPDI fragments E¶[and W111F DEE¶[.  
2. Characterisation of hPDI E¶[ protein and the previously unassigned W111F DEE¶[ 
fragment by NMR spectroscopy, to include LQYHVWLJDWLRQ RI µFDSSLQJ¶ E\ WKH x-linker 
region (a published observation seen in E¶[), full backbone assignments by triple 
resonance experiments, and additional methyl side-chain assignment. 
3. Determination of accurate and quantitative binding affinities RI ǻ-som to hPDI by 
15N/1H, 13C/1H, and 19F NMR spectroscopy, to investigate the effects of temperature, 
neighbouring domain and protein redox state on binding affinity.  
4. Elucidation of ǻ-som peptide ligand binding specificity to hPDI, using residue 
substitutions and specific peptide labelling techniques. 
5. Investigation of hPDI redox potential and ligand binding affinity by 19F NMR 
spectroscopy (specific site incorporation of the 19F nucleus into the protein enables a 
simplified view of the protein redox state or binding event). In addition, 19F incorporation 
into the peptide allows a unique ligand-observed perspective of the binding event- this is 







1.7 Project Impact 
It is anticipated that furthering our overall knowledge of hPDI will aid in a more general 
understanding of the structure/function based mechanism of hPDI, a protein that has been 
extensively studied for over 50 years, but until recently had eluded crystallisation. In 
addition, more detailed information or binding specificity may help in the rational design 
of hPDI targeted drugs. There are a multitude of potential therapeutic applications of hPDI, 
owing to its broad involvement in various fundamental cellular processes. Whilst many of 
these applications involve the up-regulation or restoration of normal hPDI cellular levels, 
the reduction or partial inhibition/inactivation of hPDI may be a more appropriate 
treatment for some disease states. Possible therapeutic applications have been suggested by 
Parakh et al. (see Figure 1.12). 
    
 
 
Figure 1.12: Possible therapeutic applications of hPDI modulation (taken from Parakh et al. 2015). 
Restoring the function of modified hPDI or increasing the levels of hPDI may work to reduce the toxic load 
of misfolded proteins present in neurodegenerative disease states. hPDI treatment may also be valuable in 
cases of vascular injury, where the enzyme could help support initial platelet adhesion. Conversely, in cases 
of cancer or cardiovascular disease, it may be more appropriate to inhibit hPDI activity, where the enzyme 






Small molecular inhibitors of PDI are being researched for various different roles including 
neuroprotection (Kaplan and Stockwell, 2015), cancer treatments (Xu et al., 2012), (Eirich 
et al., 2014) prevention of thrombi (Khodier et al., 2010), as antivirals (Khan, Simizu et al. 
2011), as well as general PDI inhibition (Ge et al., 2013). However, current small molecule 
inhibitors of PDI are mostly directed to the active sites of hPDI, and are plagued by 
cytotoxic effects and broad specificity. For example bacitracin, a peptide antibiotic used 
widely in research as an inhibitor of hPDI reduction, is not suitable for clinical use on 
account of its low specificity, nephrotoxicity and poor membrane permeability. In addition, 
commercially available bacitracin is supplied as no less than 22 structurally related 
peptides, with IC50 values of each peptide ranging between 20-ȝ0(Dickerhof et al., 
2011). It may that if the peptide specificity of hPDI could be better understood a suite of 
peptide ligands could be designed, working to block the chaperone and isomerase activities 
of hPDI, to deliver a much more target specific, clinically practical treatment.  
In addition to its diverse therapeutic applications, PDI is also used industrially to increase 
the yield of recombinantly produced protein therapeutics, many of which require formation 
of disulphide bonds for correct folding and biological activity (Bulaj, 2005), (Matos et al., 
2014). A better knowledge of the substrate specificity of PDI might allow future 
engineering to increase PDI activity, or alternatively, if we had a better understanding of 
how the activity and specificity differ among the PDI family members, a more suitable PDI 






















The production of small peptides for biological study is commonly carried out via solid-
phase synthesis, a method developed in 1963 that works by progressively coupling 
FKHPLFDOO\SURWHFWHGDPLQRDFLGV UHVLGXHV WKDWKDYH WKHLU UHDFWLYHVLGH FKDLQV µEORFNHG¶
by other chemical groups to stop non-specific reactions or branching of the peptide) to the 
N-terminus of a growing peptide chain (Merrifield, 1963). The technique allows for the 
incorporation of either standard or non-natural amino acids, and whilst initial methods 
produced low yields and were labour intensive, solid-phase synthesis is now a common 
and cost-effective method of producing peptides <50 residues. The technique is utilised 
later within this thesis for the production of fluorine-containing peptides (Chapter 5).  
For detailed study by NMR, it is preferable to have uniform isotopic enrichment of the 
sample (usually 15N and/or 13C labelling). Uniform labelling strategies allow 
multidimensional NMR and nucleus-selective editing techniques to be carried out. 





owing to the requirement of large excesses of each individually enriched and chemically 
protected amino acid. In addition to this cost, the purity of commercially available isotope-
labelled amino acids is much lower than their unlabelled counterparts, making the 
purification of the isotope-labelled peptides extremely difficult from a crude mixture. On a 
small scale, it is not commercially viable to produce uniform labelled peptides in this 
manner (personal communication with Peptide Synthetics, www.peptidesynthetics.co.uk).  
By comparison, recombinant in vivo isotopic labelling methods are much more cost 
effective. The E. coli expression system is widely exploited for protein expression, and 
equally the system lends itself well to stable isotope labelling (e.g. 13C and/or 15N) by 
growth in a minimal media using a sole 13C carbon and/or 15N nitrogen source. However, 
owing to their small size and lack of secondary structure, peptides are readily degraded by 
proteases in the E. coli cytoplasm (Shen, 1984). This is a problem that can be circumvented 
by expression of the peptide fused to a suitable protein partner. A variety of different 
fusions can be employed, including soluble (for example GB1, GST and HSA binding 
domain of protein G) (Koenig et al., 2003), (Williamson et al., 2000), (Jonasson et al., 
1998) or insoluble fusion partners (for example KSI) (Kuliopulos and Walsh, 1994), (also 
see (Hwang et al., 2014) for a good review).  
This chapter demonstrates attemSWVWRH[SUHVVDQGSXULI\ǻ-som (AGSKNFFWKTFTSS), 
the model ligand binding peptide of hPDI, using both soluble and insoluble protein fusion 
partners. Expression of the fusion protein was successful using both systems, however, 
cleavage and purification of the peptide from an insoluble recombinant product was 
complicated by various factors including poor cleavage rates, residue formylation, peptide 
loss and peptide instability upon cleavage.  
2.1.1 Recombinant Peptide Fusion Expression Strategies 
2.1.1.1 Insoluble Fusion Method (KSI) 
The are several insoluble proteins suitable for use as fusion partners, with the Ketosteroid 
Isomerase (KSI) expression system available commercially as the pET-31b(+) plasmid 
vector (a pBR322 derived plasmid), supplied by Novagen (Kuliopulos and Walsh 1994). 
The vector has a sequence encoding the insoluble bacterial protein Ketosteroid Isomerase 





Appendix 2.1 for pET-31b(+) vector map). The vector allows for the insertion of multiple 
tandem repeats of a peptide sequence (spaced by cyanogen bromide cleavable methionine 
residues) to increase overall yields. However, previous work within the laboratory has 
shown that tandem expression results in only a modest increase in peptide yield 
(unpublished observation) and the chemical cleavage by cyanogen bromide (CNBr) at the 
C-terminal side of methionine residues results in their modification to homoserine lactone, 
an undesired modification that would occur to all but the last tandem peptide. Therefore a 
stop codon was engineered immediately after the peptide coding sequence, to allow 
translation of a KSI-Met-peptide fusion, that when cleaved by CNBr would leave a KSI-
lactone protein, and an unmodified peptide (see Figure 2.1).    
  
 
Figure 2.1: Scheme showing pET-31b(+) vector KSI fusion expression system. The annealed oligos are 
ligated into AlwNI digested, dephosphorylated vector to yield a KSI-Met-peptide-STOP construct. The 
methionine residues (cleavage site of CNBr) are highlighted in blue. The stop codons are highlighted in red. 
Figure adapted from (Kuliopulos and Walsh 1994). 
 
There are many advantages to using an insoluble fusion method- insoluble proteins form 
inclusion bodies within the cytoplasm of the E. coli, which can greatly improve protein 
stability and hence expression yields as the insoluble nature of the aggregates protect the 





purification method developed within the laboratory (Williamson et al., 1996), 
(Williamson et al., 2000), (Williamson, 2001), the inclusion bodies can be easily isolated 
from the majority of other soluble and contaminating membrane proteins to >80% purity, 
negating the requirement of an affinity tag for purification. 
2.1.1.2 Solubility Enhancing Fusion Method (GB1): 
A soluble GB1 fusion vector was designed within the laboratory, engineered using a pET-
23a(+) vector  kindly gifted by Prof. C. C. Wang, Beijing, China. The vector encodes for 
the soluble B1 domain of G protein (6.2 kDa), with an N-terminal His6-tag sequence 
(please note the vector incidentally codes for two sequential His6-tags; this was not found 
to affect expression or purification so was not altered). The GB1 sequence is followed by 
BamHI and EcoRI restriction sites (please see Appendix 2.2 and 2.3 for vector maps). 
Peptide coding sequences were designed for insertion between the two cloning sites and 
engineered with a proteolytic cleavage site (either Factor Xa  (Ile-Glu/Asp-Gly-Arg-Ļ-X) 
or enterokinase (Asp-Asp-Asp-Asp-Lys-Ļ-X) and a stop codon, to allow translation of a 
His6-tag-GB1-protease cleavage site-peptide fusion. The expressed protein was purified 
using metal affinity chromatography and subsequently cleaved with the appropriate 









Figure 2.2: Scheme showing GB1 fusion expression system with Factor Xa cleavage site. The annealed 
oligos are ligated into a BamHI and EcoRI digested, dephosphorylated vector to yield a His6-tag-GB1-
protease cleavage site-peptide-STOP construct. The IEGR cleavage recognition site of  FXa is labelled and 
the stop codon is highlighted in red.  
Both Factor Xa and enterokinase were chosen due to their highly specific recognition 
sequences and apparent lack of secondary protease activity. More importantly, both 
enzymes cleave at the C-terminus of their respective recognition sequences, yielding an 
un-modified, cleaved peptide (Jenny et al., 2003), (Light and Janska, 1989). 
    
2.2 Materials and Methods 
Please note: 7KH.6,¨-som construct was made by an undergraduate student prior to the 
VWDUWRIWKLVWKHVLV7UDQVIRUPDWLRQRIWKHYHFWRUH[SUHVVLRQDQGSXULILFDWLRQRIWKH.6,¨-
VRP IXVLRQ ZHUH FDUULHG RXW E\ P\VHOI 7KH *%¨-som constructs were made by 
undergraduate students under the supervision of Dr. Richard Williamson and myself 
(2014). Transformations, initial expression and lysis steps were carried out by myself, after 
which time I began my thesis write up. Larger scale expression, cleavage and 
characterisation of the GB1 fusions were carried out by further undergraduate students 







Unless stated otherwise all laboratory reagents were supplied by Sigma Aldrich 
(Gillingham, UK).  
2.2.2 E. coli Strains and Vectors 
Both modified pET vectors are under the control of a T7 promotor. 7KH '+Į E. coli 
strain was used for all DNA manipulation steps, and E. coli  BL21 (DE3) pLysS cells were 
used for subsequent protein expression. These cells are deficient in the proteases lon and 
ompT DQG FDUU\ WKH SURSKDJH Ȝ'( ZKLFK FRQWDLQV WKH 7 EDFWHULRSKDJH JHQH , 7KLV
codes for the T7 RNA polymerase enzyme under control of the isopropyl-ȕ-D-
thiogalactopyranoside (IPTG) inducible lac UV5 promoter. T7 RNA polymerase binds 
specifically to the T7 promoter to initiate transcription. The pLysS plasmid carries the gene 
encoding T7 lysozyme- LW FRQIHUV FKORUDPSKHQLFRO UHVLVWDQFH WR WKH FHOO ORZHUV µOHDN\¶
background expression of the target protein before induction (T7 lysozyme is a natural 
inhibitor of T7 RNA polymerase) and has the additional benefit of aiding cell lysis after 
protein expression. 
2.2.3 Bacterial Culture Media 
Glycerol stocks and all transformed cells were plated out onto fresh LB agar plates (10 g/L 
tryptone, 5 g/L yeast extract, 10 g/L NaCl and 15 g/L agar) with antibiotic selection 
appropriate for each plasmid (ampicillin at 100 ȝJP/ for pET vectors, chloramphenicol at 
34 ȝJP/ for pLysS). All E. coli cultures were grown using sterile LB media (10 g/L 
tryptone, 5 g/L yeast extract, 10 g/L NaCl in MilliQ water) unless stated otherwise, again 
with the appropriate antibiotic selection in Erlenmeyer flasks 5 times the media volume.  
2.2.4 Competent Cells 
&RPSHWHQW'+ĮDQG%/'(S/\V6E. coli cells were made for DNA transformation 
using a method adapted from Sambrooks and Russell (2001). Master glycerol stocks of 
each strain were streaked out onto LB agar plates with antibiotic selection if appropriate 
(cKORUDPSKHQLFRO DW ȝJP/ IRU %/'(S/\V6 VWUDLQV DQG LQFXEDWHG RYHUQLJKW DW
37¡C. A single colony was selected and used to inoculate 50 mL of sterile SOB media (20 





MgCl2S+&XOWXUHVZHUHLQFXEDWHGDWÛ&ZLWKUSPVKDNLQJXQWLODQ$600 of 0.5 
was reached, at which point the cultures were transferred to sterile 50 mL falcon tubes and 
centrifuged at 1,811 g for 15 minVDWÛ&(DFKFHOOSHOOHWZDVUH-suspended in 25 mL of 
sterile, ice-cold 50 mM CaCl2 and incubated on ice for 30 min. Cells were then centrifuged 
as before and each pellet re-suspended in 2 mL ice-cold 50 mM CaCl2. Sterile 50% 
glycerol was added to each suspension to a final concentration of 10% glycerol, and the 
suspension portioned into sterile Eppendorfs in 200 ȝ/ aliquots, flash frozen using liquid 
nitrogen or an ethanol/dry ice bath and stored at -Û&XQWLOUHTXLUHG 
2.2.5 Transformations 
9HFWRU '1$ ZDV WUDQVIRUPHG LQWR FRPSHWHQW '+Į DQG %/'(S/\V6 E. coli cells 
prepared as stated in 2.2.4. Competent cells stored at -80¡C were defrosted on ice and split 
into sterile, pre-chilled Eppendorf tubes (60 ȝ/ DOLTXRW SHU WUDQVIRUPDWLRQ Purified 
miniprep DNA concentrations were calculated using a NanoDrop 2000c UV-Vis 
Spectrophotometer 7KHUPR6FLHQWLILFFRPSHWHQW'+ĮFHOOVZHUHWUDQVIRUPHGXVLQJ
ng DNA, and competent BL21(DE3)pLysS cells transformed with 150 ng DNA (BL21 
cells have reduced competency when compared to '+Į $IWHU WKH DGGLWLRQ RI YHFWRU
DNA, cells were incubated on ice for 10 mins, followed by a heat-shock at 42¡C for 45 
secs. After a second incubation on ice for 5 mins, 150 ȝ/RIVWHULOH/%PHGLDZDVDGGHGWR
each tube aQG LQFXEDWHG IRUKU DW Û&ZLWK USPVKDNLQJ DQGȝ/
aliquots of transformed cells were then spread onto LB agar plates containing appropriate 
antibiotics and incubated overnight at 37¡C. In addition, a negative control transformation 
XVLQJȝ/RIVWHULOH0LOOL4ZDWHUDQGDSRVLWLYHFRQWUROYHFWRUNQRZQWRWUDQVIRUPZLWK
high efficiency) were transformed each time to check overall transformation efficiency. 
2.2.6 Fusion Protein Expression 
For main grows, starter cultures of 100 mL LB media with ampicillin (100 ȝJP/ DQG
chloramphenicol (34 ȝJP/ZHUH LQRFXODWHGXVLQJDVLQJOHFRORQ\ IURP LB agar plates. 
The starter culture was grown overnight at 37¡C with 200 rpm shaking, to an A600 of 
approximately 2.0. The cells were then centrifuged in sterile 50 mL falcons at 3,220 g for 
15 mins at 4¡C, and the cell pellets re-suspended in 1-5 mL of fresh, sterile LB media. 
Each large main culture (up to 3x 400 mL cultures from 1x 100 mL starter culture) was 





The main cultures were incubated at 37¡C with shaking at 200 rpm and monitored until 
they reached an A600 of 0.7. They were then induced using 1 mM IPTG (1 M stock). After 
induction at 37¡C for 4 hours, the cells were cooled on ice for 5 mins and then harvested 
by centrifugation at 10,000 g for 10 mins at 4¡C. Each 400 mL cell pellet was then re-
suspended in 10 mL peptide lysis buffer (KSI fusions: 50 mM Tris-HCl, 2 mM EDTA, pH 
8.0, GB1 fusions: 20 mM sodium phosphate, 50 mM NaCl, pH 7.3) and stored at -20¡C 
until required. 
2.2.7 SDS-PAGE Analysis 
Reducing SDS-PAGE gels were used at all stages to characterise expression, lysis and 
subsequent purification steps of the fusion proteins. 
Reducing SDS-PAGE: Protein gels were prepared using the Laemmli Tris-Glycine buffer 
system (Laemmli, 1970), using a 12.5 or 15% w/v resolving gel (pH 8.8) and a 5% w/v 
stacking gel (pH 6.8) (see Table 2.1 for gel composition).  
 
Table 2.1: Components of reducing SDS-PAGE resolving and stacking gels.  
 Component 15% Resolving 
Gel (/20 mL) 
12.5% Resolving 
Gel (/20 mL) 
5% Stacking Gel 
(/10 mL) 
40% Acrylamide   
(37.5:1 A:B) 
7.5 mL 6.25 mL 1.25 mL 
1.5 M Tris-HCl, pH 8.8 5 mL 5 mL - 
0.5 M Tris-HCl, pH 6.8 - - 1.25 mL 
10% w/v SDS 200 ȝ/ 200 ȝ/ 100 ȝ/ 
MilliQ 7.3 mL 8.55 mL 7.4 mL 
10% AMPS 50 ȝ/ 50 ȝ/ 50 ȝ/ 
TEMED 14 ȝ/ 14 ȝ/ 10 ȝ/ 






Gels were polymerised using ammonium persulphate (AMPS) and 
tetramethylethylenediamine (TEMED) (both Bio-Rad, Hertfordshire, UK). Twenty 
millilitres of resolving gel was sufficient to pour 2-3 gels in 1.0 mm cassettes (Novex, 
Thermo Fisher Scientific). The gels were left for 3 hours at RT to polymerise. Gel samples 
were prepared for analysis using 4x gel loading buffer (0.33 M Tris-HCl, 8% w/v SDS, 
0.4% Bromophenol blue, glycerol to a final concentration of 40%- Sambrook & Russell, 
2001) made reducing with 200 mM dithiothreitol (DTTred) and incubated at 100¡C for 3 
mins. Ten microliter sample volumes were loaded, with all sample loads equivalent to 
material derived from 50 ȝ/of original culture volume (unless stated otherwise). Each gel 
was run with 10 ȝ/3UHFLVLRQ3OXVSURWHLQ standard (Bio-Rad) in the first lane and empty 
wells were run with 10 ȝ/ [ UHGXFLQJ VDPSOH EXIIHU Gels were run using 500 mL 1x 
TGS gel running buffer (5x stock of 0.95 M glycine, 0.125 M Tris and 0.5% w/v SDS, pH 
8.3) at 100 V through the stacking gel (15-20 mins) and 125 V through the resolving gel 
(approximate run time 1.5 hrs). Gels were typically stained overnight in Coomassie stain 
(40% methanol, 10% acetic acid and 1 mg/mL Brilliant Blue G) and then de-stained using 
a solution of 10% methanol, 10% acetic acid. All steps were carried out under gentle 
agitation at RT. Once de-stained, gels were stored in de-stain solution or equilibrated in 
30% methanol, 3% glycerol for 1 hour and dried between cellophane sheets. 
5HGXFLQJµ3HSWLGH*HO¶6'6-PAGE:  As ǻ-som peptide is significantly small (1.6 kDa) 
it was not observed by standard SDS-PAGE. Therefore peptide gels were prepared, using a 
modified version of the original Tris-Tricine buffer system (Schagger and von Jagow, 
1987), adapted for the resolution of small peptides (<10 kDa) by inclusion of 6 M urea in 
the resolving gel (Schagger, 2006). Gels were made using a 16% w/v resolving gel, a 1 cm 











Table 2.2: Components of reducing peptide Tris-Tricine SDS-PAGE. 
Component 16% Resolving 
Gel (/10 mL) 
10% Spacer Gel          
(/10 mL) 




3.86 mL - - 
AB-3 Polyacrylamide 
(49.5:3 A:B) 
- 2.49 mL 0.6 mL 
3x Gel Buffer (3M Tris, 
1M HCl, 0.3% SDS, pH 8.45)  
3.33 mL 3.33 mL 1.5 mL 
Urea 3.6 g - - 
MilliQ 2.81 mL 4.18 mL 3.9 mL 
10% AMPS 33.3 ȝ/ 50 ȝ/ 45 ȝ/ 
TEMED 3.33 ȝ/ 10 ȝ/ 4.5 ȝ/ 
A- acrylamide, B- bisacrylamide, SDS- sodium dodecyl sulphate, AMPS- ammonium persulphate and 
TEMED- tetramethylethylenediamine. 
 
Gel samples were prepared for analysis using 4 x peptide gel loading buffer (3% SDS 
(w/v), 6% ȕ-mercaptoethanol, 30% glycerol (w/v), 0.05% Bromophenol blue, 150 mM 
Tris-HCl, pH 7.0). Samples and buffer were diluted to 1 x with MilliQ and incubated at 
37¡C for 60 mins. Gels were run using 400 mL 1 x anode buffer (10 x stock of 1 M Tris 
and 225 mM HCl, pH 8.9) and 200 mL 1 x cathode buffer (10 x stock of 1 M Tris, 1 M 
Tricine, 1% SDS, pH 8.25), run at 30 V through the stacking gel, and 125 V through the 
spacer and resolving gels (approximate run time 2 hrs). The gels were fixed for 30 mins 
(100 mM ammonium acetate in a 50:40:10 solution of methanol: H2O: acetic acid), then 
stained for 60 mins using Coomassie stain (0.025% Brilliant Blue G in 10% acetic acid), 
and de-stained in 2 x 60 min steps using a 10% acetic acid solution. All steps were carried 
out under gentle agitation at RT. Once de-stained, gels were stored in de-stain solution or 





2.2.8 Cell Lysis 
Previously frozen cells were thawed at RT, and each 10 mL re-suspended pellet 
(equivalent to 400 mL original culture volume) was treated ZLWKȝ/RI7ULWRQ;-100 
(5% v/v in lysis buffer stock), gently mixed and left to incubate for 20 mins. This was 
foOORZHG E\ WUHDWPHQW ZLWK  ȝ/ '1DVH , %RYLQH  PJP/ VWRFN DQG  ȝ/  0
MgCl2 for a second incubation at RT for 20 mins. The lysate was then sonicated on icy 
water (3 min cycle of 10 sec pulse, 10 sec rest) and the insoluble material pelleted by 
centrifugation for 10 mins, 12,000 g at 4϶C. Samples of the total cell lysate, supernatant 
and re-suspended pellet were taken for reducing SDS-PAGE analysis. Either the insoluble 
(KSI fusion protein) or soluble (GB1 fusion protein) fractions were taken forward for 
purification. 
2.2.9 KSI Fusion Protein Isolation 
The insoluble material was re-suspended in 2.5 mL wash buffer (50 mM Tris-HCl, 10 mM 
EDTA and 0.5% Triton X-100 (w/v), pH 8.0) and homogenised for 5 mins using a hand-
held glass homogeniser. The insoluble material was recovered by centrifugation (10 mins, 
12,000 g at 4϶C), and the homogenisation step repeated twice more using 2.5 mL wash 
buffer, followed by two steps using 2.5 mL MilliQ water. A sample of washed inclusion 
bodies was taken for SDS-PAGE analysis and the remaining material stored as a wet pellet 
at -20¡C.  
2.2.10 KSI Fusion Protein Cleavage and Peptide Purification 
Washed inclusion bodies from up to 1.2 L original culture volume were re-suspended in 
0.5 mL MilliQ water and dissolved by addition of either 5 mL formic acid or TFA. The 
solubilised fusion protein mix was poured into a falcon tube containing 0.2 g CNBr, mixed 
by inversion and left to incubate at RT in the dark fume hood for 18-24 hours.  
The cleaved protein solution was diluted into 20 mL MilliQ water, flash frozen on liquid 
nitrogen and lyophilised to remove CNBr. The lyophilised material was then re-suspended 
in 2.5 mL phosphate buffer (50 mM sodium phosphate, 100 mM NaCl, pH 7.5), and 
corrected to pH 7.5 if necessary. The suspensions were left to stir overnight in the dark at 





Additionally, rHFRYHU\ RI ¨-som peptide was trialled by serial dilution from denaturing 
phosphate buffer (50 mM sodium phosphate, 100 mM NaCl, 6 M guanidine hydrochloride 
(GdnHCl), pH 7.5) into non-denaturing phosphate buffer (50 mM sodium phosphate, 100 
mM NaCl, pH 7.5). Lyophilised material was initially dissolved into 1 mL denaturing 
bufferDQGȝ/DOLTXRWVZHUHWhen each made up to 1 mL with varying amounts of each 
buffer to yield final GdnHCl concentrations of 6, 5, 4, 3.4, 3, 2.7, 2.4, 1.2 and 0.6 M. 
Samples were monitored using absorbance at 280 nm and KSI pellets were subsequently 
analysed by reducing SDS-PAGE. The samples were centrifuged at 15,700 g for 5 mins at 
RT and the pellets washed with 1 mL fresh non-reducing buffer to remove residual 
denaturant (GdnHCl precipitates SDS). Re-suspended KSI pellets were then centrifuged as 
before and taken up in 1 x sample buffer.     
5HFRYHU\ RI ¨-som peptide was also trialled by size exclusion chromatography under 
denaturing conditions  using a 50 mL CV of Sephadex G15 medium, a matrix of cross-
linked dextran (GE Healthcare). The column was stored at RT in de-gassed 20% ethanol 
and equilibrated using 1.5 CV de-gassed running buffer (50 mM sodium phosphate, 100 
mM NaCl, either 6 M or 2.4 M GdnHCl, pH 7.5). The lyophilised material was re-
suspended in 1 mL running buffer and loaded onto the column using a three way tap. The 
peptide was eluted using 1.5 CV of running buffer at a flow rate of 2 mL/min, collected in 
5 mL elution fractions and monitored using absorbance at 280 nm by an KTA FPLC 
analyser. After use the column was washed using 3 CV of de-gassed 20% ethanol and 
stored at RT for future use. 
Unlabelled peptide was purified by RP-HPLC (Waters 600/486 series HPLC with a 
preparative Vydac Resolve C18 column). Peptide was loaded and eluted using a gradient 
of acetonitrile (HPLC-grade) in HPLC-grade water (+ 0.05% TFA). Peak fractions were 
collected in 15 mL falcon tubes when the absorbance at 200 nm >0.1 AU, lyophilised and 
re-suspended in phosphate buffer. Peptide absorbance was measured at this stage using a 
wavelength of 280 nm and a phosphate buffer blank 7KH ǻ-som peptide amino acid 
sequence was submitted to ExPASy ProtParam (http://web.expasy.org/protparam/) to 
calculate extinction coefficients, and molar protein concentration was calculated using the 
Beer-Lambert Law. The extinction coefficient of the peptide was 5500 M-1cm-1. 
Additionally, samples of purified peptide were analysed by SDS-PAGE gel for comparison 





2.2.11 GB1 Fusion Protein IMAC Purification and Cleavage 
An equivalent of up to 1.2 L original cell culture lysate was loaded per 5 mL packed 
column of Chelating Sepharose Fast Flow (GE Healthcare), using multiple columns when 
scaling up. The re-usable columns were stored at 4¡C in 20% ethanol, and immediately 
prior to use were washed using 10 CV of MilliQ water. All following steps were loaded 
and eluted using gravity flow, and fractions from each elution were collected for analysis 
by reducing SDS-PAGE. All wash and elution buffers were used ice-cold to limit the 
proteolysis observed after initially using buffers at RT. 
The resin was first charged using 1 CV of 0.2 M NiSO4 and washed using 5 CV sodium 
acetate buffer (20 mM sodium acetate, 0.5 M NaCl, pH 4). The column was then 
equilibrated using 10 CV of binding buffer (20 mM sodium phosphate, 0.5 M NaCl, 10 
mM imidazole, pH 7.3). The supernatant ZDVILOWHUHGXVLQJDȝP0LQLVDUWVLQJOHXVH
syringe filter and loaded onto the column. A second 10 CV of binding buffer was used to 
wash the column followed by 5 CV of wash buffer (20 mM sodium phosphate, 0.5 M 
NaCl, 50 mM imidazole, pH 7.3), used to remove any weakly bound impurities. The nickel 
and His6-tag fusion protein were then eluted using 10 CV of strip buffer (20 mM sodium 
phosphate, 0.5 M NaCl, 20 mM EDTA, pH 7.3) and collected in 2 mL fractions. The 
absorbance of each fraction was measured at A280 nm using a wash buffer blank and a cut-
off of 0.1 AU to select fractions for reducing SDS-PAGE analysis and subsequent steps. 
After use the column was washed using 10 CV of MilliQ water and again stored in 20% 
ethanol at 4¡C for future use. 
Strip buffer elutions containing His6-tagged protein were treated according to their 
respective cleavage site, with the addition of either 0.05 U/ mL enterokinase, incubated at 
37϶&IRUKRXUVRUȝJP/)DFWRU;DLQFXEDWHGDW϶C for 16 hours.  
2.2.12 Peptide Analysis by Mass Spectrometry 
To confirm the correct peptide had been produced, portions of each recovered peptide were 
analysed using Electrospray Mass Spectrometry (coupled to analytical HPLC), kindly 








([SUHVVLRQDQG3XULILFDWLRQRI¨-som from KSI Fusions 
pET 31b(+) K6,¨-som DNA was previously generated by an undergraduate project student 
prior to the start of this thesis, and the sequence confirmed by DNA sequencing (see 
Appendix 2.4.1). This DNA ZDVWUDQVIRUPHGLQWR'+ĮFHOOVWRPDLQWDin glycerol stocks, 
and the plasmid DNA from an overnight culture of these cells was purified by mini-prep 
(QIAgen), then transformed into BL21(DE3)pLysS cells for protein expression. Growth of 
E. coli cells with the insert produced white, uniform colonies on LB agar plates, and 
showed normal doubling times in both LB and minimal media. SDS-PAGE analysis of the 
induced cell lysate showed a prominent band of the overexpressed fusion protein, which as 
anticipated was only present in the insoluble fraction (see Figure 2.3). On comparison of 
the fusion protein with the Precision Plus protein standards, the fusion appears to migrate 
between the 10-N'DVWDQGDUGV.6,KDVDPROHFXODUZHLJKWRIN'DDQGWKH¨-som 
insert is 1.6 kDa (giving a total molecular weight of 15.2 kDa)- so the fusion protein 
migrates faster than would be expected for its size. This phenomena was also observed 
with the GB1¨-som fusion (see Figure 2.11VXJJHVWLQJIXVLRQRI¨-som to either protein 
may cause faster migration through the gel. 
 
Figure 2.3: 15% Reducing SDS-PAGE analysis of .6,¨-som cell lysis and inclusion body wash steps. 
Lane 1: Precision Plus protein marker, lane 2: total cell lysate, lane 3: lysis supernatant, lanes 4-7: 
supernatants from inclusion body wash steps 1-4, laQH:DVKHGLQFOXVLRQERGLHVODQHDQGȝJDQG





The vast majority of contaminating soluble proteins were removed by centrifugation of the 
lysate to pellet the insoluble inclusion bodies (see Figure 2.3 lane 3, lysis supernatant). The 
inclusion body wash steps were successful in removing other contaminating proteins, and 
after the four wash steps .6,¨-som was estimated to be >80% pure. The major 
contaminating band removed in the wash step elutions (see lanes 4-7 of Figure 2.3) is 
likely ȕ-lactamase, a 40 kDa protein expressed by plasmid-containing cells (the enzyme 
confers ampicillin resistance). This band was especially prominent as a contaminant in 
washed inclusion bodies from overnight expressions, therefore induction was carried out at 
37¡C for 4 hrs (where comparable fusion protein expression was observed as for overnight 
induction, but with lower ȕ-lactamase expression).  
From the SDS-PAGE gel in Figure 2.3 we FDQHVWLPDWHDQH[FHVVRIȝJZDVKHGIXVLRQ
SURWHLQ SHU  ȝ/ RI RULJLQDO FXOWXUH JLYLQJ D \LHOG RI ! PJ/ $V ¨-som peptide 
constitutes 10.53% of the total fusion product by mass, the maximum theoretical yield of 
recoverable peptide is >8 mg/L.    
&OHDYDJH RI ¨-som peptide from KSI was first carried out as described in 2.2.10 using 
CNBr in formic acid. After lyophilisation, the material was re-suspended in phosphate 
buffer and centrifuged to remove the insoluble KSI. Analytical RP-HPLC analysis of the 
soluble fraction and corresponding masses (as identified by mass spectrometry) are shown 







Figure 2.4: +3/&WUDFHRI¨-som after cleavage from KSI using CNBr in formic acid. Corresponding 
masses of each relevant peak are labelled.  
 
:KLOVWWKHPDMRUSHDNREVHUYHGZDVLGHQWLILDEOHDV¨-som peptide (1606.8 Da), additional 
peaks were also seen in the analysis that eluted soon after the peptide in the HPLC trace. 
Mass spectrometry analysis revealed masses of 1634.78 and 1662.78 Da, corresponding to 
¨-som peptide +28 or +56 Da. Probing of these masses using Delta Mass (www.abrf.org) 
showed them to be a common post-translational modification observed when using formic 
acid (Goodlett et al., 1990); an N,N-di-methylation that can occur to either lysine or 
arginine residues. Since there are two lysine residues present in the peptide, it is likely that 
the observed masses correspond to single di-methylation (+28 Da) and double di-
methylation (+56 Da).  
As a result of this, shorter cleavage times using formic acid were trialled (2, 4, 8 and 16 
hrs) but these times also showed formylation of the peptide. Substitution of the formic acid 
for TFA prevented formylation from occurring (see Figure 2.5), however overall cleavage 
rates were much poorer (estimated at 50% cleavage, as shown by Figure 2.6). Extended 
cleavage times in the TFA solution (>24 hrs) were trialled to improve this cleavage rate, 








)LJXUH  +3/& WUDFH RI ¨-som after cleavage from KSI using CNBr in TFA acid (a) and 
corresponding mass identification of major peak * in HPLC trace (b). ¨-som peptide was identified as 









Figure 2.6: 16% Reducing peptide SDS-PAGE analysis of .6,¨-som cleavage in TFA. Lane 1: Precision 
Plus protein marker, lanes 2 and 3: supernatant of re-VXVSHQGHG FOHDYHG PDWHULDO VKRXOG FRQWDLQ ¨-som 
peptide but peptide is extremely dilute), lanes 4 and 5: re-suspended pellet of cleaved material (cleaved and 
un-cleaved fusion protein present), lane 6: washed inclusion bodies (un-FOHDYHG.6,¨-som). A cleavage rate 
of 50% in TFA conditions was estimated from the two KSI bands (cleaved and un-cleaved) in lanes 4 and 5. 
$OOORDGVDUHHTXLYDOHQWWRWKHPDWHULDOGHULYHGIURPȝ/RIRULJLQDOFXOWXUH 
 
Despite large losses at this cleavage step, isotopic enrichment was attempted for the 
expression of 15N,13C labelled fusion protein. Expression in defined minimal media (MM) 
(see Table 3.1 for components) typically results in lower protein expression, and 
expression of 15N,13& ODEHOOHG .6,¨-som was estimated at 20 mg/L (for comparison 
expression in LB was estimated at 80 mg/L). Typically a drop of 30-40% expression is 
observed in the laboratory upon change to MM for 15N labelling, however the drop in 
expression reported here is much lower. This is likely due to the addition of 13C labelling, 
where the 13C source is added to the MM at only half the quantity standard 12C source is 
added (this is due to cost; 13C D-glucose is around £150/g, and is required at 2 g/L).  
In addition to this drop in expression (if 50% cleavage is assumed as per reported for LB 
preparations, MM would yield ~1 mg/L cleaved peptide), peptide recovery from the 
overnight re-solubilisation step from MM expressions was very poor and not reproducible. 
It was found once cleaved the peptide adhered to the glassware and consumable plastic 
used, and cleaved peptide was also identified in the centrifuged KSI pellet. Analytical 






as was recovered from the supernatant fraction.  
It is likely that peptide expressed in LB, once cleaved, behaved similarly. A280 nm readings 
of RP-HPLC purified peptide from a 400 mL LB culture using the standard overnight re-
solubilisation technique gave an estimated peptide yield of 1.93 mg/L, a recovery rate of 
just 24% from total peptide expressed as fusion protein. For comparison, this method was 
used previously within the laboratory to produce the peptide A20fmdv2 (a 20-mer, 2.2 kDa 
in size) from LB cultures with an average yield of 16 mg/L (Wagstaff et al., 2010).  
RP-+3/& SXULILHG ¨-som peptide from LB cultures along with attempts to purify 
LVRWRSLFDOO\ HQULFKHG ¨-som from MM cultures is visualised by reducing peptide SDS-




Figure 2.7: 16% Reducing peptide SDS-3$*(DQDO\VLVRI¨-som purified from LB and MM cultures. 
Lane 1: Precision Plus protein marker, lanes 2-DQGȝJ53-+3/&SXULILHGUHFRPELQDQWǻ-som 
(from a 400 mL LB culture), lanes 6 and 7: ~10 and ~ ȝJ HTXLYDOHQW loads of soluble protein from 
overnight re-solubilisation step after cleavage (from a 400 mL MM culture- QR LGHQWLILDEOHǻ-som peptide 
present). Lanes 8 and 9: 5 and 10 ȝJV\QWKHWLFǻ-som peptide for comparison.  
 
Attempts were therefore directed to improving peptide separation from KSI after cleavage. 





denaturing 6 M GdnHCl EXIIHU WR VROXELOLVH ERWK WKH LQVROXEOH .6, SURWHLQ DQG ¨-som 
peptide. This was followed by serial dilution of the material from 6 M down to a 0.6 M 
GdnHCl buffer. KSI is highly insoluble in the absence of denaturant, and began dropping 
out of solution in samples containing <4 M GdnHCl. A280 nm values of the samples after 
centrifugation (to remove insoluble KSI) reported similar absorbances from samples 
containing <2.4 M GdnHCl, indicating that KSI was largely insoluble at these 
concentrations of denaturant, and composed the centrifuged pellet.  
Size exclusion chromatography under denaturing conditions was performed, using either 
2.4 M or 6 M GdnHCl buffers, in an attempt to resolve denatured peptide from the 
supernatant alone (2.4 M), or resolution of both peptide and solubilised KSI from the total 
re-suspension (6 M). Unfortunately the peptide did not appear to interact with the column 
matrix, and the peptide eluted in the column void volume along with KSI (shown in Figure 
2.8). This was confirmed using Dextran Blue (2 MDa) to determine the void volume of the 




Figure 2.8: Gel Filtration elution profile of cleaved KSI and ǻ-som using a 50 mL G-15 Superdex 
column under denaturing conditions (2.4 M GdnHCl). PJV\QWKHWLFDOO\SURGXFHG¨-som peptide (blue), 






Mass spectrometry collected using the soluble fraction of a 0.6 M GdnHCl buffer re-
suspension identified intact peptide, but the solution also contained a greater proportion of 
solubilised contaminants than was observed in samples re-suspended in PBS, indicating a 
size exclusion based separation step would still be preferable prior to RP-HPLC.  
After discussions with Mr. Kevin Howland (Biomolecular Science Facility Manager, 
University of Kent) it became evident that a dedicated RP-HPLC column would be 
required to purify peptides under denaturing conditions, as denaturants can alter the 
column retention time. In addition, Mr. Howland did not suggest purifying samples of the 
peptide on a RP-HPLC column if they had any possibility of containing solubilised KSI or 
KSI fragments, which could become insoluble upon removal of the denaturant in the 
mobile phase, thus blocking the column.  
This method was deemed impractical and an uneconomic use of stable isotopes to produce 
the quantity of isotopically enriched peptide as required for NMR. Consequently, attempts 
to produce recombinant peptide using an alternative fusion partner were made.  
2.3.2 ([SUHVVLRQ	3XULILFDWLRQRI¨-som from GB1 Fusions 
pET-D *%¨-som DNA with either enterokinase or Factor Xa cleavage sites were 
generated by undergraduate project students in Summer 2014 (please see Appendix 2.4 for 
sequencing). This DNA was transformed DVRXWOLQHGLQIRU.6,¨-som. Growth of E. 
coli cells with either insert produced white, uniform colonies on LB agar plates, and 
showed normal doubling times in LB. SDS-PAGE analysis of the induced cell lysate 
showed prominent bands for both overexpressed fusion proteins, which as anticipated were 
present in the soluble fraction (see Figure 2.9 for example expression and IMAC of GB1-
FXa-¨-som).  
Overexpression of the fusion protein in the post-induction pellet was observed as a single 
protein band, however an additional band appeared in the gel samples upon lysis at RT. 
These extra bands co-purified by IMAC chromatography (see Figure 2.9 (a) lanes 13-15), 
suggesting the new band could be a degraded form of the fusion protein, albeit with an 
intact His6-tag. It was imagined the fusion protein was targeted by proteases released upon 






Figure 2.9: 15% Reducing SDS-PAGE analysis of GB1-FXa-¨-som cell lysis and metal affinity 
chromatography at RT (a) and using protease inhibitors (b). Lane 1: Precision Plus protein marker, lane 
2: pre-induction cell pellet, lane 3: post-induction cell pellet, lane 4: total cell lysate, lane 5: lysis supernatant, 
lane 6: lysis pellet, lane 7: supernatant load flow through, lane 8: binding buffer flow through, lane 9: wash 
buffer flow through, lanes 10-15: fractions from strip buffer flow through. Proteolytic digest of the fusion 
protein is shown in (a), which appears to run at a larger MW (observed in lane 4 onwards).   
 
This addition was successful in inhibiting degradation observed by SDS-PAGE, and a 
single overexpressed band followed through lysis steps and IMAC chromatography for 
both fusion proteins (see Figure 2.9 (b)). It is unusual that the degraded fusion protein 
should run at a seemingly higher MW, however this phenomena was observed upon 
FOHDYDJHRIǻ-som from .6,IXVLRQVDQGDGGLWLRQDOO\XSRQFOHDYDJHRIǻ-som from intact 
GB1 fusions (see Figure 2.11). Whilst the use of protease inhibitors were shown to limit 
proteolysis, their addition would also complicate purification of the peptide downstream, 
as the inhibitors would need removing prior to cleavage of the fusion with the enzymes 





It was at this stage undergraduate project students took on the project. The students instead 
purified the fusion proteins by carrying out the lysis steps on ice, and using ice-cold buffers 
during IMAC chromatography to minimise any potential proteolytic activity, removing the 
requirement for protease inhibitors. Mass spectrometry of the purified GB1 fusions are 




Figure 2.10: Mass spectrometry analysis of GB1-FXa-¨-som (a) and GB1-enterokinase-¨-som (b) 
fusion proteins. Major species in (a) 10146.7 Da (expected 10147.0 Da) and in (b) 10279.7 Da (expected 





In both cases the major peak in each spectra identified the intact GB1 fusions at the correct 
MW: GB1-FXa-¨-som was identified as 10146.7 Da (expected MW 10147.0 Da) and 
GB1-Enterokinase-¨-som was identified as 10279.7 Da (expected MW 10280.0 Da). In 
addition, each spectra contained a +22 Da species, a sodium adduct commonly observed by 
LC-MS. Each spectra also identified a minor species of expected MW -422.4 Da, which 
corresponds to GB1¨-som ±FTSS (last four residues at C-terminus). This observation 
suggests that a minor degree of proteolysis is still occurring.    
Cleavage of the fusion proteins was carried out by the students using varying 
concentrations of protease. It was determined that either ȝJ/mL Factor Xa or 0.05 U/mL 
enterokinase resulted in efficient cleavage rates of the peptide from the GB1 fusion partner 
(>95% as determined by SDS-PAGE, Figure 2.11).   
 
 
Figure 2.11: 17% Reducing SDS-PAGE analysis of GB1¨-som cleavage by Factor Xa or enterokinase. 
Lane 1: protein ladder, lanes 2 + 4: GB1-enterokinase-¨-som pre-cleavage, lanes 3 + 5: GB1-enterokinase-¨-
som post-cleavage, lanes 6 +7: GB1-FXa-¨-som pre-cleavage, lane 8: GB1-FXa-¨-som post-cleavage. Note: 
a small proportion of degraded GB1-enterokinase-ǻ-som is clearly visible prior to cleavage with 
enterokinase.  As also observed in the expression of .6,¨-somWKH*%¨-som protein migrates at a lower 
MW, whilst cleaved GB1 protein migrates at a higher MW. Gel kindly reproduced from an undergraduate 
student report (Miss. Hannah Quinn).   
 
Analytical HPLC and mass spectrometry analysis of the cleaved mixtures was carried out 
and summarised results are shown in Figures 2.12 and 2.13. Please see Appendix 2.5 and 









Peak MW (Da) Sequence Identity Relative Intensity 
A 1083.56 Peptide (AGSKNFFWK-) 3.34% 
B 1184.61 Peptide (AGSKNFFWKT-) 4.17% 
C 1606.8 Intact ǻ-som 11.56% 




Figure 2.12+3/&WUDFHRI*%¨-som as cleaved by Factor Xa (a). Corresponding MW and relative 
intensities of each labelled peak are shown in (b). Specific and non-specific cleavage sites are denoted 
by black and red arrows respectively in (c). See Appendix 2.5 for supporting mass spectrometry of each 








Peak MW (Da) Sequence Identity Relative Intensity 
A 541.24 Peptide (-TFTSS) 3.45% 
B 1083.56 Peptide (AGSKNFFWK-) 6.27% 
C 740.37 Peptide (-NFFWK-) 8.13% 




Figure 2.13 +3/& WUDFH RI *%¨-som as cleaved by enterokinase (a). Corresponding MW and 
relative intensities of each labelled peak are shown in (b). Specific and non-specific cleavage sites are 
denoted by black and red arrows respectively in (c). See Appendix 2.6 for supporting mass spectrometry 
of each labelled peak. All peptides identified using Expasy Find Pept software 






LC-MS of the material cleaved with Factor Xa showed 80% composed of GB1 protein 
(peak D)ZKLOVWaZDVLGHQWLILHGDVLQWDFWǻ-som peptide (peak C). These values agree 
FORVHO\ ZLWK WKHRUHWLFDO \LHOGV ǻ-som constitutes 16% of the total fusion and GB1 
constitutes 84%). Two smaller peaks (A and B), together composing 7%, were also 
LGHQWLILHGDVǻ-som peptide fragments that had been correctly cleaved from GB1, but also 
cleaved after Lys and Thr residues (cleavage at this same Thr residue was observed in 
Figure 2.10- intact fusion protein before cleavage). The two peptide fragments therefore 
suggest that whilst cleavage by Factor Xa is highly specific, a small amount of proteolysis 
may still be occuring during the lysis and/or IMAC steps of GB1 fusion protein 
purification. 
LC-MS analysis of the material cleaved using enterokinase showed 82% of the mixture 
composed of GB1 protein (peak D), as expected. The peptide however was recovered as 
three partial fragments: ~8% NFFWK (peak C), ~6% AGSKNFFWK (peak B), and ~3% 
TFTSS (peak A). Therefore whilst successful cleavage of the fusion was achieved using 
enterokinase, the incubation appears to have led to cleavage at sites in the fusion other than 
the engineered cleavage site. This appears to have happened at lysine residues in the 
peptide sequence (see Figure 2.13 (c)). Whilst an unexpected result, a search of the 
literature showed it to be a previously published observation (Light and Janska, 1989), 
(Liew et al., 2005). It is also of note that the fusion protein pre-cleavage ran as multiple 
species by SDS-PAGE (see Figure 2.11), suggesting minor protein degradation may have 
additionally occurred before the enterokinase cleavage step. 
To summarise, Factor ;DFOHDYDJHKDVSURYHQWREHPRVWVXLWDEOHIRUFOHDYDJHRIǻ-som 
peptide from GB1 fusions, and GB1-FXa-ǻ-som fusion protein was successfully cleaved 
to yield 2.6 mg/L intact ǻ-som peptide. 
 
2.4 Discussion 
2.4.1 KSI Peptide Fusions 
The pET31b(+) KSI fusion system was initially used as the method for recombinant 
peptide production; the system has been used successfully within the laboratory to produce 





([SUHVVLRQRIWKH.6,¨-som fusion protein gave yields >80 mg/L culture in LB media, and 
>20 mg/L in minimal media, as estimated by SDS-PAGE analysis. 
Cleavage of the fusion protein by CNBr in formic acid cleaved with >90% efficiency, but 
mass spectrometry of the peptide showed the use of formic acid resulted in formylation of 
the peptide. Cleavage in an alternative TFA solution was less efficient, with around 50% 
efficiency after 24 hours (with longer incubations leading to degradation of the peptide). 
Attempts to purify the peptide after cleavage were met with difficulty; the cleaved peptide 
was found to adhere to KSI and/or the plastic and glassware, a problem that seemed 
magnified with material expressed in MM owing to the overall lower protein expression.  
Alternative attempts to purify the adherent peptide were made by denaturation of the 
cleaved material using GdnHCl EXW XSRQ SXULILFDWLRQ WKH ǻ-som peptide (synthetic and 
recombinant forms) was not found to interact with the size exclusion media. Depending 
upon supplier, there is a discrepancy as to the resolving limits of G-15 Sephadex media: 
GE (the original manufacturers and suppliers of this media) state on their website the 
dextran is capable RIUHVROYLQJSHSWLGHV!'D LQVL]H¨-som is 1.6 kDa and should 
therefore have been resolved). Contrastingly, Sigma state their G-15 Sephadex media is 
only suitable for resolving peptides that are 500 ± 1500 Da in size. A response from GE 
regarding this matter was not received, but it is possible the GE website should read <1500 
'D,WZDVQRWSRVVLEOHWRUHVROYH¨-som peptide using this media.   
The adherent property of the peptide may be a result of its high hydrophobicity; 
synthetically synthesised peptide was also poorly soluble and prone to aggregation in 
DTXHRXVEXIIHUVDWFRQFHQWUDWLRQV!P07RFLUFXPYHQW WKLVSUREOHPV\QWKHWLFǻ-som 
peptides were dissolved into 100% DMSO. It is interesting to note that previous success of 
this method was achieved within the laboratory for the expression of more hydrophilic 
peptides.  
Ultimately, this recombinant method was not deemed viable for the production of 
LVRWRSLFDOO\ HQULFKHG ǻ-som peptide, on account of peptide losses at the cleavage and 
recovery stages.  
2.4.2 GB1 Peptide Fusions 
The GB1 fusion system was trialled as a method for recombinant peptide production, in an 
attempt to circumvent the various problems that arose from using an insoluble fusion 





proteins gave yields >80 mg/L culture in LB media, with the fusion found exclusively 
within the soluble fraction (as determined by SDS-PAGE analysis). A combination of lysis 
steps carried out on ice and IMAC purification using ice-cold buffers somewhat limited the 
proteolysis observed when these steps were carried out at RT, and intact GB1 fusion 
protein was identified by mass spectrometry as composing >90% pooled IMAC fractions.  
Cleavage of the fusion proteins using varying concentrations of either enterokinase or FXa 
was trialled by the undergraduate students, and use of either 5 ȝJP/)DFWRU;DRU
U/mL enterokinase resulted in efficient cleavage rates of the peptide from the GB1 fusion 
(>95% as determined by SDS-PAGE).  
LC-MS analysis of the material cleaved using enterokinase showed the peptide was 
efficiently cleaved but was additionally cleaved at lysine residues within the peptide, to be 
recovered only as three small peptides. In contrast, material cleaved by Factor Xa showed 
intact peptide comprised 12% of the total cleaved sample.  
A small amount of proteolysis was still identified by SDS-PAGE and mass spectrometry 
prior to cleavage by Factor Xa. Protease inhibitors could be added to the lysis buffer to 
limit this proteolysis, however an additional purification step would be required to remove 
these inhibitors before the enzymatic cleavage, a step which conversely could lead to lower 
peptide yields.  
Nevertheless, assuming 100% cleavage by Factor Xa this is a peptide recovery rate of 
>70%, giving a final yield of 2.6 mg/L intact ǻ-som peptide.  
2.4.3 Overall Summary 
Initial attempts to purify ǻ-som peptide from an insoluble KSI fusion were met with 
limited success, despite several DWWHPSWVDWRSWLPLVDWLRQ7KHSURGXFWLRQRIǻ-som peptide 
was deemed crucial to achieve the aims of this thesis, as it is the model binding peptide of 
hPDI. This thesis instead employs the use of unlabelled and specifically fluorinated 
synthetic peptides, the latter of which can be produced for a moderately increased cost 
compared to unlabelled synthetic peptides.   
Meanwhile, work conducted by undergraduate students showed reasonable quantities of 
XQODEHOOHGǻ-som peptide could be purified from soluble GB1 fusions encoding a Factor 
Xa cleavage site. The purification of this fusion protein was shown to be successful in 
large LB culture scale-ups, and the peptide was easily isolated from the cleaved mixture to 
\LHOGDPRGHVWPJ/LQWDFWǻ-som peptide (compared to 1.9 mg/L from KSI fusions). 





mg/L are quoted (Koenig et al., 2003). Unfortunately whilst there was not time to develop 
and optimise this method further in LB or trial expression and cleavage using a defined 
minimal media, it is now hoped that a system is in place for future researchers to express 
and purify milligram quantities of isotopically enriched ¨-som peptide.  







CHAPTER 3  
 
Expression and Purification  




Biological studies of a protein by Nuclear Magnetic Resonance (NMR) typically require a 
highly pure, isotopically enriched sample of micromolar to millimolar concentration. 
Recombinant protein expression is a technique developed in the early 1970s, and today is 
widely used by scientists as a means of selectively overexpressing their protein of interest. 
A variety of different in vivo host strains have been developed, and examples of common 
cell hosts include bacteria (E. coli), yeast (S. cerevisiae, P. pastoris), insect (S. frugiperda) 
or mammalian cell lines (CHO (Chinese hamster ovary), HEK (human embryonal 
kidney)). It is also possible to selectively express proteins in vitro, using translation 
compatible whole-cell extracts (Sitaraman and Chatterjee, 2009) or by chemical synthesis 
(Nilsson et al., 2005). The cell host or expression system chosen is largely dependent on 
the type of protein to be expressed; for example, in the production of antibodies, 
expression in a mammalian cell line can prove vital for production of a correctly folded 
and post-translationally modified protein (Wurm, 2004). However, mammalian cell culture 
is both costly and labour intensive with relatively low yield, so is not always an appropriate 




or economic choice for protein expression. Chemical protein synthesis is better suited to 
small proteins and peptides, and whilst cell-free methods can allow for the stable isotopic 
protein labelling required, it is the E. coli bacterial expression system that is most widely 
exploited for expression of proteins for study by NMR. The bacteria grow rapidly in either 
rich or minimal media to a high density, generally with good protein yield and recovery 
(Baneyx, 1999). This expression system lends itself well to stable isotope labelling (e.g. 
13C or 15N) by growth in a minimal media using a sole 13C carbon and/or 15N nitrogen 
source. Recombinant proteins expressed this way can easily be engineered with small 
terminal extensions (such as a His6-tag) that can aid in affinity purification steps after cell 
lysis.  
3.1.1 E. coli Strains and Vectors  
For this project E. coli BL21 (DE3) pLysS cells were used for protein expression. BL21 
cells allow expression of genes under control of a T7 promoter, and are deficient in the 
proteases lon and ompT, making them suitable for stable protein expression (see 2.2.2 for 
further details). A modified form of the Novagen pET-23a(+) vector containing the coding 
sequence for a His6-tag upstream of the Nde1 site  was used for the expression of hPDI E¶[
and W111F DEE¶[. This construct was made and generously gifted by Prof. L Ruddock 
(University of Oulu, Finland) (see Appendix 2.2 and 3.1 for vector maps). 
WT hPDI DEE¶[ contains three Trp residues: 35Trp (heavily quenched by the adjacent 
active site in a domain), 111Trp (also in a domain), and 347Trp in the x-linker region (see 
Figures 1.2 and 7.2). The W111F mutant was initially designed as a probe for fluorescence 
that would report exclusively on the x-linker region of the protein. This mutant has been 
shown to be structurally unaffected by the substitution, and behaves in a similar manner to 
WT protein (Wang et al., 2010). With this in mind it was decided not to mutate W111F 
DEE¶[ back to WT protein. This thesis utilises selective fluorination of the Trp residues of 
DEE¶[, and 111Trp is buried within the protein, forming part of the hydrophobic core. 
Previous studies within the laboratory (Curtis-Marof et al., 2014) suggested that 
fluorination of this hidden Trp residue may impact upon protein folding (discussed further 
in Chapter 7).  
 




3.1.2 Protein Expression and Purification   
All proteins requiring isotopic enrichment for NMR were grown in a minimal medium 
containing 15N ammonium sulphate and/or 13C D-glucose as sole nitrogen and glucose 
sources respectively. Initial characterisation of the two proteins was carried out using 
protein expressed in LB media, and whilst overall protein yields were high the purified 
protein showed variable protein-dependent dimer formation, undesirable for NMR. Similar 
dimer formation also presented upon expression in a rich autoinduction media. Expression 
of the fragments in an unlabelled minimal media (MM) resulted in less dimer formation for 
both E¶[ and W111F DEE¶[. Any unlabelled protein for NMR was therefore expressed in 
MM using laboratory grade 14N ammonium sulphate and 12C D-glucose as nitrogen and 
glucose sources. 
After expression, the cells were lysed by an overnight freeze-thaw and treated with 
detergent and DNase. After lysis, the proteins were purified from the cell lysate 
supernatant using metal affinity chromatography. The proteins were desalted by overnight 
dialysis, and residual impurities were removed using anion exchange chromatography 
(theoretical pI of E¶[: 5.98 and W111F DEE¶[: 5.23). At this stage the proteins were of 
high purity, but existed as mixed monomer: dimer populations. They were separated using 
size exclusion chromatography, yielding highly pure (>95%) monomeric species suitable 
for NMR. In addition, analytical gel filtration was used to calculate each proteins 
hydrodynamic volume, and electrospray mass spectrometry was collected to accurately 
confirm the molecular weight and isotopic incorporation of W111F DEE¶[ (the E¶[ 
construct has been previously characterised (Byrne et al., 2009). 
 
3.2 Materials and Methods  
Unless stated otherwise all laboratory reagents were supplied by Sigma Aldrich 
(Gillingham, UK).  
3.2.1 Glycerol Stocks 
The E.coli strain BL21 (DE3) pLysS containing a pET-23a(+) vector with the coding 
sequences for the human PDI fragments  E¶[or W111F DEE¶[were used. Both sequences 




are expressed with an N-terminal His6-tag extension and residues 213Lys- 351Pro (E¶[) and 
1Asp- 351Pro (DEE¶[) of hPDI. The amino acid sequences of the expected recombinant 
products and relevant Expasy analysis are shown in Appendix 3.2.  
3.2.2 Bacterial Culture Media 
Glycerol stocks were streaked out onto fresh LB agar plates (10 g/L Tryptone, 5 g/L Yeast 
Extract, 10 J/1D&ODQGJ/$JDUZLWKDPSLFLOOLQȝJP/DQGFhloramphenicol 
ȝJP/DQG LQFXEDWHGRYHUQLJKWDW&)RU WKHSURGXFWLRQRI LVRWRSLFDOO\HQULFKHG
hPDI proteins, a minimal medium was used (see Table 3.1).  
 
Table 3.1: Components of minimal media. 
Component  
(stock concentrations) 




1. (NH4)2SO4 (x50) (15N)               30 g/L 
or (14N)            50 g/L 
20 mL Filter 4.51 mM 
7.57 mM 
2. PO4/NaCl (x10) Na2HPO4         68 g/L 
+KH2PO4         30 g/L 
+NaCl                5 g/L 
100 mL Autoclave 47.90 mM 
22.04 mM 
8.56 mM 
3. Na2SO4 (x1000)                      42.6 g/L 1 mL Autoclave 0.30 mM 
4. EDTA Trace  
Elements (x100) 
EDTA              10 g/L 
MnCl2                    3.2 g/L  
FeCl3                           1 g/L 
CuCl2                  20 mg/L 
CoCl2                  20 mg/L 
H3BO3                20 mg/L 
ZnCl2                  20 mg/L 







5. MgSO4 (x1000)                       246 g/L 1 mL Filter 2.04 mM 
6. CaCl2 (x1000)                      44.1 g/L 1 mL Filter 0.40 mM 
7. Biotin (x1000)                           1 g/L 1 mL Filter 4.09 µM 
8. Thiamine (x1000)                           1 g/L 1 mL Filter 3.77 µM 
9. D-Glucose (x50)  (13C)             100 g/L 
or (12C)          200 g/L      
20 mL Filter 10.74 mM 
22.20 mM 
10. MilliQ water  845 mL Autoclave  
Parts 2, 3 and 4 were added to an Erlenmeyer flask with the correct volume of MilliQ water (part 10) and 
autoclaved. All other components were filter sterilised, stored at 4¡C and added immediately prior to 
inoculation.     




PO4/NaCl, Na2SO4 and EDTA trace elements were added to the correct volume of MilliQ 
water in Erlenmeyer flasks 5 times the final media volume, sterilised by autoclaving, and 
stored at room temperature until required. All other minimal media components were made 
using MilliQ water (with the exception of Biotin, which was made in 50% ethanol 
VROXWLRQ DQG ILOWHU VWHULOLVHGXVLQJ DȝP0LQLVDUW VLQJOHXVH V\ULQJH ILOWHU VWRUHGDW
4¡C and added aseptically to the medium immediately prior to inoculation. MM promoted 
least dimer formation when compared to LB and autoinduction media, so was also used for 
unlabelled protein preparations, where (14NH4)2SO4 and 12C6H12O6 were used in place of 
their isotopic counterparts.  
3.2.3 Recombinant Protein Expression 
For main grows, starter cultures of 100 mL unlabelled MM ZLWKDPSLFLOOLQ ȝJP/
and cKORUDPSKHQLFROȝJP/ZHUHLQRFXODWHGXVLQJDVLQJOHFRORQ\IURPWKHRYHUQLJKW
plates. The starter was grown for 24 hrs at 37¡C with 200 rpm shaking, to an A600 of 
approximately 2.0 AU. The cells were then centrifuged in 50 mL falcon tubes at 3,220 g 
for 15 mins at 4¡C and the cell pellets re-suspended in 1-5 mL of fresh, sterile media. 
Each large main culture (up to 3 x 400 mL cultures from 1x 100 mL starter culture) was 
then inoculated from the starter culture re-suspension to give a starting A600 of 0.1 AU.  
With a doubling time of approximately 60 min, the cells were grown at 37¡C and 
monitored until they reached an A600 of 0.7 AU. They were then induced by the addition of 
1 mM IPTG (1 M stock). Optimised induction times that promoted greatest monomer 
formation were 2.5 hrs at 37¡C for E¶[, and overnight induction at 27¡C for W111F DEE¶[. 
After induction, the cells were cooled on ice for 5 mins and then harvested by 
centrifugation at 10,000 g for 10 mins at 4¡C. The cell pellets were then re-suspended in 
protein lysis buffer (20 mM sodium phosphate, 50 mM sodium chloride, pH 7.3) and 
stored at -20¡C until required (10 mL protein lysis buffer per each 400 mL of original 
culture pellet).   
3.2.4 Cell Lysis 
Previously frozen cells were thawed at RT. Each 10 mL re-suspended pellet (equivalent to 
P/RULJLQDOFXOWXUHYROXPHZDVWUHDWHGZLWKȝ/RI7ULWRQ;-100 (from a stock 
of 5% v/v in lysis buffer), gently mixed and left to incubate for 20 mins. This was followed 




E\WUHDWPHQWZLWKȝ/'1DVH,%RYLQHPJP/VWRFNDQGȝ/00J&O2 for a 
second incubation at RT for 20 mins. The lysate was then centrifuged at 10,000 g for 15 
mins at 4¡C and the supernatant carefully separated from the insoluble cell debris. Samples 
of the total cell lysate and supernatant were taken for reducing SDS-PAGE analysis.  
3.2.5 IMAC Chromatography 
This affinity purification step was carried out using Chelating Sepharose Fast Flow (GE 
Healthcare). The column was charged with nickel ions and the His6-tag proteins were 
eluted using EDTA, as outlined previously in 2.2.11. An equivalent of up to 800 mL 
original cell culture lysate was loaded per column, using multiple columns when scaling 
up.  
3.2.6 Dialysis 
Strip buffer fractions containing A280 nm >0.1 AU of hPDI protein were pooled, pipetted 
into dialysis tubing (12-14 kDa MWCO, Medicell International Ltd) and dialysed 
overnight using 2 L phosphate buffer (20 mM sodium phosphate, pH 7.3) at 4¡C with 
constant stirring.   
3.2.7 Anion Exchange Chromatography 
Anion exchange chromatography was carried out on the desalted proteins using a Source 
4FROXPQP/&9ȝPVL]HEHDGV*(+HDOWKFDUHconnected to an KTA FPLC 
analyser (GE Healthcare). The column was stored at RT in de-gassed 20% (v/v) ethanol, 
and equilibrated for use with a cycle of 10 CV buffer A (20 mM sodium phosphate, pH 
7.3, de-gassed), 10 CV buffer B (20 mM sodium phosphate, 0.5 M NaCl, pH 7.3, de-
gassed), followed by a second 10 CV of buffer A. A total protein amount of up to 800 mL 
HTXLYDOHQWRULJLQDOFXOWXUHZDVILOWHUHGXVLQJDȝP0LQLVDUWVLQJOHXVHV\ULQJHILOWHUDQG
loaded onto the column using a 50 mL injection superloop. The protein was eluted from 
the column with an increasing salt gradient using buffer B from 0-100% in 20 CV at a flow 
rate of 5 mL/min, collected in 2mL fractions and monitored using absorbance at 280 nm. A 
cut-off of higher than 0.1 AU at A280 nm was again used to select fractions for reducing 
SDS and native-PAGE analysis and were pooled for size exclusion chromatography. After 
use the anion exchange column was washed using 10 CV of de-gassed 20% (v/v) ethanol 
and stored at RT for future use. 




3.2.8 Size Exclusion Chromatography 
Both preparative and analytical size exclusion chromatography were carried out on pooled 
proteins from anion exchange using a 300 mL CV of Superdex 200 medium, a matrix of 
cross-linked dextran and agarose (GE Healthcare). The column was stored at RT in de-
gassed 20% ethanol, and equilibrated overnight using 1.5 CV de-gassed running buffer (20 
mM sodium phosphate, 150 mM NaCl, pH 7.3).   
For preparative size exclusion chromatography, pooled protein from a single anion 
exchange run was concentrated to a volume of approximately 1 mL using a Vivaspin 20 
Centrifugal Filter (10 kDa MWCO, Sartorius), and loaded onto the column under gravity 
flow using a three way tap. The protein was eluted using 1.5 CV of running buffer at a 
flow rate of 2 mL/min, collected in 5 mL fractions and monitored using absorbance at 280 
nm. After use the column was washed using 1.5 CV of de-gassed 20% (v/v) ethanol and 
stored at RT for future use. 
For analytical size exclusion chromatography, the column was calibrated using 1 mg each 
of Cytochrome C (12.4 kDa), Carbonic Anhydrase (29 kDa), Bovine Serum Albumin (66 
kDa), Alcohol Dehydrogenase (15N'DDQGȕ$P\ODVH N'D MW Gel Filtration 
Marker Kit 12,000-200,000 Da). An additional 1 mg of Apoferritin (443 kDa) was also 
used, and 1 mg Dextran Blue (2 MDa) to determine the void volume of the column.    
3.2.9 Gels: Reducing SDS-PAGE and Native-PAGE 
Reducing SDS-PAGE and native-PAGE gels were used at all stages to assess and confirm 
expression, lysis and subsequent purification steps of the proteins. 
Reducing SDS-PAGE gels were prepared, run and stained as previously outlined in 2.2.7.  
Native-PAGE gels were also prepared using the Tris-Glycine buffer system, with a 12.5% 
w/v resolving gel (pH 8.3) and no stacking gel. The gel recipe follows those in Table 2.1, 
RPLWWLQJ WKHVRGLXPGRGHF\O VXOSKDWH 6'6DQGVXEVWLWXWLQJZLWKȝ/0LOOL4ZDWHU
The gel samples were prepared using 4x non-reducing sample buffer (as previously 
described for SDS-PAGE but without SDS and DTT, and no heat incubation). Each lane 
ZDV ORDGHGZLWKȝ/ VDPSOH DQGJHOVZHUH UXQQHJDWLYH WRSRVLWLYH WKHRUHWLFDO S,RI
both proteins is lower than pH 8.3) in 1x TG gel running buffer (TGS buffer with SDS 




omitted), at 12 mA for 4-6 hrs. Native gels were stained, de-stained and dried as for SDS-
PAGE gels.       
3.2.10 Concentration Determination  
Protein absorbance was measured throughout the purification process using an Ultrospec 
2000 UV/Visible Spectrophotometer (Pharmacia Biotech) and a suitable buffer blank at a 
wavelength of 280 nm. Protein amino acid sequences were submitted to ExPASy 
ProtParam (http://web.expasy.org/protparam/) to calculate extinction coefficients, and 
molar protein concentrations were calculated using the Beer-Lambert Law. The extinction 
coefficient of E¶[ was 8,605 M-1cm-1 and for W111F DEE¶[ was 24,660 M-1cm-1.  
3.2.11 Mass Determination and Isotope Incorporation   
The molecular weight of unlabelled and isotopically enriched monomeric W111F DEE¶[ 
protein was determined using Electrospray Mass Spectrometry, performed by Kevin 
Howland, Biomolecular Science Facility Manager, University of Kent. 
 
3.3 Results  
3.3.1 Expression of E¶[ and W111F DEE¶[ 
Expression of E. coli BL21 (DE3) pLysS with hPDI construct inserts produced white 
uniform colonies on LB agar plates and showed  doubling times of approximately 30 min 
in LB medium and 60 min in minimal medium. After induction both fragments were 
processed using the same lysis and purification protocol, and the following results show 
expression and purification of 15N labelled E¶[ and W111F DEE¶[ protein.  
3.3.2 IMAC Chromatography 
Both hPDI fragments were expressed as soluble proteins (as shown in Figure 3.1). By 
comparison with the Precision Plus protein standards, the 17 kDa E¶[protein runs with a 
molecular weight around 15 kDa, and W111F DEE¶[ also runs smaller than expected with 
an apparent molecular weight between 25 and 37 kDa (actually 41 kDa). Purification by 
His6-tag affinity successfully removed the majority of contaminating proteins from the 




lysate supernatant, but some higher and lower molecular weight impurities were still 




Figure 3.1: 12.5% reducing SDS-PAGE analysis of E¶[(a) and W111F DEE¶[ (b): expression, lysis and 
IMAC chromatography. Lane 1: Precision Plus protein marker, lane 2: pre-induction cell pellet, lane 3: 
post-induction cell pellet, lane 4: total cell lysate, lane 5: lysis supernatant, lane 6: lysis pellet, lane 7: 
supernatant load flow through, lane 8: binding buffer flow through, lane 9: wash buffer flow through, lanes 









3.3.3 Anion Exchange Chromatography 
Anion exchange chromatography was successful in removing a large number of the 
remaining impurities from the protein samples. E¶[ began eluting upon 8% Buffer B, and 
W111F DEE¶[ slightly later at 27% Buffer B (see Figure 3.2). The chromatogram shows a 
single but non symmetrical peak for E¶[ and multiple elution peaks for W111F DEE¶[, both 
suggestive of the presence of multiple purified species. Fractions across the peaks from 
both proteins were run on reducing SDS and native-PAGE gels (Figure 3.3) for analysis.  
     
 
 
Figure 3.2: Anion exchange profile of 800 mL equivalent culture volume E¶[ and W111F DEE¶[ protein 
using a 5 mL Source 30Q Column. The UV absorbance at 280 nm is coloured blue (E¶[) or red (DEE¶[) and 
the conductivity is shown in green.  
 
Reducing SDS-PAGE analysis (Figure 3.3 (a) and (b)) of the peaks showed a single 
species for both proteins; however native-PAGE of each protein yielded two distinct 
species (Figure 3.3 (c) and (d)). It is well documented that hPDI fragments containing the  
E¶ domain form homodimers (Wallis et al., 2009), therefore it is likely that the peaks 
correspond to monomer and dimer species.  




In the case of W111F DEE¶[ native-PAGE shows the monomer elutes first before the 
dimer (Figure 3.3 (d)), and anion exchange provided adequate resolution to pool largely 
monomer fractions. The E¶[ peak however is an unresolved mixture of monomer and 
dimer protein (with a small proportion of another species) (Figure 3.3 (c)), so the entire 
peak was pooled for size-based separation of the two species by size exclusion 
chromatography.    
  
Figure 3.3: 12.5% Reducing SDS-PAGE analysis of anion exchange fractions of E¶[ (a) and W111F 
DEE¶[ (b). Native-PAGE analysis of corresponding samples of E¶[ (c) and W111F DEE¶[ (d). Lane 1: 
Precision Plus protein marker (gels (a) and (b) only), lanes 2-10 in (a) are fractions across the anion exchange 
peak (50-80 mL), and lanes 2-15 in (b) are fractions across the two anion exchange peaks (70-100 mL), as 
shown in Figure 3.2. Numbered lanes in (c) and (d) correspond to the samples run in lanes in (a) and (b). 
Lane * in (c) is purified monomeric E¶[ protein for comparison.   
 
3.3.4 Size Exclusion Chromatography 
Preparative Size Exclusion- The anion exchange peak fractions containing monomer 
protein were pooled, concentrated by ultrafiltration and loaded in 1 mL volumes onto the 




Superdex 200 column. Both proteins eluted in two distinct peaks. A typical elution profile 
of E¶[ and W111F DEE¶[ is shown in Figure 3.4. W111F DEE¶[ monomer was simplest to 
isolate from its dimer species upon anion exchange, thus the protein elutes largely as 
monomer on size exclusion, with a minor dimer peak. Elution of E¶[ varied depending on 
preparation; it was found that higher protein expression yields generated a larger fraction 
of dimer upon purification.  
 
 
Figure 3.4: Size exclusion chromatography profile of 800 mL equivalent culture volume E¶[ and 
W111F DEE¶[ protein using a 300 mL Superdex 200 Column. Monomer peak fractions were pooled for 
NMR studies. The UV absorbance at 280 nm is coloured blue (E¶[) or red (DEE¶[) and the conductivity is 
shown in green. 
 
Analytical Size Exclusion- To determine the molecular weight of each protein species the 
size exclusion column was calibrated using a set of protein standards to generate a 
calibration curve, plotted as Kav, the gel phase distribution coefficient, versus log MW. The 
Kav of each protein was determined using equation 3.1: 




3.1          ܭୟ୴ ൌ ௏೐ି௏బ௏೎ି௏బ 
Where Ve is the peak elution volume, V0 is the void volume (as determined by Dextran 
Blue), and Vc is the geometric column volume. The standard calibration curve was then 
used to determine the molecular weight of each proteins monomer and dimer species (see 
Figure 3.5). Molecular weight calculations from the calibrated curve show that 15N E¶[ 
monomer behaves as a protein with a slightly larger (12.4%) hydrodynamic volume than 





Figure 3.5: Size exclusion column calibration curve. The standard proteins used are represented by black 
circles. 15N labelled E¶[ is a yellow (monomer) or green (dimer) cross, and 15N W111F DEE¶[ is a red 








Table 3.2: Expected and measured molecular weights of 15N E¶[ and 15N W111F DEE¶[. 
The expected molecular weights were calculated based on amino acid sequence and assuming 98.9% 15N 
incorporation (see section 3.3.5). The measured molecular weights were obtained using the size exclusion 
column calibration curve in Fig 3.5. 
 
The largest molecular weight peaks visualised on size exclusion chromatography are 
approximately double the molecular weight of their corresponding monomer species, 
strongly suggesting dimer forms of the two proteins. However, both protein dimers ran 
larger than expected- E¶[ 12.5% larger and the W111F DEE¶[ dimer 5.7% larger. 
Sample Stability on Storage- The rate of conversion of monomer to dimer was studied for 
each protein at different storage temperatures (4oC, -20oC and -80oC). 1 mL aliquots of 
purified monomeric protein at 1 mg/mL in NMR buffer (20 mM sodium phosphate, 50 
mM NaCl, pH 7.0) were either flash frozen on liquid nitrogen and stored at -80¡C, or 
transferred to a -20¡C freezer. After 1 week of storage E¶[ was present largely in a dimeric 
form, regardless of the storage temperature. W111F DEE¶[ also formed a large proportion 
of dimer after storage for 1 week at -20¡C, but remained predominantly monomeric after 
storage for the same length of time at -80¡C. Only a small amount of dimer was observed, 
although a new smaller molecular weight peak was also present, suggesting possible 
degradation of the protein (see Figure 3.6). W111F DEE¶[ was stable in its monomeric 
form after weekly storage at 4϶C at concentrations of <1 mM, and E¶[ at concentrations 
<0.4 mM (higher concentrations promoted dimer formation as determined by size 
exclusion). As a result of these findings, protein was expressed and purified immediately 
prior to each NMR experiment, with minimal storage time at 4϶C only, for optimal protein 
spectra. 
 
hPDI Fragment Oligomeric State Expected MW (Da) Measured MW (Da) 




















Figure 3.6: Size exclusion profile of 1 mg W111F DEE¶[ protein using a 300 mL Superdex 200 Column. 
The blue trace was freshly purified monomeric W111F DEE¶[, the red trace W111F DEE¶[ stored at -20¡C for 
1 week, and the green trace W111F DEE¶[ stored at -80¡C for 1 week.  
 
3.3.5 Mass Determination and Isotopic Incorporation by Mass Spectrometry  
The E¶[ construct has been worked on extensively within the laboratory, and the 
monomeric protein mass previously determined (Byrne et al., 2009). Therefore in this 
thesis only mass spectrometry analysis of W111F DEE¶[ was carried out.   
The predicted molecular weight of W111F DEE¶[ + His6-tag (as determined from its amino 
acid sequence) is 40534.7 Da. Mass spectrometry analysis confirmed the protein has a 
molecular weight of 40534.0 Da; the 0.7 Da difference is well within the 0.01% error range 
of analysis (+ 4.05 Da). There was also an additional species present in the sample, 
corresponding WRDPDVVLQFUHDVHRI'DVHH)LJXUH7KLVLVFRQVLVWHQWZLWKDQĮ-
N-6-phosphogluconoylation of the His6-tag, a modification documented in recombinant 
proteins that should not affect the recombinant protein (Geoghegan et al., 1999). The 
modification is present in both the unlabelled and 15N labelled protein samples (see Figure 
3.8).  




The major species present in 15N labelled W111F DEE¶[ protein has a molecular weight of 
41004.4 Da. The mass change for 100% 15N incorporation would be +475 Da; therefore the 
mass spectrometry analysis reports an incorporation extent of 98.9%.   
 
Figure 3.7: Mass spectrometry analysis of unlabelled W111F DEE¶[.  
 
Figure 3.8: Mass spectrometry analysis of 15N labelled W111F DEE¶[.  
 
3.3.6 Final Yields 
Accurate monomeric protein yields were determined using A280 values of pooled size 
exclusion chromatography fractions against a buffer blank. Total yields of monomeric E¶[ 




and W111F DEE¶[ protein are summarised in tables 3.3 and 3.4. An overnight induction of 
E¶[ at 27¡C was trialled, as was growth of both proteins in an auto-induction media. Both 
resulted in a marked increase in dimer formation where the dimer was the major species 
seen on size exclusion. Overnight expression of W111F DEE¶[ at 27¡C, and expression of 
E¶[ for 2.5 hrs at 37¡C were found to be optimal expression conditions; whilst this resulted 
in slightly lower overall protein expression levels, subsequent purification showed the 
highest ratio of monomer to dimer protein, simplifying purification and decreasing the risk 
of purifying a heterogeneous protein sample for NMR.  
A drop in expression is always expected when switching from a rich (LB) to a defined 
(minimal) media, similarly a drop is seen between 15N labelling and 15N/13C labelling, on 
account of only using 1 g/L 13C source in place of a 2 g/L 12C source.  
 







Table 3.4: Average total yields of monomeric W111F DEE¶[ from varying expression conditions as 
purified by size exclusion chromatography.  
 3 hour induction at 
37oC 
12 hour induction at 
27oC 
abb'x  Yield (mg/L) Yield (mg/L) 
LB 54 (significant dimer present)  63 (significant dimer present) 
Unlabelled Minimal - 42 
15N Minimal 18 38 
15N/13C Minimal - 10 
 
 2.5 hour induction at 37oC 
b'x Yield (mg/L) 
LB 30 (significant dimer present) 
Unlabelled Minimal 19 
15N Minimal 21 
15N/13C Minimal 11 




3.4 Discussion  
Both E¶[ and W111F DEE¶[ were expressed as soluble proteins in rich and minimal media. 
The His6-tagged proteins were readily purified by metal affinity chromatography from the 
majority of other contaminating soluble E.coli proteins. Second-step purification using 
anion exchange chromatography generated a broad, single asymmetrical peak for E¶[ and 
two separate peaks for W111F DEE¶[. Both elution profiles were suggestive of multiple 
conformational forms. It has been previously published that hPDI fragments containing the 
E¶ domain form non-covalent homodimers (Wallis et al., 2009), (Byrne et al., 2009) so this 
result was not unexpected. As such, samples from across both elution profiles ran as single 
species on reducing SDS-PAGE, however by native-PAGE two distinct species were 
observed. Whilst some separation of W111F DEE¶[ monomer/dimer was achieved at this 
stage, a further purification step of size exclusion chromatography was necessary to 
sufficiently separate the monomer and dimer forms of both proteins.  
The molecular weights of the monomer and dimer species as determined by analytical size 
exclusion chromatography generally agreed with the expected molecular weights. Both E¶[ 
monomer and dimer ran on average 12.5% larger than expected. Full length hPDI is also 
published as having an anomalously large elution profile on gel filtration (Li et al., 2006), 
on account of its open and elliptical conformation. W111F DEE¶[ monomer and dimer 
molecular weights agreed more closely with the expected values, with the monomer 
behaving 7% smaller and the dimer 5% larger. This suggests that W111F DEE¶[ monomer 
may exist in a more compact state compared to full-length hPDI, before adopting a more 
similar open conformation upon dimerization. 
Mass spectrometry of the W111F DEE¶[ monomer protein confirmed a correct mass 
(40,534 Da) and mass spectrometry of 15N labelled protein showed a good incorporation 
rate of 98.9%. Both unlabelled and 15N labelled protein showed a minor species with a 
 'D PDVV LQFUHDVH 7KLV PRGLILFDWLRQ LV FRQVLVWHQW ZLWK DQ Į-N-6-
phosphogluconoylation of the His6-tag (Geoghegan et al., 1999),WZDVQ¶WVKRZQWRDIIHFW
metal affinity chromatography purification of the protein, and the minor modified species 
was not resolvable from unmodified protein using size exclusion chromatography, on 
account of its comparatively small mass increase. Analysis of the modification was not 




pursued further. It is a well-documented modification, and like the His6-tag itself is not 
likely to adversely impact upon protein structure or activity.  
Final yields of monomer from both proteins were dependent on both growth medium and 
expression conditions. Both proteins gave lowest overall protein yields using minimal 
media; conversely this media also gave the highest monomer proportions. Induction for 2.5 
hours at 37¡C for E¶[ and overnight expression at 27¡C for W111F DEE¶[ gave the highest 
purified monomer yields. It may be that upon over expression in rich media (where 
expression rates are faster), the recombinant protein builds up to an overall higher 
concentration, and is therefore more likely to form stable dimers.  It is likely that these 
dimers are present from the point of cell lysis. 
It is interesting to note that, with exception of 15N/13C labelled protein, W111F DEE¶[ 
monomer yields were approximately double that of monomeric E¶[, thought to be partly 
due to a greater monomer yield of W111F DEE¶[ at the onset of protein purification. 
W111F DEE¶[ was also more easily resolved from its dimeric form, both by anion 
exchange chromatography and size exclusion chromatography (for size exclusion this is 
likely due to the larger MW difference between monomer and dimer protein). A more 
suitable narrow-range size exclusion media could be sourced to increase separation of the 
monomer and dimer species of E¶[, and so increase the overall monomeric yield.       
In vivo, hPDI exists in a monomer:dimer equilibrium, a ratio that is thought to be 
influenced by the number of PDI substrates present within the ER at a given time. 
Dimerisation of hPDI renders the two hydrophobic ligand binding sites inaccessible to mis-
folded ligands, thus reducing PDI activity (for a recent review and structure of the dimer 
interface see (Bastos-Aristizabal et al., 2014a). In vitro hPDI forms dimers at high, but still 
physiological concentrations- as is reported in this Chapter. Unfortunately purified dimer is 
of little use in a laboratory setting, as it cannot be returned to its monomeric form. It is 
highly preferable that only homogenous, monomeric samples be taken forward for analysis 
using NMR spectroscopy, particularly if the dimeric protein shows reduced activity.   
Both overall monomeric protein yields and the storage and stability experiments suggest 
that of the two hPDI fragments, W111F DEE¶[ is more stable in a monomeric form at 
higher concentrations (dimerisation was promoted by storage for 1 week at 4϶C at 
concentrations >1mM W111F DEE¶[  and >0.4mM E¶[). The differing results show that 




when handling hPDI fragments their propensity to form dimers is something to be mindful 
of, particularly when running multi-dimensional NMR experiments, which can span time 












Assignment of hPDI E¶[ and  
W111F DEE¶[ by NMR Spectroscopy 
 
4.1 Introduction  
Protein assignment by NMR spectroscopy allows identification and correlation of each 
active NMR nuclei within a protein. Specific 15N and 13C labelling techniques are exploited 
WRDOORZVHTXHQWLDODVVLJQPHQWRIDSURWHLQ¶VEDFNERQHDQGRUVLGH-chain (Wthrich, 1986). 
The approach relies upon each residue of the protein displaying a distinctive spin system- 
first each spin system is identified, then correlations between these systems are matched by 
use of a set of through-bond triple resonance experiments, to assign adjacent spin systems 
that correspond to amino acids sequential in primary sequence. The method is well used 
and reviewed, and allows the assignment of even large proteins in a relatively short period 
of time (Frueh, 2014; Gbl et al., 2014). NMR backbone and side-chain assignments can 
be used to accurately map changes in the protein in response to temperature, pH, protein 
redox state, or upon addition of other components to the system such as a binding ligand.           
This thesis focuses on two fragments of hPDI: E¶[ and DEE¶[. E¶[ is the smallest 
monomeric fragment of hPDI required for peptide ligand binding, and the W111F DEE¶[ 
fragment whilst also capable of peptide ligand binding also contains a redox active 




catalytic site in its a domain. The W111F DEE¶[ fragment has been used previously in 
fluorescence and limited proteolysis studies (Wang et al., 2010a), but NMR assignment of 
the protein fragment was not carried out as part of this work. Characterisation of the E¶[ 
fragment has previously been undertaken (Byrne et al., 2009; Nguyen et al., 2008).  
Work in this thesis showed each protein gave optimal spectra at 37¡C, and due to 
significant differences in the spectra of the E¶[ protein to previously assigned spectra 
(resonances were collected under differing temperature and buffer conditions), triple 
resonance backbone assignments of both protein fragments was carried out. In addition to 
this, methyl side-chain assignments were also made for the E¶[ fragment. These 
assignments enabled the investigation of peptide ligand binding in the presence or absence 
of neighbouring domains to the E¶ domain, or under different protein redox states, as 
discussed in subsequent Chapters.        
4.1.1 15N,1H-HSQC Experiments  
The 15N,1H-Heteronuclear Single Quantum Correlation (HSQC) is often the first two-
dimensional NMR experiment performed on a biological protein. It is a 2D experiment that 
is optimised to show correlations between 1H directly bonded to NMR active 15N nuclei. 
The large majority of peaks visible will be the backbone amide groups, so one peak will be 
visible for each amino acid residue, with the omission of Pro residues (which do not have 
an amide proton for the correlation to be detected). Peaks can also be seen for Trp indole 
groups, and under acidic conditions the side chain groups of Asn and Gln. A 15N,1H-HSQC 
can be used to give general information about the protein quality- for example, if the 
protein is folded, and if the temperature and pH parameters are optimal. A 15N,1H-HSQC 
assigned using triple resonance experiments can inform on changes to the chemical 
environment that particular residues sense upon redox change or peptide ligand binding.  
4.1.2 13C,1H-HSQC Experiments  
The 13C,1H-Heteronuclear Single Quantum Correlation (HSQC) experiment is the carbon 
equivalent of the 15N,1H-HSQC. It is another 2D experiment that is optimised to show all 
C-H correlations, between 1H directly bonded to NMR active 13C nuclei. Each carbon 
chemical environment can be observed in a specific area of the spectrum (see Figure 4.1) 




and the 13C,1H-HSQC can be used much like a 15N,1H-HSQC, to report on protein status or 




Figure 4.1: 13C,1H-HSQC spectra of 0.25mM 13C E¶[. Specific C-H chemical groups are highlighted. 
Tetramethylsilane (Si(CH3)4) is used as a reference (0 ppm), as eash of its protons are equivalent and highly 
shielded. Protons in CH3, CH2 and CH groups become progressively more de-shielded, becoming more 
exposed to the magnetic field and hence display a chemical shift >0 ppm. Aromatic CH protons typically 
show the largest chemical shifts as the delocalised electrons in the benzene ring cause the nuclei to 
experience a stronger magnetic field.    
 
4.1.3 Chemical Shift Perturbation Mapping  
Chemical shift perturbation mapping is a method routinely used to measure sensitive 
changes in a protein; these perturbations report on the extent of shielding or de-shielding of 
the observed QXFOHL7KH\DUHPHDVXUHGXVLQJWKHµFKHPLFDOVKLIW¶PHDVXUHGLQSDUWVSHU
PLOOLRQSSPµSSP¶LVDYDOXHSURSRUWLRQDOWRWKHSHDNSRVLWLRQLQ+]WKDWDOVRIDFWRUVLQ




the spectrometer frequency, allowing shifts to be directly compared independently of the 
spectrometer field strength. In this thesis they are used to show changes that occur from a 
change in temperature, redox state or upon addition of a binding ligand/protein.  
15N,1H-HSQCs are perhaps the most widely used spectra in biological NMR to track 
changes in a protein via chemical shift perturbation; each chemical shift reports on the 
unique chemical environment that a given backbone amide experiences in the protein. 
These chemical shifts can be mapped onto a protein sequence or structure to highlight 
specific residues involved in the event. For 1H and 15N nuclei, perturbations can be 
influenced by both through bond or through space interactions. It is also important to 
emphasise that chemical shift perturbations are exclusively reporting on a change in 
chemical environment. This means that in the case of ligand binding, the perturbations can 
either report directly upon the ligand binding event itself, or if the protein undergoes a 
structural re-arrangement upon binding, then alternatively the induced conformational 
change the protein experiences as well.  
13C chemical shift perturbations are also used within this thesis to study ligand binding in 
more detail. Carbon chemical shifts are increasingly being used to monitor ligand binding, 
because 13C nuclei are less sensitive to structural changes in the protein, and should 
therefore be more sensitive reporters of direct ligand-binding events (Williamson, 2013). 
The study in this thesis focuses on the methyl region of the 13C,1H-HSQC, as these 
chemical groups form the hydrophobic side-chains of the aliphatic amino acids alanine, 
threonine, valine, leucine and isoleucine. Aliphatic residues are scattered throughout the 
E¶[ protein core, but also compose a large proportion of the hydrophobic binding site. 
7KHVH PHWK\O µUHSRUWHUV¶ RI OLJDQG ELQGLQJ DUH XVHG WR JLYH PRUH VSHFLILF LQIRUPDWLRQ
about residues involved in the binding event.   
4.1.4 Sequential Backbone Assignment of E¶[ and W111F DEE¶[ by Triple Resonance 
Triple resonance experiments typically allow a large percentage of the 1HN, 15N, 13CĮ and 
13Cȕ protein resonances to be unambiguously assigned. Assignment by 
HNCACB/HN(CO)CACB or HNCA/HN(CO)CA experiments were carried out using 
15N/13C isotopically enriched samples of E¶[ or W111F DEE¶[ to aid in backbone 
assignment of the protein fragments. A backbone assignment allows each N-H peak in a 
15N,1H- HSQC to be assigned to a specific amino acid residue. Triple resonance 




experiments generate 1H, 13C and 15N shifts for each residue, which with suitable software 
can be viewed in such a way that any given amide 1H and 15N correlation contains either 
the 13C resonances of the correlated residue and its sequentially preceding residue, denoted 
DVµL¶DQGµL-¶+1&$&%DQG+1&$RUMXVWWKH 13C resonance of  the preceding residue 
µL-¶+1&2&$+1&2&$&%7KHH[SHULPHQWVDUHQDPHGIRUWKHW\SHRIFRUUHODWLRQV
they detect, and Figure 4.2 demonstrates how these correlations are linked for the 




Figure 4.2: Dipeptide assignment of a protein backbone showing correlations obtained in HNCACB 
and HN(CO)CACB experiments. +1&$&%FRUUHODWHVHDFK1+VWULSZLWKWKH&ĮDQG&ȕVKLIWVRILWVRZQ
residue (i) and that of the preceding (i-1) residue (shown in purple). HN(CO)CACB correlates each NH strip 
with just the preceding (i-1) residues CĮ and Cȕ shifts (shown in green). HNCA and HN(CO)CA experiments 
correlate shifts in the same manner, with omission of the Cȕ shifts.  
 
Large proteins tend to give poorer NMR spectra as a result of slower molecular tumbling. 
HNCA (Kay et al., 1990) and HN(CO)CA (Bax and Ikura, 1991) experiments were used to 
assign the W111F DEE¶[ backbone; these experiments are typically used for proteins >150 
residues, and give the same information as the HNCACB and HN(CO)CACB, with the 
omission of Cȕ resonances.    




The data from each triple resonance experiment was analysed using CcpNmr Analysis 
software, which ranks each data strip in order of best fit. The analysis relies upon 
characteristic carbon chemical shifts of each amino acid, which are assigned based on the 
random coil chemical shifts of amino acids (Wishart et al., 1995b). There are generally 
VHYHUDOPDWFKLQJµVWULSV¶VRWKHILWVFDQILUVWEHPDQXDOO\DVVLJQHGXVLQJWKHFKDUDFWHULVWLF
chemical shift patterns of alanine, glycine, serine and threonine CĮ and/or Cȕ resonances 
(see Figure 4.3), to assign small sequential sequences of the amino acid chain. After initial 
unambiguous assignment of small lengths of the protein, the segments can be lengthened 
and pieced together after other potential matches have been eliminated. Assignments can 




)LJXUH  5DQGRP FRLO FKHPLFDO VKLIWVIRU &Į   DQG &ȕ  ) resonances. Adapted from data 
published by Wishart and Sykes (1994). 
 
4.1.5 Secondary Structure Prediction  
The CcpNMR Analysis software contains an inbuilt programme called DANGLE 
(Dihedral Angles from Global Likelihood Estimates), that can be used for secondary 
structure predictions of proteins from their assigned resonances (Cheung et al., 2010). It 
uses an algorithm that can predict the most likely secondary structure of a protein, by 




factoring in the amino acid type and its corresponding chemical shift in relation to its 
neighbouring residues. Protein backbones tend to adopt regular structural arrangements 
that are defined by dihedral angles, specific angles of rotation about the N-&ĮERQGV ݊ 
Phi) and C-&ĮERQGVȥ3VL%DFNERQHVHFRQGDU\Vtructures and their angles are typically 




Figure 4.4: A Ramachandran plot representation. The illustration (a) shows the Phi angles (݊) between N-
&ĮERQGVDQGWKH3VLDQJOHVȥEHWZHHQ&-&ĮERQGV7\SLFDODQJOHVRIHDFKVHFRQGDU\VWUXFWXUHW\SHDUH
highlighted on the graph in grey (b). L-H (left-handed) and R-H (right-handed).      
 
4.1.6 Sequential Side-Chain Assignment: HCCH-TOCSY  
The HCCH-TOCSY experiment, along with backbone CĮ and Cȕ assignments, allows the 
side-chain resonances of a protein to be assigned. It uses 13C enriched protein and works by 
transferring magnetisation from side-chain 1H nuclei to the attached 13C nuclei, and then 
back to 1H for detection. In each CH strip, all of the side chain 1H resonances of that 
residue are potentially visible. Using the CĮ and Cȕ shifts of the backbone assignment, 
there will be a point that lies on the diagonal of the spectrum that has the same proton 
chemical shift and a distinctive strip of shifts. By navigating to these shifts, assignment of 
WKH+ĮDQG+ȕUHVRQDQFHVLVSRVVLEOH8VLQJUHIHUHQFHUDQGRPFRLOSURWRQFKHPLFDOVKLIWV




as a guide (sHH)LJXUHWKHDVVLJQPHQWRIWKH+Ȗ+įDQG+İUHVRQDQFHVRIWKHVWULSLV
also possible, and can be subsequently mapped onto the 13C,1H-HSQC. The HCCH-
TOCSY was used to unambiguously assign the 13C,1H-HSQC methyl region of E¶[ in the 
absence and presence of ligand, to highlight hydrophobic side-chains that may be involved 




)LJXUH  3URWRQ UDQGRP FRLO FRQIRUPDWLRQ FKHPLFDO VKLIWV IRU +1 +Į +ȕ +Ȗ +į DQG +İ
resonances. Residues along the x-axis in bold contain CH3 groups to be assigned. Shifts adapted from 
(Wishart et al., 1995a). 
 
4.2 Materials and Methods  
4.2.1 NMR Sample Preparation  
Monomeric protein isotopically labelled and purified as outlined in Chapter 3 was buffer 
exchanged into NMR buffer (20 mM sodium phosphate, 50 mM NaCl, pH 7.0) using a 
Vivaspin 20 Centrifugal Filter (10 kDa MWCO, Sartorius) and then concentrated down 
into stocks to use as required (concentration determined by A280 nm absorbance). Typical 
samples contained 0.1-1 mM protein, 5% D2O and 0.05% sodium azide, and for W111F 
DEE¶[ an excess of reducing/oxidising agent. Deuterated samples were prepared in the 




same manner by using a deuterated NMR buffer (20 mM sodium phosphate and 50 mM 
NaCl in D22S+6DPSOHVZHUHPDGHXS WR D WRWDO YROXPHRIȝ/XVLQJ105
buffer in a sterile eppendorf, before being transferred to a 5mm Shigemi NMR tube (BMS-
005V, Sigma).  
4.2.2 NMR Data Acquisition and Processing 
NMR data was acquired with the assistance of Drs. Mark Howard and Michelle Rowe at 
the University of Kent using a 4-channel, 5-amplifier Bruker Avance III 14.1 T (600MHz 
1H) NMR spectrometer equipped with a 5mm QCI-F cryoprobe, except where stated. All 
NMR experiments were solvent suppressed using either WATERGATE suppression by 
GrAdient-Tailored Excitation (Piotto et al., 1992) or excitation sculpting (Hwang and 
Shaka, 1995) to reduce the water signal intensity. All experiments were carried out at 
37¡C, pH 7.0 unless stated otherwise. 1H chemical shift referencing was carried out using 
the position of the 1H2O resonance at the given temperature. 15N and 13C chemical shifts 
were referenced using spectrometer internal referencing but also confirmed or modified 
using the gyromagnetic ratio relationship (Wishart and Sykes, 1994).  
All 1D data was processed using Bruker Topspin 3.2 software, and 2D and 3D NMR data 
was processed using NMRPipe software (Delaglio et al., 1995).  
4.2.2.1 15N,1H-HSQC Experiments of hPDI E¶[ and W111F DEE¶[ 
15N,1H-HSQC spectra were collected of each protein fragment over 45 mins with 2048 
points in the F2 (1H) dimension and 256 points in the F1 dimension (15N). Assigned 
15N,1H-HSQC spectra are used throughout this thesis to observe the effect of temperature 
or redox state, and in subsequent chapters to monitor peptide ligand binding. Reduced or 
oxidised spectra of W111F DEE¶[ were acquired using a 10x molar excess of either DTT or 
GSSG respectively. Temperature experiments were carried out using samples of reduced 
W111F DEE¶[ and spectra collected at 25, 27.5, 30, 32.5, 35 and 37¡C. Temperature 
titrations were also used to enable the assignment of W111F DEE¶[ spectra at 25¡C, to 
allow its comparison to other assigned hPDI spectra. Temperature experiments were 
carried out using samples of reduced E¶[ and spectra collected at 10, 15, 20, 25, 30, 35 and 
37¡C.  
 




4.2.2.2 13C,1H-HSQC Experiments of hPDI E¶[ 
13C,1H-HSQC spectra of 0.4 mM E¶[ were acquired over 90 mins with 2048 points in the 
F2 dimension (1H) and 512 points in the F1 dimension (13C) in deuterated NMR buffer. 
Assigned 13C,1H-HSQC spectra were used in subsequent chapters to monitor peptide 
ligand binding. 
4.2.2.3 Sequential Backbone Assignment of E¶[ and W111F DEE¶[  
E¶[Triple Resonance: Backbone resonance assignments were collected using a 0.4 mM 
13C/15N labelled sample of E¶[. Triple resonance datasets HNCACB and HN(CO)CACB 
were acquired with 2048 points in the F3 dimension (1H), 32 points in the F2 dimension 
(15N) and 256 points in the F1 dimension (13C).  
W111F DEE¶[ Triple Resonance: Backbone resonance assignments were collected using a 
0.4 mM 13C/15N labelled sample of W111F DEE¶[. Triple resonance datasets HNCA and 
HN(CO)CA were acquired with 2048 points in the F3 dimension (1H), 40 points in the F2 
dimension (15N) and 128 points in the F1 dimension (13C). Carrier frequencies for 
experiments were set to 4.586 ppm for 1H, 41.521 ppm for 13C and 117.868 ppm for 15N.      
4.2.2.4 Sequential Side-Chain Assignment of E¶[ 
Side-chain resonance assignments were collected using a 0.4 mM 13C/15N labelled sample 
of E¶[. HCCH-TOCSY spectra were acquired with 1024 points in the F3 dimension (1H), 
60 points in the F2 dimension (15N) and 256 points in the F1 dimension (13C) in deuterated 
NMR buffer. Carrier frequencies for experiments were set to 4.586 ppm for 1H, 45.919 
ppm for 13C and 119.454 ppm for 15N.  
4.2.3 NMR Data Analysis 
Analysis of 2D and 3D spectra was carried out using CcpNmr Analysis software Version 2 
(Vranken et al., 2005).  
4.2.3.1 Triple Resonance Backbone and Side-Chain Assignments 
Sequential backbone assignment of E¶[ and W111F DEE¶[ was achieved using triple 
resonance datasets, assigned as outlined in the introduction of this chapter, using random 




coil chemical shifts (starting with the characteristic resonances of alanine, glycine, serine 
and threonine) as determined by Wishart et al. (Wishart et al., 1995b). 
4.2.3.2 Minimal Chemical Shift Perturbation Mapping  
Chemical shift perturbation mapping was used to identify changes to specific residues of 
the protein upon a change in chemical environment (in this instance changes in reduced or 
oxidised protein). Minimal chemical shift perturbations are used to compare peaks from a 
fully assigned spectrum with the nearest peaks in a related but unassigned spectrum. This 
is useful when spectra are sufficiently different that unassigned peaks from a spectrum 
cannot be unambiguously identified from nearest neighbouring peaks of an assigned 
spectrum. One such example was the significant shift or line broadening changes observed 
as a result of oxidising W111F DEE¶[and comparing this to the assigned spectrum from 
the reduced protein.  Minimal chemical shifts can sometimes be an underestimation of true 
shifts occurring, but require assignment of only one spectrum.  
Minimal chemical shift perturbations were calculated using equation 4.1:- 
 
:KHUH¨1HN DQG¨15N are the chemical shift perturbations (ppm) of a peak in the 1HN and 
15N dimensions respectively. The minimal change in chemical shift perturbation was 
plotted graphically against residue number. 15N shifts are weighted by 1/6 their actual size, 
to compensate for the large chemical shift range they report over when compared to proton 
chemical shifts; the chemical shift range of 15N is ~30 ppm compared to 1HN ~5 ppm.      
4.2.3.3 Secondary Structure Predictions of E¶[ and W111F DEE¶[ 
Using the 1HN, 15N, and 13CĮ chemical shifts obtained from triple resonance experiments of 
E¶[ and W111F DEE¶[, Ramachandran plots of each residue were generated using 
&FS105$QDO\VLVVRIWZDUH¶VLQEXLOW'$1*/(SURJUDPPH'LKHGUDO$QJOHVIURP*OREDO
Likelihood Estimates). This software takes chemical shift assignments and compares them 
against a database of published protein structures and their chemical shifts, to generate a 
likely prediction of secondary structure. The software analyses the population distribution 




expected for each specific residue (for example glycine has much greater conformational 
freedom (݊ DQGȥ WKDQPRVW UHVLGXHVVRFDQDSSHDURYHUD ODUJHUUDQJHRIUHJLRQV WKDQ
shown by Figure 4.4). Prediction limits were set such that any residue with several 
predicted ݊ȥDQJOHUHJLRQVZDVH[FOXGHGIURPWKHVHFRQGDU\SUHGLFWLRQ(DFKUHVLdue was 
DVVLJQHGDOLNHO\VHFRQGDU\VWUXFWXUHWKDWZDVHLWKHUUDQGRPFRLOȕ-VWUDQGRUĮ-helix.    
 
4.3 Results  
4.3.1 Effect of Redox State on W111F DEE¶[ 
Preliminary NMR studies of W111F DEE¶[ showed that the protein is folded, stable and 
gives fair spectra at 37¡C. Spectra were collected for oxidised and reduced protein at pH 
7.0 using a 10x molar excess of GSSG or DTTred respectively (see Figure 4.6). The 
reduced form of the protein (Figure 4.6 (b)) gave a greater number of well-resolved peaks 
when compared to the oxidised spectra (Figure 4.6 (a)), therefore triple resonance 
experiments were carried out using the reduced form of W111F DEE¶[.    






Figure 4.6: 15N,1H-HSQC spectra of 0.25mM W111F DEE¶[ + 5 mM GSSG (a) or + 5 mM DTTred (b). 
Resolution and number of peaks improves when the protein is in a reduced form.  
 
4.3.2 Sequential Backbone Assignment of Reduced W111F DEE¶[ 
Sequential backbone assignments of the 1HN, 15NH, and 13CĮ nuclei of W111F DEE¶[ were 
made using the triple resonance experiments HNCA and HN(CO)CA. Sequential 
assignments were made by using the characteristic shifts of residues such as glycine, serine 
RU WKUHRQLQH WKHQ µZDONLQJ¶ WKURXJK WR WKH next residue. A typical example of the 
sequential assignment process is shown in Figure 4.7 for A55-I60. Ignoring the His6-tag 




and unassignable Pro residues, backbone assignments were made for 68% of the amide 
1H,15N and 13CĮ resonances (see Appendix 4.1 for assignment tables). Triple resonance 
assignments were transferred onto a 15N,1H-HSQC of W111F DEE¶[ (as shown in Figure 




Figure 4.7: Protein backbone triple resonance sequential assignment example of W111F DEE¶[ . HNCA 
(purple) and HN(CO)CA (green) strips demonstrating the assignment stretch for residues A55 to I60. 
Sequential matches between the strips are shown by dotted lines. The corresponding 15N chemical shift of 
each plane is shown above each strip (ppm).  




Figure 4.8: 15N,1H-HSQC spectra of W111F DEE¶[(37¡C). All assignable amide and indole resonances are 
labelled on the spectra. Triple resonance experiments HNCA and HN(CO)CA were run using fully reduced 
protein. 




4.3.3 Effect of Temperature on W111F DEE¶[ 
Within the laboratory larger multi-domain fragments of hPDI (>30kDa) are typically 
studied at 37¡C, as this temperature yields spectra with greatest peak resolution. Smaller 
individual domains have typically been assigned at 25¡C. To enable comparison of the 
W111F DEE¶[ fragment of hPDI with other individual domain assignments, 15N,1H-HSQC 
spectra were collected of the protein at 37¡C, 35¡C, 32.5¡C, 30¡C, 27.5¡C and 25¡C 
(spectra shown in Figure 4.9). Temperature dependent shifts could then be tracked 
throughout the titration series to assign the spectra at 25¡C (see Figure 4.10) to 63% of the 
backbone amide 1H and 15N resonances.  
 
Figure 4.9: Temperature titration 15N,1H-HSQC spectra of W111F DEE¶[. Spectra collected at 37¡C (a), 
35¡C (b), 32.5¡C (c), 30¡C (d), 27.5¡C (e) and 25¡C (f) allowed assignments of W111F abE¶[ at 37¡C to be 
mapped onto spectra at 25¡C, for comparison with individual domain spectra.  





Figure 4.9: 15N,1H-HSQC spectra of W111F DEE¶[(25¡C). All assignable amide and indole resonances are 
labelled on the spectra. Assignments were mapped onto the protein using a titration series of temperatures 
DQGDVVLJQPHQWVPDGHDW&µ;¶VGHQRWHDVVLJQPHQWVWKDWDUHYLVLEOHORZHULQWKHQRLVHOHYHO 




4.3.4 Sequential Backbone Assignment of E¶[ 
The E¶[ fragment of hPDI has previously been assigned at pH 6.5 and 25¡C. As shown 
previously within the laboratory, observed protein chemical shifts of W111F DEE¶[ 
fragment are highly sensitive to temperature, and a direct transfer of previously assigned 





Figure 4.11 Overlaid 15N,1H-HSQC spectra of E¶[pH 7.0 and 37¡C (blue), and E¶[at pH 6.5 and 25¡C 
(red).  (Referencing was based on 1H carrier positions of 4.72 ppm at 25϶C and 4.586 ppm at 37϶C). 
 
To allow a direct comparison of the W111F DEE¶[ and E¶[ fragments at 37¡C, sequential 
backbone assignments of the 1HN, 15NH, 13CĮ and 13Cȕ nuclei were made using the triple 
resonance experiments HNCACB and HN(CO)CACB. Ignoring the His6-tag and 
unassignable Pro residues, backbone assignments were made for 85% of the amide 1H and 
15N, and 76% of the 13CĮ and 13Cȕ resonances (see Appendix 4.2 for assignment tables). 
Sequential assignments were made by using the characteristic shifts of residues such as 
VHULQHWKUHRQLQHDODQLQHDQGJO\FLQHWKHQµZDONLQJ¶WKURXJKWRWKHQH[WUHVLGXH$W\SLFDO




example of the sequential assignment process is shown in Figure 4.12. Triple resonance 




Figure 4.12: Protein backbone triple resonance sequential assignment example of E¶[ . HNCACB and 
HN(CO)CACB strips demonstrating the assignment stretch for residues L255 to T260. The HNCACB shows 
CĮ  (purple) and Cȕ \HOORZUHVRQDQFHVRIWKHµL¶DQGµL-¶UHVLGXHVDQGWKH+1&2&$&%VSHFWUDVKRZV
the resonances of just the CĮ  and Cȕ µL-¶UHVLGXHVJUHHQ6HTXHQWLal matches between strips are shown by 
dashed lines. The corresponding 15N chemical shift of each plane is shown above each strip. Please note that 
S256 is missing its Cȕ, so in this instance could only be followed by its CĮ resonance (all Gly residues had 
already been assigned). 





Figure 4.13: 15N,1H-HSQC spectra of E¶[(37¡C). All assignable amide and indole resonances are labelled 
on the spectra. Assignments were made using the HNCACB/HN(CO)CACB pair of triple resonance 
experiments.  




4.3.5 Side-Chain Assignment of E¶[ 
Methyl 13C side-chain assignments of the alanine, threonine, valine, leucine and isoleucine 
resonances of E¶[ were made using the HCCH-TOCSY experiment, in addition to the 
triple resonance backbone assignments. 13&&ĮDQG&ȕDVVLJQPHnts could be linked to the 
HCCH-72&6<WRDVVLJQWKH+ĮDQG+ȕUHVRQDQFHVDQGVXEVHTXHQWO\WKH+Ȗ+įDQG+İ
resonances, using the random proton chemical shifts as illustrated in Figure 4.5. A typical 
example of strips used in the assignment process is shown in Figure 4.14 for residue I334. 
Side-chain assignments were made for 89% of the methyl 1H and 13C resonances (see 
Appendix 4.3 for assignment tables). Figure 4.15 shows the assigned 13C,1H-HSQC methyl 




Figure 4.14: Example C-+µVWULSV¶VKRZLQJFRUUHODWLRQVREWDLQHGLQWKH+&&+-TOCSY experiment of 
334Ile. HCCH-TOCSY correlates all proton resonances bound to a particular 13C nucleus. The corresponding 
13C chemical shift of each plane is shown to the right of each strip. 
 
 






Figure 4.15: 13C,1H-HSQC spectra of E¶[ (a) and methyl region (b). Assignable methyl resonances (as 
highlighted by the dashed box in (a)) are labelled on the methyl region in (b).  




4.3.6 Secondary Structure Predictions of E¶[ and W111F DEE¶[ 
The 1HN, 15N and 13CĮ and/or 13Cȕ assignments of E¶[ and W111F DEE¶[ were used for 
VHFRQGDU\VWUXFWXUHSUHGLFWLRQE\'$1*/(7KHSURJUDPPHSUHGLFWHGWKH3VLȥDQG3KL
(݊) angles along with the most likely secondary structure of each amino acid, generating 
three possible outcomes: random coil, strand or helix. Typical Ramachandran plot 
examples of W111F DEE¶[ are shown in Figure 4.16 for residues S171, G233, D277 and 
E313. Angles predicted for a single location (Figure 4.16 (a) and (c)) weUHDVVLJQHGDVȕ-
VWUDQGDQGĮ-helix respectively. When two islands of angles were present (Figure 4.16 (b)) 
a random coil was assigned. Residues that generated more than two islands of angles 
(Figure 4.16 (d)) were not included in the secondary structure prediction.  
 
 
Figure 4.16: Example of secondary structure prediction of W111F DEE¶[ as generated by DANGLE. 
6SUHGLFWHGDVȕ-VWUDQGD*SUHGLFWHGDVFRLOE'SUHGLFWHGDVĮ-helix (c) and E313 excluded 
from secondary structure calculation as multiple island locations were present (d). 




The secondary structure predictions for E¶[ and W111F DEE¶[, with the corresponding 
region of the reduced hPDI DEE¶[D¶ crystal structure (4EKZ.pdb) for comparison, are 
shown in Figure 4.17 and Figure 4.18 respectively. DANGLE was successful in predicting 
secondary structure of both E¶[ and W111F DEE¶[, with the predicted structures in overall 
agreement with the published crystal structure of near full-length protein. 
Small differences were seen in the W111F DEE¶[ structure predictions and the crystal 
VWUXFWXUH DQ DGGLWLRQDO Į-KHOL[ DQG ȕ-strand in the a GRPDLQ DQG VPDOO ȕ-strands at the 
start of the b domain and end of the E¶ domain, which were present only in the crystal 
structure. These secondary structure elements were not predicted from the triple resonance 
data due to missing assignments of these stretches by NMR. Additionally, no secondary 
structure of the x-linker was predicted for either fragment, thought to be due in part to the 
linker regions low assignment (56%), caused by its conformational activity in solution.     
 
 
Figure 4.17: Backbone assignments and predicted secondary structure of E¶[. The E¶[ predicted 
secondary structure sequence is shown in purple, with the corresponding sequence of reduced DEE¶[D¶ crystal 
VWUXFWXUH(.=SGEIRUFRPSDULVRQVKRZQLQEOXHȕ-VWUDQGVWUXFWXUHLVGHQRWHGE\DUURZVDQGĮ-helices by 
cylinders. Domain boundaries are E¶ (P218-G332) in orange and x-linker (K333-P351) in blue. Residues that 
could not be assigned as a result of ambiguous or missing triple resonance data are highlighted in the primary 
sequence in purple. Residues not included in the secondary structure predictions due to their ݊ DQGȥDQJOHV
mapping to more than two clusters are shown underlined.    





Figure 4.18: Backbone assignments and predicted secondary structure of W111F DEE¶[. The W111F 
DEE¶[predicted secondary structure sequence is shown in red, with the corresponding sequence of reduced 
DEE¶[D¶ FU\VWDOVWUXFWXUH(.=SGEIRUFRPSDULVRQLQEOXHȕ-VWUDQGVWUXFWXUHLVGHQRWHGE\DUURZVDQGĮ-
helices by cylinders. Domain boundaries are a (D7-G117) in purple, b (A119-Q216) in yellow, E¶ (P218-
G332) in orange and x-linker (K333-P351) in blue. Residues that could not be assigned as a result of 
ambiguous or missing triple resonance data are highlighted in the primary sequence in red. Residues not 
included in the secondary structure predictions due to their ݊ aQGȥDQJOHVPDSSLQJWRPRUHWKDQWZRFOXVWHUV
are shown underlined.    




 4.4 Discussion  
4.4.1 Effect of Redox State on W111F DEE¶[ 
15N,1H-HSQC spectra of either fully reduced or oxidised W111F DEE¶[ were collected as 
outlined in 4.2.2. Spectrum differences were pronounced, with the oxidised spectra 
displaying far fewer peaks with an overall poorer resolution. The majority of peaks visible 
in oxidised protein spectra were located within the narrow random coil chemical shift 
range (8.0-8.5 ppm), with dispersed resonances that are indicative of structure in the 
reduced protein appearing at a much lower intensity in the oxidised spectra. The two 
spectra shown in Figure 4.6 suggest that in its oxidised state W111F DEE¶[ is subject to 
significant line broadening, such that many residues do not appear in the spectrum. Much 
like other hPDI fragments, the reduced form of the protein gives rise to well-resolved 
peaks and suggests more conformational stability under the NMR conditions used. Overall 
these spectra confirm that the reduced form of W111F DEE¶[ protein is better suited for 
assignment by NMR triple resonance experiments, with the protein showing a greater 
resolution and peak number when compared to its oxidised counterpart.   
It is published that hPDI DEE¶[D¶ undergoes significant structural change upon 
reduction/oxidation, with the reduced form of protein adopting a more compact 
conformation (Wang et al., 2013). Wang et al. determined that it is the E¶[D¶ region of 
DEE¶[D¶ that exhibits greatest structural change upon reduction/oxidation. This is in direct 
contrast to yPDI, where the EE¶region is rigid, and the a domain is most flexible (Tian et 
al., 2008). Figure 4.19 shows minimal chemical shift perturbations of reduced and oxidised 
W111F DEE¶[ protein, and highlights shifting residues of varying magnitude throughout 
the entire protein. This work indicates that in solution all domains of W111F DEE¶[ are 
perturbed by changing redox state, however the majority of shifting residues comprise the 
redox active a domain. Minimal chemical shift perturbation mapping can underestimate the 
true extent that resonances move, as it maps shifts of assigned residues to the next nearest 
resonance. Hence large shifts can be underestimated if the true chemical shift change is of 
considerable magnitude or in a crowded region of the spectra.  
 





 Figure 4.19: Minimal chemical shift perturbation map of reduced and oxidised W111F DEE¶[ protein 




In agreement with Wang et al. findings are the NMR solution assignments discussed next 
in section 4.4.2. The E¶[ portion of W111F DEE¶[ presented the greatest number of 
unassigned resonances- 48% of its resonances were unassignable (48% of E¶ and 44% of 
the x-linker), compared to an average of 23% of ab resonances (23% in a and 22% in b 
domain).  
105 VSHFWURVFRS\ VKRZV DQ µDYHUDJH¶ RI DOO SRVVLEOH FRQIRUPDWLRQV D SURWHLQ DGRSWV
meaning that a residue can exist as a single peak, or if in slow exchange can appear as 
multiple peaks, that may broaden out or disappear as the exchange rate increases, 
preventing their correct assignment in solution. It is entirely possible that the unassigned 
resonances of the E¶ domain and x-linker region exhibit the highest shifts upon change in 
redox state. 
4.4.2 Sequential Backbone Assignment of Reduced W111F DEE¶[ 
NMR backbone assignments of W111F DEE¶[ were completed to assign the 15N,1H-HSQC 
spectra to 68%, as shown in section 4.3.2. HNCA and HN(CO)CA triple resonance 
experiments were used to correlate 1H and 15N with the CĮ nuclei of the i and i-1 residues. 
The assignments correspond to 77% of a domain, 78% of b domain, 52% of E¶ domain and 
56% of the x-linker region (see Appendix 4.1 for assignment tables). Given the size of 
W111F DEE¶[ protein (40.5 kDa), predictably there were several cases of ambiguity in the 
triple resonance data, leading to several unassignable resonances.           
Furthermore, triple resonance assignment of the backbone also confirms that W347 indole 
is present in two distinct chemical environments, as seen in spectra of the E¶[ fragment 
(Byrne et al., 2009). This suggests the x-linker of W111F DEE¶[ also exhibits a capped and 
uncapped conformation (see Figure 4.20).  
 






Figure 4.20: Overlaid 15N,1H-HSQC spectra of E¶[ (red) and W111F DEE¶[ (blue) tryptophan indole 
NH region. 
 
Figure 4.18 shows the primary amino acid sequence of W111F DEE¶[ with the residues 
that could not be assigned as either a result of ambiguous or missing triple resonance data 
highlighted in red. Additional assignments could have been made from the ambiguous 
data, if additional Cȕ triple resonances had been collected, to remove such ambiguity. This 
data was not collected however, due to the size of W111F DEE¶[; as protein increase in 
molecular weight, their associated correlation times in solution become longer, which has 
the effect of increasing the nuclear transverse relaxation rate. This rate is proportional to 
the NMR resonance line width and so this series of proportionalities explains increasing 
line broadening with molecular weight. Cȕ resonances would likely broaden out to such an 
extent that many would be absent from the triple resonance data collected. This limitation 
can be resolved by running triple resonance experiments using a triple-labelled 
(15N,13C,2H-labelled) protein sample. Deuteration using D2O in place of H2O removes 
around 70-80% of sidechain 1H, improving the relaxation rate and thus the spectral quality 
(LeMaster, 1990).  
It was apparent from the triple resonance data that there are several regions of W111F 
DEE¶[ that were unassignable because of missing resonances in the HNCA/HN(CO)CA 




experiment pair, most notably in the E¶[ portion of the protein. Missing stretches included 
K259-F265 and I272-T279 of E¶ domain, and P336-P344 of the x-linker. Absence of these 
residues are likely to be due to the conformational exchange exhibited when in solution, as 
previously documented at Kent when assigning the E¶[ fragment (Byrne et al., 2009b).  
Due to the high cost of generating a deuterated sample, together with the conformational 
exchange seen of the E¶[fragment, it was decided not to proceed with deuteration, and that 
the achieved backbone assignments would be sufficient for planned NMR studies.    
4.4.3 Effect of Temperature on W111F DEE¶[ 
Previous studies of E¶[ and other hPDI domains within our laboratory show small hPDI 
fragments give fair spectra at 25¡C, with the E¶[ fragment previously assigned at this 
temperature (Byrne et al., 2009b). Spectra of W111F DEE¶[ collected at 25¡C were poor, 
with considerable peak broadening and reduced signal intensity, due to both the size of the 
fragment and the increased viscosity of water at lower temperatures. In light of this, all 
subsequent spectra and triple resonance data were instead collected at 37¡C. Running 
experiments at an increased temperature can narrow peak lines and boost signal, whilst 
also more closely mimicking physiological conditions. Additonally, studies by Wang et al. 
on WT DEE¶[ showed the fragment displays lower chaperone activity at 20¡C compared to 
40¡C (Wang et al., 2010), something not shown by full-length hPDI. They suggest this is 
because at low temperatures DEE¶[ exists as a predominantly capped form, with ligand 
having to compete more strongly with the x-linker to bind- an event that is thought to be 
limited by the presence of D¶ domain in full-length hPDI. This is interesting to note, 
because spectra of W111F DEE¶[ collected for this thesis at 25¡C still show defined 
µFDSSHG¶DQGµXQFDSSHG¶UHVRQances of the x-linker residue W347, as did spectra of E¶[ 
collected as low as 10¡C (shown in Figure 4.21).    
Nevertheless, higher temperatures can shift the NMR timescale to show molecules in fast 
exchange, meaning conformational exchange rates will be increased. This is particularly 
significant for E¶[ and W111F DEE¶[, as it may promote the rate of capping and uncapping 
of the x-linker region to E¶ domain, to facilitate ligand binding.  
The assignments for W111F DEE¶[ carried out at 37¡C were mapped onto the spectrum of 
the protein collected at 25¡C for comparison with previous single domain assignments 




collected at the lower temperature. 92% of the backbone assignments made at 37¡C could 
be mapped onto the spectrum at 25¡C, however this is only 63% of all possible assignable 
resonances. This limited the comparison of W111F DEE¶[ at 25¡C with previously 





Figure 4.21: Overlaid 15N,1H-HSQC indole region E¶[ collected at 37, 35, 30, 25, 20, 15 and 10¡C (E¶[) 
and W111F DEE¶[ collected at 37, 35, 32.5, 30, 27.5 and 25¡C. The figure highlights the presence of capped 
and uncapped W347 forms at all temperatures.  
 
4.4.4 Sequential Backbone and Methyl Side-Chain Assignment of E¶[ 
Backbone Assignment: As mentioned in 4.4.3, W111F DEE¶[ gives best spectra at 37¡C. 
Spectra of E¶[ collected at 37¡C were sufficiently different to the previously assigned 
spectra within the laboratory (collected at pH 6.5 and 25¡C), highlighting sensitive pH and 
temperature-mediated perturbations of several resonances. Therefore NMR backbone 
assignments of E¶[ were also completed to assign the 15N,1H-HSQC spectra. 




HNCACB and HN(CO)CACB triple resonance experiments were used to successfully 
assign the 15N,1H-HSQC spectra to 85%, by correlating 1H and 15N resonances with the CĮ 
and Cȕ nuclei of the i and i-1 residues, as shown in section 4.3.2 (see Appendix 4.2 for 
assignment tables). This additional information improved assignment of the E¶ domain to 
89% (compared to just 52% assignment of E¶ in W111F DEE¶[). In comparison to W111F 
DEE¶[, there were fewer ambiguous assignments, in part due to the collection of the 
additional Cȕ resonances, but also the smaller size of E¶[ meant fewer overlapping 
resonances. Figure 4.17 shows the amino acid sequence of E¶[ with the residues that could 
not be assigned, as either a result of ambiguous or missing triple resonance data, 
highlighted in purple.  
A 56% assignment of the x-linker region of E¶[ directly supports W111F DEE¶[ 
assignment of the x-linker (also to 56%), and previous published data of E¶[ (Byrne et al., 
2009) with the largest unassigned stretch of the protein again being P336-E345 of the x-
linker region. This was due to missing resonances in the triple resonance data, thought to 
be due to the high conformational activity the x-linker region displays in solution.  
Side-chain Assignment: 13C methyl side-chains were assigned to more accurately probe 
direct ligand-binding events of the protein, by allowing detailed assignment of the 
hydrophobic ligand binding site. As mentioned previously, the 15N amide backbone 
assignments whilst being easier to collect are more limited to reporting on changes of the 
protein backbone, and are also more sensitive to induced structural changes the protein 
experiences than sidechain 13C nuclei are. This work was carried out on the smaller E¶[ 
fragment of hPDI; it is only 18.5 kDa in size, giving good resolution of individual peaks in 
a 13C,1H-HSQC spectra. In addition to this, both CĮ and Cȕ data were collected on E¶[, and 
the backbone was assigned to a higher degree, allowing a more complete assignment of 
E¶[ sidechains than would have been achievable using the larger W111F DEE¶[ fragment. 
Of the 66 assignable methyl sidechains of all alanine, threonine, valine, leucine and 
LVROHXFLQH UHVLGXHV SUHYLRXVO\ µEDFNERQH¶ DVVLJQHG LQ WKH 15N,1H-HSQC, 89% were 
assigned using the HCCH-TOCSY, by correlating all 1H resonances attached to each 13C 
nuclei, as explained in section 4.1.6 (see Appendix 4.3 for assignment tables). The majority 
of the 11% unassigned methyl resonances comprised the published ligand binding site.  
 




4.4.5 Secondary Structure Predictions of E¶[ and W111F DEE¶[ by DANGLE  
The DANGLE secondary structure predictions of E¶[ and W111F DEE¶[ both agree with 
one another, and also closely match the secondary structure seen in the crystal structure of 
DEE¶[D¶ published by Wang et al. (Wang et al., 2013). 
Prediction for the W111F DEE¶[ fragment, where overall backbone assignment was lower, 
yielded several stretches of unassigned residues, leaving DANGLE unable to accurately 
predict these regions (see Figure 4.18). There were several small differences between the 
structure predictions of this fragment and the DEE¶[D¶ crystal structure. These include the 
DGGLWLRQ RI WKUHH VPDOO ȕ-VWUDQGV DQG DQ Į-helix that are only present in the crystal 
structure: S71-Q76 and K97-Y99 in a domain, T121-L123 at the start of b domain and 
K309-L310 in E¶ domain. These predictions were simply not possible using the triple 
resonance data, as stretches D72-Y77, A94-T100 and  P118-P124 of W111F DEE¶[ were 
unassignable.  Residues K309-L310 were flanked on either side by unassigned residues, 
therefore it is likely that DANGLE was unable to correctly predict secondary structure of 
these residues. Also in contrast to the DEE¶[D¶ crystal structure was the x-linker region of 
both E¶[ and W111F DEE¶[ , which were not assigned any secondary structure (see Figures 
4.17 and 4.18). In the DEE¶[D¶ crystal structure the x-linker LVVKRZQWRFRQWDLQDVPDOOȕ-
strand composed of residues P336-/ DQG DQ Į-helix of residues E345-W347. The 
I272A E¶[ µFDSSLQJPXWDQW¶FU\VWDOVWUXFWXUHDOVRUHSRUWVWKHVDPHVHFRQGDU\VWUXFWXUHRI
x-linker (Nguyen et al., 2008). A large region of x-linker resonances were unassignable 
by triple resonance due to the conformational activity x-linker exhibits in solution, so it is 
also possible there was not enough information for DANGLE to correctly predict 
secondary structure for this region.  
In full-length hPDI, it is proposed the x-linker adopts a secondary conformation, with 
recent strucutral work of the EE¶[D¶ fragment of hPDI demonstrating that in reduced 
crystal structures the x-linker is found tightly packed into the D¶ domain (Wang et al., 
2012). This packing could also explain the differences seen, as the D¶ domain is not present 
in either the E¶[ or W111F DEE¶[fragments for this phenomena to occur. It has also been 
shown that presence of the Dƍ domain in DEE¶[D¶ hPDI somewhat limits the ability of the x-
linker to move between a capped and uncapped conformation (Wang et al., 2013)- this 
could also help to explain the differences seen in the crystal and solution predicted 




structures. It is interesting to note however that the same paper shows the x-linker region 
undergoes a 45¡ rotation in reduced/oxidised DEE¶[D¶, demonstrating that it remains highly 
flexible even in the presence of the D¶ domain.  






CHAPTER 5  
 
Ligand Binding Studies of E¶[ and W111F 
DEE¶[ by NMR Spectroscopy 
 
5.1 Introduction  
Given 3',¶V UROHDVDFULWLFDO(5-resident protein folding catalyst, it is hardly surprising 
WKHPDMRULW\RI3', UHVHDUFK WHQGV WR IRFXVRQ WKHSURWHLQ¶VR[LGRUHGXFWDVHRU LVRPHUDVH
activity. Yet PDI is also capable of binding small peptide ligands, at a primary binding 
pocket in its E¶ domain (Klappa et al., 1998). This pocket is also crucial for the binding of 
larger, unfolded or mis-folded proteins, in addition to ErRĮ WKH JUHDWHVW FRQWULEXWRU WR
hPDI re-oxidation in vivo (Tavender and Bulleid, 2010). Hence this binding site makes for 
an attractive target for which to design therapeutics, as any peptide that is able to compete 
ZLWK SK\VLRORJLFDO OLJDQGV WR µEORFN¶ WKH E¶ binding pocket could reduce both the 
chaperone and isomerase activities of hPDI.  
The binding site of hPDI was mapped using NMR spectroscopy in 2009 (Byrne et al., 
2009), yet ligand specificity of hPDI is still poorly understood and to date no structural 
models exist for the protein bound to a target peptide ligand. Specificity of the PDI family 
member PDIp has been studied more comprehensively, and it was shown either a Trp or 
Tyr residue in the peptide sequence is sufficient for binding recognition (Ruddock et al., 
2000). Substrate recognition by hPDI is anticipated to be somewhat more complex. 




This Chapter introduces the use of NMR spectroscopy to first quantitate the binding 
DIILQLW\RIK3', WR LWVKLVWRULFPRGHOSHSWLGHǻ-som, followed by detailed analysis using 
fluorinated residues and specific residue substitutions to probe the binding specificity. 
There are several advantages of using NMR to study ligand binding over other bio-
molecular techniques like isothermal titration calorimetry, surface plasmon resonance or 
Frster resonance energy transfer. Principally NMR allows the binding interaction to be 
observed at an atomic level, meaning that as well as direct ligand binding affinities, highly 
detailed structural information about the binding interaction can also be generated. With 
the collection of various other NMR spectra, this information can even be used to generate 
structural models of the protein-ligand complex. 
5.1.1 Ligand Binding by 15N,1H-HSQC spectra 
A well-documented method of measuring ligand binding by NMR spectroscopy is via 
chemical shift perturbation, a technique comprehensively reviewed by both Fielding and 
Williamson (Fielding, 2003; Williamson, 2013). The approach requires the collection of a 
set of spectra of the protein sample with varying concentrations of ligand in each spectra. 
The overlaid spectra can inform on the binding event and highlight residues that are 
involved in the binding interaction.    
Ligand binding by NMR spectroscopy is traditionally measured using chemical shift 
perturbation of resonances in overlaid 15N,1H-HSQC spectra. Results presented in Chapter 
4 have already highlighted how sensitive the protein backbone is to changes in redox state, 
and shifts of a similar magnitude can also be observed in the protein upon addition of a 
binding ligand.  
This particular method uses the controlled titration of a ligand into a constant amount of 
protein, to observe how the protein shifts and changes upon binding. The method is 
traditionally protein-observed, therefore only the protein is isotopically enriched, so the 
resonances in the spectra are not complicated by the addition of a ligand. The perturbation 
of each protein resonance can be measured throughout the titration series, weighted as 
previously outlined in Equation 4.1, and plot graphically against ligand concentration to 
equate a dissociation constant (Kd). Equation 5.1 defines the relationship between protein 
and ligand in free and bound complex states (of a single binding site model):- 




 ?Ǥ ?ܦ݅ݏݏ݋ܿ݅ܽݐ݅݋݊ܥ݋݊ݏݐܽ݊ݐሺܭௗሻ ൌ ሾܲሿሾܮሿሾܲܮሿ  
Where [P] is concentration of free protein, [L] is concentration of free ligand, and [PL] 
concentration of the protein-ligand complex. 
Kd is a concentration of ligand at which half the protein ligand binding sites become 
occupied, so the smaller the value, the tighter the binding affinity. Determination of Kd by 
105 W\SLFDOO\ ZRUNV EHVW DW WKH µZHDN¶ HQG RI ELRORJLFDO DIILQLW\ P0-ȝ0 Uange) 
(Vaynberg and Qin, 2006), and is therefore well-suited to probe ligand affinity of hPDI, 
ZKHUHLWLVHVWLPDWHGWKHELQGLQJDIILQLW\WR¨-som is 0.1-1mM (Byrne et al., 2009b).  
Exchange rates in NMR can be in fast or slow timescales. Ligand binding is easiest to 
measure when the exchange rate between free and ligand bound states is fast, as is the case 
IRUK3',ELQGLQJRI¨-som. Signals in the overlaid spectra will gradually move from their 
signal in the free spectra, to their signal in the bound spectra, and intermediate spectra will 
UHSRUW D µZHLJKWHG DYHUDJH¶ WUDMHFWRU\ RI ERXQG DQG IUHH VKLIWV DV VKRZQ E\ )LJXUH 
(a)). 
 
Figure 5.1: 15N,1H-HSQC NMR peak shape with fast (a) and slow (b) exchange rates. In fast exchange 
(e.g. ligand binding), the peaks move smoothly from free to bound states upon addition of increasing 
amounts of ligand. Figure adapted from (Williamson, 2013). ). In slow exchange (e.g: redox change), the 
reduced peak decreases in intensity as the oxidised peak increases in intensity, upon addition of an increased 
oxidising:reducing agent ratio. 




During the titration series the total concentrations of [L] and [P] are known, each the sum 
of free [L] or [P] and bound complex [PL] forms. If the binding event is in fast exchange 
we know that the observed chemical shift perturbation is an average of all the shifts in free 
and complex bound states, and we assume that the fractions of free and bound are equal to 
1. Together these assumptions are used to calculate a dissociation constant (Kd), by fitting 
experimental data to Equation 5.2, taken from (Morton et al., 1996) :- 
 ?Ǥ ? ? ? ? ሺ ?ሾሿ ?ሾሿሻǦටȋȋ ?ሾሿ ?ȏȐȌ ?Ǧ ?ሾሿሾሿȌ ?ȏȐ !
:KHUH¨LVWKHREVHUYHGFKHPLFDOVKLIWSHUWXUEDWLRQLQ+]¨o the maximum chemical shift 
perturbation in Hz, [P] and [L] the protein and ligand concentrations respectively. 
Williamson has also explained the mathematical generation of this equation, and the 
derivation can be found in Appendix 5.1 (Williamson, 2013). 
 
5.1.2 Ligand Binding by 13C,1H-HSQC spectra 
Ligand binding was also probed using overlaid methyl regions of assigned 13C,1H-HSQCs. 
It was carried out with the intention that any observed shifts might report more sensitively 
upon the ligand-binding event (as 13C nuclei are thought to be less influenced by structural 
change upon binding, and 15N shifts can report on both direct ligand binding or induced 
conformational change upon binding). Few methyl resonances of the ligand binding site 
could be assigned, but surprisingly the data still reported accurately throughout the protein 
on what is likely to be a ligand-induced conformational change. Hence, 13C,1H-HSQCs 
were not a suitable method to use to observe ligand binding, due to limited assignable 
reporters within the binding site.  
5.1.3 3D 15N NOESY-HSQCs of E¶[ and W111F DEE¶[ 
The 15N NOESY-HSQC is a through-space experiment that reports inter and/or 
intramolecular interactions in 3D, collected by combining a 15N-NOESY with a 15N-HSQC 
step (Marion et al., 1989; Zuiderweg and Fesik, 1989). Magnetisation is transferred 
between all hydrogens using the Nuclear Overhauser Effect (NOE), to neighbouring 15N 
nuclei, and then back again for detection. Using an assigned 15N,1H-HSQC of the protein, 




it is possible to look at the NOE resonances of each NH group from all other nearby 
hydrogen atoms, typically within a 5-6 distance, where intensity of the peak will be 
dependent on the distance between each atom.  
Spectra were run in anticipation of observing extra NOE peaks (intermolecular peaks) in 
the SURWHLQVSHFWUDXSRQDGGLWLRQRIWKHELQGLQJOLJDQG¨-som. If extra peaks are observed, 
then isotope edited NOESY spectra can be used to distinguish between the intra- and inter- 
molecular contacts (Fesik et al., 1988) to generate structural restraints, that can be used 
with docking software to generate structural ligand-bound models (Constantine, Davis et 
al. 2006). Data was collected using E¶[ and W111F DEE¶[ at several temperatures and field 
strengths, but insufficient intermolecular NOEs were observed between protein and 
binding ligand to allow further structure determination.     
5.1.4 Synthetic Peptide Fluorination 
'XHWRWKHYDULRXVGLIILFXOWLHVHQFRXQWHUHGLQDWWHPSWVWRSURGXFHUHFRPELQDQWLVRWRSLFDOO\
ODEHOOHGǻ-VRPVHH&KDSWHUV\QWKHWLFDOO\IOXRULQDWHGIRUPVRIWKHSHSWLGHZHUHRUGHUHG
IURP 3HSWLGH 6\QWKHWLFV )DUHKDP 6\QWKHWLF IOXRULQDWLRQ DOORZHG XV WR FLUFXPYHQW
UHFRPELQDQW SHSWLGH SUREOHPV ZKLOVW XWLOLVLQJ .HQW¶V KLJKO\ VHQVLWLYH ) FU\RSUREH WR
YLHZELQGLQJWRK3',IURPDXQLTXHOLJDQG-REVHUYHGSHUVSHFWLYH)IOXRULQHLVFORVHWR
 QDWXUDO DEXQGDQFH DQG LV DOVR DFWLYH E\ 105 VSHFWURVFRS\ *HULJ 
$GGLWLRQDOO\ LW KDV WKH EHQHILW RI KDYLQJ H[WUHPHO\ ORZ XSWDNH LQ QDWXUH PHDQLQJ WKHUH
ZLOO EH QR FRQWDPLQDWLQJ SURWHLQ EDFNJURXQG VLJQDO RI 105 VDPSOHV 'DYLG DQG %
+DUSHU 
It is well documented that other molecular chaperones rely upon hydrophobic residues for 
ligand recognition (Hammond and Helenius, 1995), and it was expected hPDI recognises 
its ligands by a similar mechanism, as previous work has shown ligand binding is a 
hydrophobically driven event (Klappa et al., 1997). Therefore we have targeted the three 
K\GURSKRELF SKHQ\ODODQLQH UHVLGXHV RI ǻ-som for fluorination. This chapter reports the 
incorporation of 4-fluoro-phenylalanine (4-F-Phe) (see Figure 5.2) LQWRǻ-som peptide, as 
an additional method to monitor peptide ligand binding to hPDI.  
 






Figure 5.2: Chemical structure of 4-Fluoro Phenylalanine. The fluorinated amino acid is made by 
substituting the C-4 hydrogen for a fluorine atom (highlighted in red). 
 
The introduction of fluorine into phenylalanine residues should have limited effect when 
compared to substitution of an entire residue, but successive fluorination, whilst initially 
stabilising hydrophobic interactions, can also destabilise them (Salwiczek et al., 2012). 
Therefore, careful attempts were made to observe any effects fluorination conferred to the 
peptides, and a comprehensive study of fluorinated and non-fluorinated peptides was 
undertaken. Results inferred by fluorinated peptides were used to create non-fluorinated 
alanine substitutions to validate these findings. 
5.1.5 Ligand Binding by 19F 1D spectra 
Selective fluorination of the peptide allows ligand binding of hPDI to be viewed from the 
direct ligand-observed perspective. Data was collected by controlled titration of 15N E¶[ 
SURWHLQ LQWRDFRQVWDQWDPRXQWRI IOXRULQDWHG¨-som peptide, to observe how the peptide 
experiences the binding event. 19F data was treated in a similar manner to 15N,1H-HSQC 
shifts, but instead uses peak maxima shift in Hz instead of 2D weighted chemical shifts. 
These shifts were plotted against protein concentration and Equation 5.2 was used to 
generate a dissociation constant. This method was exclusively ligand-observed, but the 
same experiments were repeated by 15N,1H-HSQC spectra (as outlined in 5.1.1), to gain 
confidence in the binding affinities generated by 19F 1D spectra.      




5.2 Materials and Methods  
5.2.1 NMR Sample Preparation  
Monomeric protein isotopically labelled and purified as outlined in Chapter 3 was buffer 
exchanged using a Vivaspin 20 Centrifugal Filter (10 kDa MWCO, Sartorius) into NMR 
buffer (20 mM sodium phosphate, 50 mM NaCl, pH 7.0) and then concentrated down into 
stocks to use as required (determined by A280 nm absorbance). 
Ligand Binding: Protein stocks were made to 0.3 mM or 0.45 mM in NMR buffer, and 
peptide stocks were made to 20 mM or 10 mM in 100% DMSO-d6 (several peptides 
showed poor solubility in aqueous buffers). Table 5.1 shows the peptides used for ligand 
binding experiments. 















Fluorinated Phe residues are shown by 4-F-Phe (4-fluorophenylalanine). Phe-Ala substitutions are 
highlighted in red. 




   E¶[  OLJDQG µSURWHLQ-REVHUYHG¶VDPSOHVZHUHPDGHXVLQJDFRQVWDQWP0SURWHLQ
varying concentrations of peptide, 5% total DMSO-d6, 10% D2O and 0.05% sodium azide, 
PDGH WR D WRWDO YROXPHRIȝ/XVLQJ105 EXIIHU VHH7DEOH IRU W\SLFDO WLWUDWLRQ
series sample preparations). Samples of 1:0, 1:0.25, 1:0.5 1:1, 1:1.5, 1:2 and 1:2.5 protein: 
ligand ratios were collected.   
  
Table 5.2: TypiFDO µSURWHLQ-REVHUYHG¶ WLWUDWLRQ VHULHV XVLQJ  P0 15N E¶[ and varying 
FRQFHQWUDWLRQVRI¨-som peptide. 
 ¨-som [mM] 0 0.0625 0.125 0.25 0.375 0.5 0.625 
Protein (0.3 
mM stock) 
291.7 291.7 291.7 291.7 291.7 291.7 291.7 
Peptide (20 
mM stock) 
- 1.09 2.19 4.38 6.56 8.75 10.94 
DMSO-d6 17.5 16.41 15.31 13.12 10.94 8.75 6.56 
D2O 35 35 35 35 35 35 35 
Sodium azide 
(5% stock) 
3.5 3.5 3.5 3.5 3.5 3.5 3.5 
NMR Buffer 
(de-gassed) 
2.3 2.3 2.3 2.3 2.3 2.3 2.3 
TOTAL: 350 350 350 350 350 350 350 
$OOYROXPHVDUHLQȝ/ 
 
W111F DEE¶[ µSURWHLQ-REVHUYHG¶VDPSOHVZHUHPDGHDVIRUE¶[, with the addition of a 5x 
molar concentration of DTTred or GSSG to reduce or oxidise the protein respectively. Due 
to the instability of oxidised protein at high concentrations, oxidised spectra were collected 
using 0.2 mM protein, and molar ratios were kept constant (so the titration series finished 
at a 2.5 molar excess peptide).   
E¶[  OLJDQG µOLJDQG-REVHUYHG¶ VDPSOHV ZHUH PDGH XVLQJ D FRQVWDQW  P0 SHSWLGH
varying concentrations of E¶[ protein, a 5% total DMSO-d6, 10% D2O and 0.05% sodium 





1:1, 1:1.5, 1:2 and 1:2.5 ligand:protein ratio were collected.    
5.2.2 NMR Data Acquisition and Processing 
NMR data was acquired at the University of Kent using a a 4-channel, 5-amplifier Bruker 
Avance III 14.1T (600MHz 1H) NMR spectrometer equipped with a 5 mm QCI-F 
cryoprobe, unless otherwise stated. All experiments were carried out at 37¡C, pH 7.0, 
unless otherwise stated. 1H chemical shift referencing was carried out using the position of 
the 1H2O resonance at the given temperature. 15N and 13C chemical shifts were referenced 
using a spectrometer-based macro, and 19F chemical shifts were referenced using the 
position of TFA (-76.55 ppm).  
All 1D data was processed using Bruker Topspin software, and 2D or 3D NMR data was 
processed using NMRPipe software (Delaglio et al., 1995).  
5.2.2.1 15N,1H-HSQC Experiments of E¶[ and W111F DEE¶[ 
15N,1H-HSQC spectra were acquired of each protein fragment with varying amounts of 
peptide ligand or oxidising: reducing agent as previously outlined in 4.2.2.1. 
5.2.2.2 19F 1D Experiments of E¶[ and W111F DEE¶[ 
19F 1D spectra were acquired of each peptide ligand with varying amounts of E¶[ over 60 
minutes with 256 points in the F1 (19F) dimension. The italicised peptides in Table 5.1 
show the peptides that 19F data was collected for.  
5.2.2.3 13C,1H-HSQC Experiments of E¶[ 
13C,1H-HSQC spectra were acquired of 0.3 mM E¶[ ZLWKDQGZLWKRXWP0¨-som as 
previously outlined in 4.2.2.2. 
5.2.2.4 15N NOESY-HSQC Experiments of E¶[and W111F DEE¶[ 
15N NOESY-HSQC spectra of 0.4 mM 15N E¶[ with and without 2.5x molar excesV¨-som 
were collected at 37¡C at Mill Hill using an 800 MHz spectrometer. Additional spectra 
were collected at 10¡C at the University of Kent. Data at Kent was acquired with 2048 
points in the F3 dimension (1H), 220 points in the F2 dimension (1H) and 32 points in the 
F1 dimension (15N). 




Additionally, 15N NOESY-HSQC spectra of 0.4 mM W111F 15N DEE¶[ with and without 
[ PRODU H[FHVV ¨-som were collected at 10¡C at Mill Hill using a 950 MHz 
spectrometer. 
5.2.3 NMR Data Analysis 
All subsequent data analysis of 1D spectra was carried out using Bruker Topspin software , 
and all 2D and 3D spectra analysis was carried out using CcpNmr Analysis software 
Version 2 (Vranken et al., 2005).  
5.2.3.1 19F Peptide Assignment 
Singly fluorinated peptides each yielded a single peak that tracked throughout the 19F 
spectra upon addition of E¶[ protein. It was hoped that the peak trajectories would overlay 
ZHOO ZLWK WKHLU HTXLYDOHQW SHDNV LQ VSHFWUD RI ) ¨-som, but this was not the case. 
13C,19F 2D spectra collected at 37¡C were blank, meaning unambiguous assignment of  
)¨-som could not be carried out. Instead, the tight 19F calculated Kd fits of the single 
IOXRULQDWHGSHSWLGHVZHUHXVHG WR LGHQWLI\ WKH IOXRULQHSHDNV LQ WKH)¨-som spectra 
(explained further in 5.3.6).                 
5.2.3.2 Chemical Shift Perturbation Mapping 
The backbone assignments of E¶[ and W111F DEE¶[ described in Chapter 4 were used to 
assign all subsequent 15N,1H-HSQCs. Peak assignments were automatically copied across 
onto overlaid spectra by the software upon increasing addition of peptide ligand. Peaks 
were then manually moved to their new peak maxima. Whilst time consuming, manual fits 
were found to give better graphical fits than the automatic peak picking software available 
in Analysis.   
Chemical shift perturbations were then weighted if required for further analysis:- 
Using 15N data: Chemical shift perturbations measured in 15N,1H-HSQCs were calculated 
using equation 4.1, to weight observed 15N shifts relative to their 1H shifts.  
Using 19F data: Chemical shifts monitored via 19F spectra were collected in 1D, therefore 
did not need weighting. Each fluorine peak maxima was measured and directly plotted 
against protein concentration.     




In 19) VSHFWUD RI ) ¨-som, the F1 and F2 peaks are reporting a sufficiently similar 
chemical environment that they appear as a single peak. The peak resolves into two 
separate peaks upon a 2:1 addition of E¶[ protein. Attempts to integrate the peak into two 
separate peaks were not successful, therefore data points prior to this concentration were 
measured by using the peak maxima of the overlapped peak. This does not appear to have 
adversely affected graphical fits, so it is likely that the peaks are closely on top of one 
another at lower concentrations of protein.           
Using 13C data: Upon attempting to weight 13C methyl shifts relative to their respective 1H 
shifts, nothing could be found published within the literature for methyl shifts specifically. 
Therefore chemical shift perturbations were calculated similarly to 15N,1H-HSQC shifts 
(Williamson et al., 1997), to allow for the difference in spectral width of 13C shifts relative 
to 1H shifts, using equation 5.3:- 
 
:KHUH¨1+DQG¨13C are the chemical shift perturbations (ppm) of a peak in the 1H and 13C 
dimensions respectively. 13C methyl shifts were weighted by 1/8.1 their actual size, to 
compensate for the chemical shift range they report over when compared to proton 
chemical shifts (observed chemical shift range of 13C was 17 ppm compared  to observed 
1H chemical shift range of 2.1 ppm).   
 
5.3 Results  
Upon addition of ligand there were typically 44 shifting residues from the E¶[ 15N,1H-
HSQCs and 33 shifting residues from the reduced W111F DEE¶[ 15N,1H-HSQCs that fit 
graphically to give the stated dissociation constants of each section. For each results 
section a representative sample of graphs are shown- additional raw data can be found in 
the Appendix as stated in each section.  
 




5.3.1 Effect of Neighbouring Domains on Peptide Ligand Binding  
Dissociation constants were calculated from practical data by careful titration of increasing 
FRQFHQWUDWLRQVRI¨-som ligand into either 0.25 mM E¶[ or W111F DEE¶[ protein. 7 data 
points were collected for each protein, corresponding to a titration endpoint of 2.5:1 molar 
ratio of ligand:protein. The overlaid spectra of E¶[ shown in Figure 5.3 (a) and of W111F 
DEE¶[ LQEGHPRQVWUDWHWKHREVHUYHGVKLIWVXSRQDGGLWLRQRILQFUHDVLQJ¨-som ligand, and 
in each case show the W347 indole resonance shifting from D µFDSSHG¶ WR µXQFDSSHG¶
conformation; ligand is competing to displace the x-linker region from the E¶ ligand 
binding site.   
The 44 residues of E¶[ that fitted the curve gave an average dissociation constant of 103 + 
ȝ0(see Figure 5.4 for sample fits). Similarly, the 33 residues of reduced W111F DEE¶[ 
that fitted the curve gave an average dissociation constant of 73 + ȝ0 (see Figure 5.5 
for sample fits). These values are both in agreement with the estimated binding affinity of 
¨-som of 0.1-1 mM (Byrne et al., 2009), suggesting that binding affinity is at the tighter 
end of this estimated region.  
The data points collected fit well to the dissociation curves but gave large errors, likely due 
to the limitations of the curve fits not reaching a full occupancy plateau- a large error can 
EH DVVRFLDWHG ZLWK H[WUDSRODWLQJ WKH FXUYH ILWV WR UHDFK ǻo (Fielding, 2003). This is a 
particular problem when fitting weak affinities, as is the case here, but likewise the fits 
were also limited practically, by both protein and peptide concentrations: preliminary work 
FDUULHG RXW ZLWK WKH ¨-som peptides showed several precipitate at concentrations higher 
than 0.75 mM when in aqueous buffer solutions (so 0.625 mM was used as the maximum 
ligand concentration). Equally, a minimum of 0.25 mM protein in each sample was 
required for collection of high quality spectra within a reasonable time period. 
 






Figure 5.3: Overlaid 15N,1H-HSQC spectra of 0.25 mM 15N E¶[ (a) and W111F DEE¶[ (b) + increasing 
DPRXQWVRI¨-som. Spectra: +0 P0¨-som (black), +0.125 P0 ¨-som (red), +0.375 P0 ¨-som (cyan), 
P0¨-som (blue). Arrows in (a) indicate the direction example peaks track throughout the titration 
series. Sample graph fits seen in Figures 5.4 and 5.5 are highlighted on each spectra. 





Figure 5.4:  Example dissociation constant titration curves using overlaid 15N,1H-HSQC data of 0.25 
mM 15N E¶[  LQFUHDVLQJDPRXQWVRI¨-som. The curves give an average dissociation constant of 103 + 
ȝ0 





Figure 5.5:  Example dissociation constant titration curves using 15N,1H-HSQC data of 0.25 mM 15N 
reduced W111F DEE¶[ LQFUHDVLQJDPRXQWVRI¨-som. The curves give an average dissociation constant of 
73 + ȝ0 




Chemical shift perturbations of both protein fragments reveal that it is largely the same 
areas of the E¶ domain that are perturbed upon ligand binding as published previously 
(Byrne et al., 2009b): this includes a chain of residues at the start of the E¶ domain that 
IRUPDQĮ-helix bordering the c-terminal end of the binding site (T224-G233), and residues 
//DQG<ZKLFKDOOIRUPWKHȕ-VKHHWµIORRU¶RIWKHELQGLQJVLWH,QDGGLWLRQ
L338 and W347 indole resonance of the x-linker region were also perturbed upon binding, 
showing displacement of the x-linker (see Figure 5.6 for chemical shift perturbations of 




Figure 5.6: Chemical shift perturbation map of the E¶[ portion of either 0.25 mM E¶[ (red) or 0.25 mM 
reduced W111F DEE¶[ EOXH XSRQ DGGLWLRQ RI  P0 ¨-som. 7KH µab¶ SRUWLRQ RI :) DEE¶[ 
experiences very minor shifts (average shifts of 0.011 ppm) that did not fit graphically, and so were not 
included in the shift map.       
 
The overlaid perturbation maps show that there are more trackable resonances in E¶[ 
spectra than in W111F DEE¶[(35 in W111F DEE¶[ as opposed to 46 in E¶[), particularly 
those of x-linker and the ligand binding site. Due to its large size, spectra of W111F DEE¶[ 
were subject to residue overlap- a significant number of trajectories could not be accurately 




tracked throughout the titration series, and therefore could not be included in the shift maps 
or further analysis. 6KLIWVREVHUYHGLQWKHµab¶SRUWLRQRIW111F DEE¶[ fragment are not 
included in the maps; there were no observable resonances of a domain that shifted 
significantly upon binding, and the 19 shifts observed in b domain were very small in 
comparison to shifts witnessed in E¶[ (average 0.011 ppm). It appears only E¶ domain and 
the x-linker region are significantly perturbed upon peptide ligand binding.  
Significantly shifting residues for surface maps were determined using the method 
described by (Schumann et al., 2007). This method involves rounds of standard deviation 
ı FDOFXODWLRQV UHPRYLQJ UHVLGXHV VKLIWLQJ JUHDWHU WKDQ WKH PHDQ  ı IURP WKH
calculations, thereby limiting skew of the data (by a few residues that may shift a 
disproportionately large amount). ShiftV DUH FRORXUHG LQ )LJXUH  DV ! PHDQ  ı
EOXH!PHDQıJUHHQ!PHDQı\HOORZ!PHDQıRUDQJH!PHDQı
UHGDQG!PHDQı SXUSOH7KH%-SGEE¶[ structure was used to map shifts for 
both E¶[ and W111F DEE¶[ fragments, as QRVLJQLILFDQWVKLIWVZHUHREVHUYDEOHLQWKHµab¶
portion of W111F DEE¶[WRPDS,QDGGLWLRQWKH%-SGEVWUXFWXUHLVWKH,$µFDSSHG¶
mutant of E¶[, where the x-linker occludes the binding site, allowing for easy 
identification of the binding site.  
Surface maps of the E¶[ fragment of both E¶[ and W111F DEE¶[ show two major regions 
of significantly shifting residues- the first being residues reporting throughout the binding 
VLWH LGHQWLILHG E\ WKH UHJLRQ µFDSSHG¶ E\ WKH x-linker in Figure 5.7 (a) and (b)), and a 
UHJLRQ RI VKLIWLQJ UHVLGXHV RQ WKH RSSRVLWH VLGHRI WKH SURWHLQ WKDW FRUUHVSRQG WR WKH Į-
helix bordering the c-terminal end of the binding site, T224-G233). It is likely that these 
residues are reporting upon a binding induced conformational change to the protein, as 
they are not directly involved in the binding event itself.  
Each protein reports a similar surface and magnitude of chemical shifts, but W111F DEE¶[
reports a somewhat less well-defined binding surface due to the limitations discussed 
above. The similar Kd values generated, along with the small shifts witnessed in b domain 
and lack of observable shifts in a domain upon ligand binding, suggest these domains are 
not involved in the binding event. Work carried out within the laboratory on the reduced 
DEE¶[D¶ fragment of hPDI showed the average dissociation constant to be 108 + ȝ0DW
37¡C. This figure is also in close agreement with the values determined by this thesis. 




Together this suggests that the peptide ligand binding affinity of E¶ domain is not 




Figure 5.7: Models of hPDI E¶[ (3BJ5.pdb) showing significantly shifting backbone resonances of E¶[ 
protein (a) and W111F DEE¶[ SURWHLQ E XSRQ  PRODU H[FHVV RI ELQGLQJ OLJDQG ¨-som. Amide 
UHVRQDQFHVVKLIWLQJ!PHDQıEOXH!PHDQıJUHHQ!PHDQı\HOORZ!PHDQıRUDQJH
!PHDQıUHGDQG!PHDQıSXUSOH7RDLGVLWHLGHQWLILFation the x-linker is coloured magenta, and 
all other assigned residues are coloured teal. Unassigned residues are coloured grey. Molecular graphics 
created with YASARA (www.yasara.org).  




5.3.2 Effect of Protein Redox State on Peptide Ligand Binding  
Whilst dissociation constants of the E¶[ and reduced W111F DEE¶[ fragments of hPDI 
reported in 5.3.1 are in agreement with one another, a ligand titration of oxidised W111F 
DEE¶[ was also carried out to determine if active site oxidation in a domain had any effect 
upon ligand binding affinity. Spectra collected of the oxidised titration are shown in Figure 
5.8, and example dissociation constant titration curves are shown by Figure 5.9. Note that 
as oxidised spectra of W111F DEE¶[ is sufficiently different to its reduced spectra (as 
shown previously by Figure 4.6) the titration series was carried out using unassigned 
resonances, but the graphical fits correspond to the numbered resonances present on the 




Figure 5.8: Overlaid 15N,1H-HSQC spectra of 0.2 mM oxidised W111F DEE¶[ + increasing amounts of 
¨-som. Spectra: + P0 ¨-VRP EOXH  P0 ¨-VRP UHG  P0 ¨-VRP F\DQ  P0 ¨-som 
(black). Unassigned sample graph peak fits for each protein are labelled. 





Figure 5.9:  Example dissociation constant titration curves using overlaid 15N,1H-HSQC data of 0.2 
mM 15N oxidised DEE¶[ LQFUHDVLQJDPRXQWVRI¨-som. The curves give an average dissociation constant 
of 100 + ȝ0!




Some 21 residues could be tracked throughout the titration series, to give an average 
dissociation constant of 100 + 79 µM. This is again in close agreement with the value of 
both the E¶[ and reduced W111F DEE¶[fragments.  
From these findings the decision was made to probe ligand binding further using the E¶[ 
fragment; peptide ligand binding does not appear to be influenced by protein redox state or 
neighbouring domains. Due to its smaller size, the E¶[ fragment gives more simplified 
NMR spectra with a greater percentage of assignments, whilst still reporting on ligand 
binding representative to full-length protein. 
5.3.3 Further Evidence of Capping 
Capping is a published event that occurs in fragments of hPDI that are terminated at the 
end of the x-linker region (Nguyen et al., 2008). Further evidence of the capping event 
was shown in Chapter 4, of both the E¶[ and W111F DEE¶[ fragments, where triple 
resonance assigned 15N,1H-HSQC spectra of each fragment show two resonances for the 
3477USLQGROHVHH)LJXUH7KHWZRUHVRQDQFHVFRUUHVSRQGWRµFDSSHG¶DQGµXQFDSSHG¶
forms of the x-linker. Upon addition of a binding ligand to each fragment (that competes 
with the x-linker to bind the peptide ligand binding site), only a single peak for 347Trp is 
YLVLEOH VHH )LJXUH  7KLV SHDN WUDFNV WKURXJKRXW WKH WLWUDWLRQ IURP WKH µFDSSHG¶
UHVRQDQFH WRZDUGV WKH µXQFDSSHG¶ UHVRQDQFH XSRQ LQFUHDVLQJ FRQFHQWUDWLRQV RI OLJDQG
suggesting that, unlike capping, the ligand binding event is in fast exchange. As the 
FRQFHQWUDWLRQRIOLJDQGLVLQFUHDVHGWKHSURWHLQUHSRUWVDVKLIWWRZDUGVDPRUHµXQFDSSHG¶
form (as the binding site becomes increasingly more occupied by ligand than x-linker). 
This observation is further evidence that the x-linker is able to bind to and modulate the 
hydrophobic peptide ligand binding site of the E¶domain in E¶[and W111F DEE¶[hPDI 
fragments.  
Interestingly, at the end point of the E¶[ ligand titration, the bound ligand 347Trp indole 
peak does not overlay with the uncapped 347Trp indole resonance (see Figure 5.10) to 
suggest a fully uncapped form of protein. Equally the graphical fits do not reach a plateau, 
suggesting 100% occupancy of the binding sites has not been reached (as discussed 
previously in 5.3.1).  
 







Figure 5.10: Overlaid 15N,1H-HSQC spectra of 0.25 mM 15N protein (blue) and 0.25 mM  15N protein 
 P0  ¨-som (red), for E¶[ in (a) and W111F DEE¶[ in (b). The indole 347Trp resonances are 








5.3.4 15N NOESY-HSQCs for Evidence of Binding !
NOESY-HSQC experiments were carried out using both E¶[and W111F DEE¶[ fragments, 
in an attempt to gain structural restraints and through-VSDFH HYLGHQFH RI ǻ-som binding, 
with the intention of creating a ligand bound solution structure of the fragments. Figure 
5.11 shows an example plane of NOESY peaks collected at 37¡C for residue 345Glu, one of 




Figure 5.11: Overlaid NOESY strips of 0.4 mM E¶[ (green) and 0.4 mM E¶[+ 1 mM ¨-som (purple). 
Window (a) shows resonance 345*OXVKLIWLQJXSRQELQGLQJ¨-som, and the corresponding 1H-1H strip in (b) 
shows an additional NOE peak at approximately 4.3 ppm in the ligand bound (purple) spectra.  
 
3UHOLPLQDU\VSHFWUDKDYHVXJJHVWHG¨-som is very conformationally active at 37¡C (with 
spectra of the peptide collected at this temperature completely blank), so experiments were 




repeated at 10¡C to see if a lower running temperature could increase the number of extra 
NOE peaks observed (run using both E¶[ and W111F DEE¶[ fragments). Unfortunately a 
lower running temperature was detrimental to the spectral quality. Each experiment was 
checked for NOESY peaks with and without addition of 2.5 molar H[FHVVRI¨-som, but in 
this instance NOESY experiments did not yield a sufficient number of extra NOE peaks to 
perform structural restraint calculations.  
5.3.5 Ligand Binding by 13C,1H-HSQC spectra 
As reported in Chapter 4, 89% of the possible E¶[ methyl 1H and 13C resonances were 
made (see Figure 4.15) using the HCCH-TOCSY experiments. A HCCH-TOCSY with 
ligand was collected, and a 13C,1H-HSQC of 0.3 mM 13C E¶[ DQGP0XQODEHOOHG¨-
som was assigned, with the intention of gaining more site-specific information of the 
binding event.   
Observed chemical shift perturbations upon addition of ligand were weighted similarly to 
15N,1H shifts, by weighting the 13C shifts relative to their 1H shifts. Figure 5.12 
demonstrates the shifts witnessed throughout E¶[ protein, with the average methyl shift 
being 0.031 ppm (raw data can be found in Appendix 5.2).  
 
Figure 5.12: Overlaid 13C,1H-HSQC methyl region spectra of 0.3 mM 13C E¶[ (black) and 0.3 mM 13C 
E¶[P0¨-som (red).  




It was apparent that the 13C data could not be treated similarly to the 15N data; whilst of a 
FRPSDUDEOHPDJQLWXGHQRVKLIWVZHUHıJUHDWHUWKDQWKHPHDQ6KLIWVZHUHLQVWHDGUDQNHG
by size, as shown in Figure 5.13.  
 
 
Figure 5.13: 13&PHWK\OFKHPLFDOVKLIWSHUWXUEDWLRQVXSRQDGGLWLRQRIP0¨-som to 0.3 mM E¶[, 
ranked by size. 6KLIWLQJUHVRQDQFHVV!SSPZHUHIRXQGWREHȕ-strand, 0.055-SSPZHUHĮ-helical, 
and 0.04-0.055 ppm were additional internal residues.    
 
A threshold shift of 0.04 ppm was chosen from the graph, and all shifts greater than this 
were mapped onto the E¶[ structure (see Figure 5.14). Shifts were witnessed throughout 
WKHHQWLUHSURWHLQFRUHEXWWKHVXUIDFHPDSVKRZVKRZIHZRIWKHPHWK\OµUHSRUWHUV¶ZHUe 
actually surface exposed- just three of the assignable methyl resonances were present 
within the binding site and surface exposed: 228Ala, 231Ile and 303Leu (labelled).  
It is interesting to note that the largest shifts (> 0.09 ppm, coloured red) corresponded to 
core beta strand residues, and shifts 0.055-0.09 ppm (coloured orange) corresponded only 
to residues in alpha helices. Shifts between 0.04-0.055 ppm (coloured yellow) also all 
corresponded to internal residues.  
Whilst in this instance collection of 13C chemical shifts did not yield more detailed 
binding-site specific data as anticipated, the shifts still help to confirm a conformational 




change the protein structure undergoes upon ligand binding, as also observed by 15N,1H-





Figure 5.14: Model of hPDI E¶[ (3BJ5.pdb) showing significantly shifting methyl resonances upon 2.5 
PRODUH[FHVVRIELQGLQJ OLJDQG¨-som, and surface map showing exposed methyls. Methyl resonances 
shifting >0.04ppm are coloured yellow, >0.055ppm are coloured orange, and >0.09ppm are coloured red. To 
aid site identification the x-linker is coloured magenta, and the rest of the molecule coloured grey.  
Molecular graphics created using Yasara (www.yasara.org) 
 
5.3.6 Use of Fluorinated Ligands to Monitor Peptide Ligand Binding 
Ligand binding studies were carried out using fluorinated analogues of the model binding 
SHSWLGHǻ-som, in an attempt to gain more detailed information of the binding specificity of 
hPDI. The three Phe residues of the peptide were each fluorinated in turn (F1, F2 and F3 
¨-VRPDORQJZLWKDSHSWLGHZKHUHDOOWKUHHUHVLGXHVZHUHIOXRULQDWHG)¨-som). As 
large residues with hydrophobic, aromatic side chains, their presence in the peptide 
sequence was thought to play a key role in the chaperone-like ligand recognition of hPDI 
WRǻ-som.   




Dissociation constants of E¶[ and each fluorinated peptide were calculated from practical 
data, first by the titration of increasing concentrations of E¶[ protein into 0.15 mM of each 
fluorinated ligand. These titrations were monitored by 19F 1D spectra, to view ligand-
observed chemical shift perturbations. The titration series was then repeated, using 
constant protein and varying ligand, and monitored by 15N,1H-HSQC to track traditional 
protein-observed chemical shift perturbations (as outlined in 5.2.1). The 15N,1H-HSQC 
tracked spectra of protein-observed titrations (start and finish overlays) are shown below in 
Figure 5.15. Overlaid 19F 1D ligand-observed spectra of single fluorinated peptides (F1, 





Figure 5.15: Overlaid 15N,1H-+64&VSHFWUDP0E¶[EODFNDQG+P0)¨-som (red)(a), 
 P0 ) ¨-som (cyan)(b),  P0 ) ¨-som (pink)(c) and +0.6 P0 ) ¨-som 
(purple)(d). 





Figure 5.16: Overlaid 19)VSHFWUDP0)¨-som+ increasing 15N E¶[ titration series 
 
Figure 5.17: Overlaid 19)VSHFWUDP0)¨-som + increasing 15N E¶[ titration series 





Figure 5.18: Overlaid 19)VSHFWUDP0)¨-som + increasing 15N E¶[ titration series 
 
Figure 5.19: Overlaid 19)VSHFWUDP0)¨-som + increasing 15N E¶[ titration series 




Please note, only 19F-observed graphical fits are shown below in Figure 5.20, but all 
fluorine experiments were repeated using constant protein in 15N,1H-HSQC protein-





Figure 'LVVRFLDWLRQFRQVWDQWWLWUDWLRQFXUYHVRI)¨-som peptide: F1 peak (a), F2 peak (b) 
DQG)SHDN F'LVVRFLDWLRQFRQVWDQW WLWUDWLRQFXUYHVXVLQJVLQJOH IOXRULQDWHG¨-VRPSHSWLGH)¨-
VRPG)¨-VRPHDQG)¨-som (f).  
 
The results of each single and triple fluorinated peptide as observed by 15N,1H-HSQC, and 
the individual fits of all 19F 1D ligand-observed peak fits are summarised in Tables 5.3 and 
5.4.  
Protein observed binding: The 44 residues of E¶[ ZLWK WULSOH IOXRULQDWHG)ǻ-som 
peptide that fitted to the curve gave an average dissociation constant of 48 + ȝ07KLV
YDOXH ZDV VOLJKWO\ WLJKWHU WKDQ WKH DIILQLW\ ZLWK XQIOXRULQDWHG ǻ-som, however a modest 




increase was anticipated as a potential result of increased hydrophobicity fluorine could 
confer to the peptide, working to stabilise a hydrophobically driven binding interaction. 
+RZHYHUWKHFDOFXODWHGYDOXHLVVWLOOZHOOZLWKLQWKHHUURUUDQJHRIXQODEHOOHGǻ-som (103 
+ 4ȝ07KHJHQHUDWHG value is also in agreement with other work carried out within the 
laboratory, using fluorinated E¶[ protein and unlabelled ligand (Curtis-Marof et al., 2014).  
 
Table 5.3: Kd GLVVRFLDWLRQFRQVWDQWVRIDOOVLQJOHIOXRULQDWHG¨-som peptides with 15N E¶[ as determined 
by either 15N,1H-HSQC or 19F 1D spectra. 
Peptide Sequence  Protein 15N Tracked     
o0 
Ligand 19F  Tracked 
(Single-F) /oM 
$*6.1)):.7)766 ¨-VRP 103 + 47 N/A 
$*6.1)):.7)766 )¨-VRP 61 + 47 109 + 13 
$*6.1)):.7)766 )¨-VRP 51 + 30 27 + 3 
$*6.1)):.7)766 )¨-VRP 84 + 53 97 + 21 
The observed fluorinated Phe residue for each experiment is underlined in bold.  
 
Table 5.4: Kd GLVVRFLDWLRQ FRQVWDQWV RI ) ¨-som peptide with 15N E¶[ as determined by either 
15N,1H-HSQC or 19F 1D spectra. 
Peptide Sequence  Protein 15N 
Tracked o0 
Ligand 19F  Tracked 
(Triple-F) /oM 
$*6.1)):.7)766 ¨-VRP 103 + 47 N/A 
$*6.1)):.7)766 )¨-VRP N/A 108 + 15 
$*6.1)):.7)766 )¨-VRP N/A 33 + 11 
$*6.1)):.7)766 )¨-VRP N/A 45 + 14 
$*6.1)):.7)766 )¨-VRP 48 + 35* 62 + 13* 
The observed fluorinated Phe residue(s) for each experiment are underlined in bold. *These Kd values are 
calculated as the mean of all individual Kd results obtained. 




Further analysis of the 15N,1H-HSQC protein spectra showed the peptide appears to bind to 
the protein in the same manner as un-fluorinated peptide; residues track throughout the 
titration series in the same direction, and with comparable magnitude.  
The chemical shift perturbation map in Figure 5.21 shows how the protein shifts upon 




Figure 5.21: Chemical shift perturbation map of 0.25mM 15N E¶[ DQG P0 ¨-som (blue) or 
P0)¨-som (red). 
 
It is clear that shifts are highly comparable in both magnitude and residue perturbed for 
both peptides, and similar results were obtained when using each singly fluorinated 
peptide. Overall the 15N,1H-HSQC protein-observed data showed that the fluorinated 
peptides behave in a similar manner to un-IOXRULQDWHG ǻ-som, as highlighted  by their 
highly similar chemical shift perturbations and similar calculated Kd values. 
Ligand observed binding: Each single fluorinated peptide yielded a single peak in the 
spectra that tracked smoothly throughout the titration upon addition of increasing amounts 
of E¶[ protein. The calculated Kd values given in Table 5.3 demonstrate that 19F data is 




concurrent with the 15N,1H-HSQC data; all single fluorinated 19F ligand-observed Kd fits 
are in agreement with their protein-observed Kd equivalents. A comparison of the three 
VLQJOH IOXRULQDWHG SHSWLGHV VKRZV WKDW LW LV ) ǻ-som that reports a moderately tighter 
binding affinity when compared to the other two Phe residues, as reported by both 15N,1H-
HSQC and 19)'VSHFWUD7KLVVXJJHVWVWKDWWKH)3KHSRVLWLRQRI¨-som peptide may be 
crucial for the binding interaction to occur. 
It was hoped that the single fluorine chemical shift trajectories would overlay well enough 
with the triple fluorinated peptide spectra to be able to assign each resonance- however it 
was soon apparent that peptide assignments could not simply be mapped over. In spectra of 
)¨-som, the F1 and F2 resonances report such similar chemical shift perturbations 
that they appear as a single peak until the addition of 0.075 mM E¶[ protein (see Figure 
5.19). The two residues are adjacent in the peptide sequence, and it is likely they 
experience highly similar chemical environments (and hence report similar chemical shift 
perturbations). Deconvolution attempts of the combined peak were unsuccessful, so the 
first two data points of each titration were fitted using the overlapped peak maxima (which 
PD\ H[SODLQ WKH VOLJKWO\ SRRUHU ILW RI ) SHDN RI ) ¨-som in Figure 5.20(a)). 
Sensitivity of chemical shift perturbations to more widespread fluorination was most 
apparent for the F3 peak, which tracked to the right as a single fluorinated peptide, and to 
WKHOHIWDVWKHWULSOHIOXRULQDWHG)¨-som peptide (see Figure 5.18 for single F3 peak, 
DQG )LJXUH  IRU ) SHDN DV SDUW RI ) ¨-som). Several 2D 19F,13C NMR 
experiments using 13C natural abundance were carried out in an attempt to unambiguously 
DVVLJQ HDFK SHDN LQ ) ǻ-VRP EXW DV SUHYLRXVO\ REVHUYHG IRU VSHFWUD RI ¨-som 
collected at 37¡C they were blank. Instead,  the tight 19F calculated Kd fits of the single 
fluorinated peptides were used to assign WKHIOXRULQHSHDNVLQWKH)¨-som spectra.  
Overall the 19F observed data gave extremely good fits, with smaller errors. It appears that 
IOXRULQDWHG SHSWLGHV EHKDYH LQ D VLPLODU PDQQHU WR XQIOXRULQDWHG ǻ-som, as observed by 
both protein and ligand viewpoints. The most prominent differences observed were not 
between fluorinated and unfluorinated peptides as anticipated, but between the individual 
Phe resonances of the fluorinated peptides. Kd of individual 19) SHDNV RI ) ǻ-som 
peptide were in agreePHQWZLWKWKHYDOXHVFDOFXODWHGIURPWKH)DQG)¨-som peptides 
(see 19F-FDOFXODWHGYDOXHVLQ7DEOHVDQGZLWK)YDOXHVTXRWHGZLWKLQȝ0DQG
)YDOXHVZLWKLQȝ0+RZHYHU)ǻ-som reported a notably different Kd value in the 




single and triple fluorinated peptides, reporting a two-fold tighter affinity as the triple 
fluorinated peptide. This finding, coupled with its trajectory change, suggests the F3 Phe 
residue is perhaps more sensitive to widespread fluorination across the peptide than F1 or 
F2 Phe residues are, or alternatively the residue may play a more prominent role in the 
binding event, that is stabilised by the widespread fluorination.  
5.3.7 Effect of Alanine Substitutions on Peptide Ligand Binding  
Titrations carried out using selectively fluorinated peptides hinted that particular residues 
may contribute more to the binding interaction than others. To investigate this further, 
alanine substitutions were introduced at each of the three Phe residues that were previously 
fluorinated. Single, double and triple Phe-Ala substitutions were made, resulting in 7 new 
peptides that were used to calculate dissociation constants, by protein observed titrations. 
15N,1H-HSQC spectra of 0.25 mM 15N E¶[ P0¨-som,  overlaid with 0.25 mM 
15N b¶[ + 0.625 mM each alanine substituted peptide are given for comparison in Figure 
5.22, along with the Kd values of each peptide with E¶[ protein in Table 5.5. All Kd values 
were generated from an average of 44 shifting residues in the protein as reported 
previously. Graphical fits of this data for each peptide can be found in Appendix 5.4.  
 
 





Figure 5.22: 15N,1H-+64&RYHUODLGVSHFWUDRIP0E¶[P0¨-som (black) overlaid with 
each alanine substituted peptide ligand (0.625 mM). 




Table 5.5: Kd GLVVRFLDWLRQFRQVWDQWVRIVLQJOHGRXEOHDQGWULSOHDODQLQHVXEVWLWXWHG¨-som peptides as 
calculated by 15N,1H-HSQC. 
Peptide Sequence  15N Tracked o0 
$*6.1)):.7)766 ¨-VRP 103 + 47 
$*6.1$):.7)766 3KHĺ$¨-som 199 + 100 
$*6.1)$:.7)766 3KHĺ$¨-som 123 + 96 
$*6.1)):.7$766 3KHĺ$¨-som 261 + 101 
$*6.1$$:.7)766 3KHĺ$¨-som 242 + 177 
$*6.1$):.7$766 3KHĺ$¨-som 587 + 174  
$*6.1)$:.7$766 3KHĺ$¨-som 412 + 219 
$*6.1$$:.7$766 3KHĺ$¨-som 'RHVQ¶WELQG 
The alanine substitutions for each peptide are underlined in bold.  
 
3URJUHVVLYH 3KHĺ$OD PXWDWLRQ SHSWLGHV VKRZHG ZHDNHU ELQGLQJ DIILQLWLHV WR E¶[ ZLWK
DURXQG D WZR-IROG ZHDNHU DIILQLW\7KHVH ILQGLQJV GHPRQVWUDWH WKDW ZKLOVW QR VLQJOH 3KH
UHVLGXHLVFUXFLDOIRUWKHELQGLQJLQWHUDFWLRQWRRFFXUDOOWKUHH3KHUHVLGXHVPXVWFRQWULEXWH
WR ELQGLQJ LQ SDUW DV UHPRYDO RI DQ\ VLQJOH 3KH UHVLGXH UHVXOWHG LQ D ZHDNHU ELQGLQJ
DIILQLW\,QWHUHVWLQJO\LWZDVVXEVWLWXWLRQRIWKH)3KH3KHWKDWUHVXOWHGLQWKHJUHDWHVW
QHJDWLYH FKDQJH WR ELQGLQJ DIILQLW\    ȝ0 7KH GDWD FROOHFWHG XVLQJ WKH
IOXRULQDWHG SHSWLGHV VXJJHVWHG WKDW WKH ) 3KH UHVLGXH PD\ EH PRVW SLYRWDO EXW
LQWHUHVWLQJO\ WKH 3KH WR DODQLQH VXEVWLWXWLRQ LV WKH WLJKWHVW ELQGLQJ RI WKH VLQJOH PXWDQW
SHSWLGHVLHLWLVOHDVWDIIHFWHGE\WKHDODQLQHVXEVWLWXWLRQ 
7KHGRXEOHPXWDQWVDOO GLVSOD\HGZHDNHUELQGLQJDIILQLWLHV WKDQ WKHVLQJOHPXWDQWVZLWK
SHSWLGHV LQFOXGLQJ WKH3KHĺ$ VXEVWLWXWLRQ UHSRUWLQJ WKH ODUJHVW QHJDWLYHHIIHFW RQ WKH
SURWHLQ¶VDELOLW\ WRELQG WKHSHSWLGHVRPHRU-IROGUHGXFHGELQGLQJ7KH3KHĺ$
VXEVWLWXWLRQ UHVXOWHG  LQ D VLPLODU .G WR WKH VLQJOH PXWDQW SHSWLGHV ZKHUHDV GRXEOH
VXEVWLWXWLRQVLQYROYLQJ3KHGLVSOD\HGZHDNHUELQGLQJWKDQERWKWKH3KHĺ$DQGDOO
VLQJOHVXEVWLWXWHGSHSWLGHV7KLVLVDQLQWHUHVWLQJREVHUYDWLRQEHFDXVHLWLQGLFDWHVSULPDU\ 
UHFRJQLWLRQ RI ¨-VRP E\ K3', PD\ LQYROYH WKH &-WHUPLQDO UHJLRQ RI WKH SHSWLGH 7KLV






The shifts observed using the triple Phe to Ala substituted peptide were too small at the end 
of the titration to weight and fit accurately (the vast majority were smaller than 0.01 ppm). 
The lack of observable shifts in the spectra is highlighted in Figure 5.23, and Figure 5.24 
shows the magnitude of shifts observed when compared to an equivalent concentration of 
¨-VRP 7KH VPDOO VKLIWV REVHUYHG DSSHDUHG WR EH UDQGRPO\ VFDWWHUHG XSRQ WKH SURWHLQ¶V
surface, and are similar in distribution to shifts seen in the protein when using a non-
binding control peptide; helix-28 from human serum albumin (see Figures 5.25 and 5.26).  
The loss of recognition of E¶[ to this peptide demonstrates that all three phenylalanine 
residues together are crucial for the binding interaction to occur. Substitution of any one 
Phe residue weakens binding affinity, showing they all in some part contribute to binding. 
The data reported here also suggests that Phe 11 contributes most to the binding, as its 
substitution to alanine has the greatest negative effect on binding in all observed peptides. 




Figure 5.23: 15N,1H-HSQC spectra of 0.25 mM 15N E¶[ (blue) and 0.25 mM 15N E¶[ + 0.625 mM F1,2,3-
$OD¨-som (brown). 






Figure 5.24: Chemical shift perturbation map of 0.25 mM E¶[ P0¨-som (blue) and 0.25 mM 





Figure 5.25: 15N,1H-HSQC spectra of 0.25 mM 15N E¶[ (blue) and 0.25 mM 15N E¶[ + 0.625 mM HSA 
helix-28 (teal).  






Figure 5.26: Chemical shift perturbation map of 0.25 mM E¶[ upon addition of 0.625 mM non-binding 
control peptide HSA helix-28. 
 
5.4 Discussion 






RI WKH ELQGLQJ HYHQW IURP D µOLJDQG-REVHUYHG¶ SHUVSHFWLYH EXW KDV DOVR KLJKOLJKWHG WKH





ELQGLQJ RI WKH SHSWLGH WR E¶[ ZKLFK IXUWKHU GHPRQVWUDWHV WKDW OLNH RWKHU PROHFXODU
FKDSHURQHV K\GURSKRELF DURPDWLF DPLQR DFLGV PXVW SOD\ D NH\ UROH LQ K3',¶V OLJDQG
UHFRJQLWLRQ ,W LVDOVRRIQRWHWKDWIOXRULQHLV WKHRQO\FKDQQHOZLWKZKLFK¨-VRPSHSWLGH








GXH WR WKH ODFN RI EDFNJURXQG QRLVH DQG WKXV JUHDWO\ VLPSOLILHG VSHFWUD RU VLPSO\ WKH
LQFUHDVHG UHVROXWLRQ WKDW LV DYDLODEOHZKHQXVLQJ IOXRULQHDVDQ105SUREH2QDYHUDJH
WKH)QXFOHXVLVVXUURXQGHGE\HOHFWURQVDQGKHQFHZLOOUHSRUWPRUHVHQVLWLYHO\RQLWV





SHSWLGH$ FRPSDULVRQ RI SURWHLQ FKHPLFDO VKLIW SHUWXUEDWLRQV FRQILUPHG WKDW IOXRULQDWHG
SHSWLGHDSSHDUVWRELQGDQGLQWHUDFWZLWKE¶[SURWHLQLQDVLPLODUPDQQHUWRXQ-IOXRULQDWHG
SHSWLGH DQG WKHGLUHFWLRQDQGH[WHQWRIREVHUYHGFKHPLFDO VKLIW SHUWXUEDWLRQV DUHKLJKO\
FRPSDUDEOH 
7KH)OLJDQG-REVHUYHGPHWKRGKDVVHYHUDODGYDQWDJHVRYHUWUDGLWLRQDOXQLIRUPODEHOOLQJ
WHFKQLTXHV )LUVWO\ IOXRULQDWHG SHSWLGHV DUH HDVLO\ V\QWKHVL]HG DQG FRVW OLWWOH PRUH WKDQ
QRQ-IOXRULQDWHG SHSWLGHV 3HSWLGH 6\QWKHWLFV TXRWH a H[WUD SHU  PJ SHSWLGH
$GGLWLRQDOO\WKLVDSSURDFKGRHVQRWUHTXLUHIXOODVVLJQPHQWRIWKHSHSWLGH 
7KH VLQJOH 3KH SHSWLGHV HDFK SURGXFHG XQDPELJXRXV VSHFWUD ZLWK D VLQJOH SHDN 7KH
VSHFWUDRI)¨-VRPZHUHSHUKDSVPRUHFRPSOLFDWHGDVWKH)DQG)SHDNVLQLWLDOO\
RYHUODS$WWHPSWVZHUHPDGHWRDVVLJQHDFKRIWKH )SHDNVRI)¨-VRPEXWDJDLQ
PDQ\ RI WKH & VSHFWUD FROOHFWHG ZHUH EODQN 6SHFWUD RI GRXEOH IOXRULQDWHG ǻ-VRP
SHSWLGHVPD\KDYHEHHQKHOSIXO WRDLGLQWKHSHDNDVVLJQPHQWXVLQJRYHUODLG )VSHFWUD
EXW WKHUH ZDV QR JXDUDQWHH WKDW WKH REVHUYHG SHDNV ZRXOG RYHUOD\ ZLWK WKH WULSOH
IOXRULQDWHGSHSWLGHDVZDVDSSDUHQWZLWKWKHVLQJOH3KHSHSWLGHV8OWLPDWHO\WKLVZDVQRW










RI DOO WKUHH UHVLGXHV SUHYHQWHG DQ\ ELQGLQJ LQWHUDFWLRQ IURP RFFXUULQJ DOO VLQJOH 3KH
VXEVWLWXWLRQVZHUHVKRZQWRZHDNHQWKHELQGLQJDIILQLW\DOEHLWWRGLIIHUHQWH[WHQWVZLWK
WKHWZR3KH-$ODVXEVWLWXWLRQVJHQHUDOO\ZHDNHQLQJELQGLQJDIILQLQW\IXUWKHUVWLOO 
7KH DODQLQH VXEVWLWXWLRQV DOVR YDOLGDWHG WKH UHVXOWV REWDLQHG E\ ) REVHUYHG VSHFWUD E\
IXUWKHUVXJJHVWLQJWKDWWKHF-WHUPLQDOUHJLRQRIWKHSHSWLGHPD\H[HUWDJUHDWHUFRQWULEXWLRQ
WR WKHELQGLQJHYHQW WKDQ WKHQ-WHUPLQDO UHJLRQ7KHDODQLQHVXEVWLWXWHGSHSWLGHV LQGLFDWH
WKDWRIWKHWKUHHSKHQ\ODODQLQHUHVLGXHVLWLV3KH)WKDWKDVWKHJUHDWHVWFRQWULEXWLRQ
WR ELQGLQJ DV LW KDV WKH JUHDWHVW QHJDWLYH HIIHFW RQ ELQGLQJ ZKHQ VXEVWLWXWHG 7KH )
REVHUYHG GDWD DOVR VKRZHG WKDW WKLV UHVLGXH ZDV PRVW VHQVLWLYH WR PRUH ZLGHVSUHDG
IOXRULQDWLRQRIWKHSHSWLGH 
Together thLVZRUNVXJJHVWVWKDWUHFRJQLWLRQRI¨-som peptide may be mediated more by 
Phe residues, as opposed to Trp or Tyr residues, which is the case for PDIp ligand 
recognition (Ruddock et al., 2000a). This may go some way to explain how a synthetic 
peptide used within our laboratory, Pep-20 (YKLDKESYPVFYLFR), binds to hPDI 
PRGHUDWHO\PRUHWLJKWO\WKDQ¨-som (unpublished data). It contains two Phe residues in its 
c-terminal region, and no tryptophan residues. The work in this Chapter could easily be 
extended to include titrations using a fluoro-Trp or fluoro-7\U¨-som peptide, or fluoro-
Phe incorporated Pep-20 peptides, to investigate this idea further.    
5.4.2 Proof of Binding by NOESY-HSQCs 
NOESY-HSQC spectra were run at a variety of field strengths and temperatures, using 
either E¶[ and W111F DEE¶[ IUDJPHQWV ZLWK DQG ZLWKRXW ¨-som peptide, in attempts to 
identify intramolecular NOEs, for evidence of binding. This data would have been useful 
as it could have enabled structural restraints to be calculated for eventual generation of a 
ligand bound structure. Only 5 new NOE resonances were visible in E¶[ spectra with 
peptide at 37¡C, which whilst confirming binding, was deemed a scant number of NOEs 
with which to proceed any further. Different running temperatures and field strengths did 
not improve the number of NOE resonances collected, which may in part be due to 
incompatible running temperatures of protein and peptide. Natural abundance spectrDRI¨-
som could only be collected at temperatures lower than 10¡C- any higher than this and the 
peptide is so conformationally active that all peaks broaden out and the spectra appear 




blank. Chapter 4 showed that running protein spectra at temperatures lower than 37¡C (at 
25¡C) lead to much broader peaks and a significant loss of resolution. Thus, NOESY 
spectra collected at 10¡C were noticeably poorer than spectra collected at 37¡C, and still 
lacked any extra NOEs. A ligand-bound structure would help to greatly expand our 
knowledge of hPDI ligand binding, but in this case it appears that NMR techniques are 
somewhat limited by running compatibility of ligand and protein.  
5.4.3 Ligand Binding by 13C Methyl Shifts  
Ligand binding was also probed using overlaid methyl region 13C,1H-HSQCs of E¶[ 
protein, in the presence and absence of a binding ligand. Whilst data collected using 
15N,1H-HSQCs could be used to accurately quantify binding affinities, each titration shows 
a large number of resonances that shift upon binding, of which not all are directly involved 
in the binding event itself (i.e. some are reporting on induced structural changes). The 
carbon nuclei is thought to be less influenced by these structural changes, and we hoped 
using 13C,1H-HSQCs would be a more direct reporter of ligand binding. 13C,1H-HSQC 
spectra can be collected in similar time frame to 15N,1H-HSQC spectra, and 13C labelling is 
becoming  increasingly more affordable. This method of studying ligand binding is also 
gaining increased popularity for its application in studies of larger proteins, and as a 
preliminary screening tool (Hajduk et al., 2000), (Huth et al., 2007). Signals remain sharp 
and well-resolved even when using low concentrations of protein, and with recent 
developments in NMR sensitivity, spectra can even be collected on unlabelled proteins in a 
timely manner (Quinternet et al., 2012). Unfortunately, E¶[ protein lacked a functional 
number of assignable methyl reporters in its binding site (just three surface exposed methyl 
residues were assigned), which limited the detail this method could provide. The data did 
however, provide further evidence of a ligand-induced conformational change upon 
binding, and methyl resonances throughout the protein core reported perturbation upon 














Redox Studies of W111F DEE¶[  
by NMR Spectroscopy 
 
6.1 Introduction  
The ability of hPDI to carry out its catalytic roles as an oxidoreductase and isomerase is 
dependent on both the redox status of the ER cellular compartment in which PDI is 
localised, as well as the proteins own redox potential. A redox potential, also referred to as 
a reduction potential ሺܧ௢ᇱ ሻ, is a measure of a substances tendency to either gain or donate 
electrons, thereby becoming reduced or oxidised. In solution, a substance with a higher 
redox potential will have a tendency to gain electrons from another substance with a lower 
(less positive or more negative) redox potential. Thus, the substance with the lower redox 
potential will become oxidised, as it loses its electrons to the substance with a higher redox 
potential, which in turn will become reduced.  
Redox potential is a measurement that helps to define a proteins role in vivo; for example 
thioredoxin is a strong reductant with a calculated redox potential of -230 mV (Watson et 
al., 2003). hPDI active site reduction potentials are somewhat less reducing by comparison, 
and are reported as ܧ௢ᇱ  -162 mV for a domain and ܧ௢ᇱ  -169 mV for D¶ domain (Chambers et 




al., 2010). Whilst the ER is known to be an oxidising environment to facilitate disulphide 
bond formation, in this compartment hPDI is known to act as an oxidase, reductase and 
isomerase. This in vivo activity is defined not only by the proteins redox potential, but also 
its biochemical and kinetic ability to interact with other redox active substrates or smaller 
thiol containing compounds, and their relative concentrations (Sevier and Kaiser, 2002).  
In vitro, the ability of PDI to reduce or oxidise model substrates can be controlled by 
adjustment of the redox buffer (Freedman, 1995). The Kent NMR group have recently 
shown how 15N,1H-HSQCs can be used to probe the redox state of different proteins in 
solution (Taylor et al., 2013). The NMR based method was used to calculate the reduction 
potential of hPDI a (ܧ௢ᇱ  -145.3 + 1.0 mV) and hPDI ab (ܧ௢ᇱ  -158 + 2.4 mV). This Chapter 
reports calculation of the redox potential of the W111F DEE¶[ fragment, for comparison 
with the previously published data. 
6.1.1 Redox Potential by NMR Spectroscopy   
Redox potential by NMR is achieved by collecting a set of 15N,1H-HSQC spectra of the 
protein sample in redox equilibrium with a compound of known redox potential. Relative 
proportions of reduced and oxidised protein are calculated from the spectra and fit 
graphically to determine a redox potential. The published work uses a glutathione redox 
pair (GSH:GSSG) (Taylor et al., 2013), but the method is equally amenable to other redox 
pairs and this work also uses dithiothreitol (DTTred:DTTox). 
The exchange rate observed by NMR between reduced and oxidised hPDI is within the 
slow exchange rate timescale. This means that as the ratio of oxidising agent is increased, 
WKH µUHGXFHG¶ SHDNV LQ WKH RYHUODLG VSHFWUD ZLOO GHFUHDVH DQG WKH µR[LGLVHG¶ SHDNV ZLOO
increase in intensity (as shown in Figure 5.1 (b)). Hence relative proportions of reduced 
and oxidised protein can be recorded from the NMR spectra using peak height or volume 
from either reduced or oxidised peaks  (Taylor et al., 2013). The line broadening of 
resonances observed upon oxidation would complicate the dataset if both sets of peaks 
were monitored simultaneously, so in this instance only the assigned, reduced peaks were 
followed.  
The peak intensities collected from each spectra are made relative to their corresponding 
peak in a fully reduced spectra (Fred), and the relative value is used to determine an 




equilibrium constant (Keq) by fitting to the Hill equation, as shown by Equations 6.1 (a) for 
glutathione or (b) for dithiothreitol:-         ?Ǥ ?ሺܽሻܨ௥௘ௗ ൌ ሺሾܩܵܪሿଶ ሾܩܵܵܩሿሻ ሺܭ௘௤ ൅ ሾܩܵܪሿଶ ሾܩܵܵܩሿሻ ? ?ൗ  ሺܾሻܨ௥௘ௗ ൌ ሺሾܦܶܶ௥௘ௗሿ ሾܦܶܶ௢௫ሿሻ ሺܭ௘௤ ൅ ሾܦܶܶ௥௘ௗሿ ሾܦܶܶ௢௫ሿሻ ? ?ൗ  
Note that the equation used to generate Keq is dependent upon which redox pair is used; 
oxidised glutathione (GSSG) yields two molecules of reduced glutathione (GSH), whereas 
oxidised dithiothreitol (DTTox) yields one molecule of reduced dithiothreitol (DTTred). 
The reduction potential of the protein can then be determined using the Nernst Equation 
(Equation 6.2):-  ?Ǥ ?ܰ݁ݎ݊ݏݐܧݍݑܽݐ݅݋݊ǣܧ଴ᇱ ൌ  ܧ଴ሺோ௘ௗ௨௖௜௡௚஺௚௘௡௧ሻᇱ െ ሺܴܶ ݊ܨሻ ? ሺܭ௘௤ሻ 
Where ܧ଴ᇱ  is reduction potential, R is the molar gas constant, T is the temperature in 
Kelvin, ݊ is the number of reactive electrons in the red/ox process (in this case 2), and F is 
the Faraday constant. 
This method of redox potential calculation is particularly useful when studying proteins 
with multiple redox active sites, as is the case in a multi-domain protein such as hPDI. If 
the 15N,1H-HSQC spectra is assigned, resonances for each redox active domain can be 
analysed separately to determine individual domain redox potentials.  
6.1.2 Alternative Methods of Measuring hPDI Redox Potential 
hPDI redox potentials have previously been calculated by radiolabelling and HPLC 
(Lundstrom and Holmgren, 1993), (Darby and Creighton, 1995)7KHVHPHWKRGV µIUHH]H¶
the redox status of hPDI by acid quenching, followed by alkylation of the free thiols under 
denaturing conditions. Relative amounts of reduced and oxidised protein can then be 
determined, but if multiple redox active sites are present in the protein only an average 
redox potential of all sites can be calculated.  
Recent work has been carried out using a differential alkylation method, whereby the free 
thiols trapped by acid quenching are first alkylated using iodoacetate. The alkylated sample 
is run reduced on SDS-PAGE, and the band gel excised. The free thiols (that would have 
originally been disulphide bonded upon quenching, but are now in a reduced form) are 




then alkylated using 1,2 13C bromoacetate, and the protein is analysed by mass 
spectrometry (Chambers et al., 2010). Like our NMR spectroscopy method, this technique 
also allows individual redox potentials to be calculated for each catalytic domain of PDI.   
 
6.2 Materials and Methods 
6.2.1 NMR Sample Preparation  
Monomeric protein isotopically labelled and purified as outlined in Chapter 3 was buffer 
exchanged using a Vivaspin 20 Centrifugal Filter (10 kDa MWCO, Sartorius) into NMR 
buffer (20 mM sodium phosphate, 50 mM NaCl, pH 7.0) and then concentrated down 
(determined by A280 nm absorbance) into stocks to use as required. 
W111F DEE¶[protein stocks were made to 0.45 mM in NMR buffer, and reducing agents 
(DTTred and GSH) or oxidising agents (DTTox and GSSG) were made to 100 mM, 10 mM 
and 1 mM stock concentrations. Samples were prepared using 0.25 mM W111F DEE¶[, 
varying ratios of oxidising: reducing agents (5 mM total concentration), 10% D2O and 
VRGLXPD]LGHPDGHWRDWRWDOYROXPHRIȝ/XVLQJ105EXIIHUVHH$SSHQGL[
6.1 for a table of prepared samples). Prior to use, NMR buffer was degassed by sparging 
with nitrogen gas for two hours. All samples were made up in sterile Eppendorfs 
immediately prior to use and transferred to 5 mm Shigemi NMR tubes (BMS-005V, 
Sigma). 
6.2.2 NMR Data Acquisition and Processing 
NMR data was acquired at the University of Kent using a a 4-channel, 5-amplifier Bruker 
Avance III 14.1T (600MHz 1H) NMR spectrometer equipped with a 5mm QCI-F 
cryoprobe, unless otherwise stated. All experiments were carried out at 37¡C, pH 7.0, 
unless otherwise stated. 1H chemical shift referencing was carried out using the position of 
the 1H2O resonance at the given temperature. 15N chemical shifts were referenced using a 
spectrometer-based macro.  
All 2D NMR data was processed using NMRPipe software (Delaglio et al., 1995).  
 




6.2.2.1 15N,1H-HSQC Experiments of W111F DEE¶[ 
15N,1H-HSQC spectra were acquired of each protein fragment as previously outlined in 
4.2.2.1 using varying ratios of oxidising: reducing agent. 
6.2.3 NMR Data Analysis 
All subsequent data analysis of 2D spectra was carried out using CcpNmr Analysis 
software Version 2 (Vranken et al., 2005).  
6.2.3.1 Redox Potential of W111F DEE¶[ 
To measure protein redox potentials, peak volume intensities were collected from assigned 
peaks in spectra of W111F DEE¶[, and made relative to their corresponding peaks in the 
fully reduced spectra.  
Data was initially collected using the GSH:GSSG redox pair, and fitted to the Hill equation 
defined by Equation 6.1 (a) to determine an equilibrium constant. Fred was then plotted 
against Keq to determine a redox potential. Inspection of the graphs showed that when peak 
intensities collected using the higher concentrations of GSH ( > 4.5 mM) were made 
relative to a fully reduced spectra (collected using 5 mM DTTred), peaks appeared to 
µSODWHDX¶DWD)red ~0.6. These graphs highlighted that the glutathione system had reached 
its reducing ability at ~60% reduced, and hence could not fully reduce W111F DEE¶[. This 
result had not been observed in the laboratory when using hPDI fragments a and ab. 
Consequently an additional redox pair were chosen to collect data of the protein in a more 
reduced state. Since DTT has already been shown to be capable of fully reducing hPDI, 
and its oxidised form is readily available, it was chosen as a suitable alternative. It has the 
added benefit of being only moderately more reducing than glutathione, such that the 
equilibria of both redox pairs can be shifted to give buffers of the same redox potential (see 
table in Appendix 6.1).  
By using the Nernst Equation (Equation 6.2) to calculate individual redox potentials of 
each sample, data points were fitted using reduction potential along the x-axis instead of 
Keq. This allowed for data collected using different redox pairs (either dithiothreitol or 
glutathione) to be directly compared on the same graph. 
 




6.2.3.2 Graphical Fits 
All graphical fits were made using Kaleidagraph software version 4.1 (Synergy Software). 
The curve fit equation can be found in Appendix 6.2.  
 
6.3 Results  
There were 19 residues of W111F DEE¶[ that could be tracked accurately throughout the 
15N,1H-HSQC series to report on protein redox state. A representative sample of graphs 
are shown in this section, and additional raw data can be found in Appendix 6.2. 
6.3.1 Equating Redox Potential of W111F DEE¶[ by 15N,1H-HSQC   
The redox potential of W111F DEE¶[ was first attempted from practical data using the 
careful titration of differing ratios of the redox pair GSH:GSSG (ܧ௢ᇱ  -240 mV). Control 
spectra using 5 mM GSSG (fully oxidised) and 5 mM DTTred (fully reduced) were 
collected. There were 19 residues that could be tracked accurately throughout the redox 
series, and 12 example tracked resonances are highlighted in Figure 6.1.  
All reduced peak volume intensities collected from each spectra were made relative to the 
corresponding resonance in the fully reduced spectra. In addition to the two control 
spectra, 15 data points were collected using differing ratios of GSSG:GSH, that totalled 5 
mM red/ox agent.  
An overlay of protein spectra collected using 5 mM GSH and 5mM DTTred showed that the 
SURWHLQDSSHDUHG LQ DPL[HG UHGR[VWDWHZKHQ µUHGXFLQJ¶XVLQJJOXWDWKLRQHZLWKYDULRXV
peaks only present in oxidised spectra still being present in the 5 mM GSH spectra. This 
was not an expected result, as our laboratory have previously shown that the hPDI 
fragments a (at 0.065 mM) and ab (at 0.3 mM) are fully reduced by 5 mM GSH (Taylor et 
al., 2013). It has been suggested in the literature that there is cross-talk between the 
individual domains of hPDI- and ab fragment was shown by our laboratory to be 
moderately more reducing than a is as a single domain. It appears that W111F DEE¶[ is 
more reducing still, such that GSH is no longer able to fully reduce the active site of a 
domain.      






Figure 6.1: Overlaid 15N,1H-HSQC spectra of 0.25 mM 15N W111F DEE¶[ reduced using 5 mM DTTred 




Figure 6.2: Fraction reduced plot of 78Gly, fit using GSH:GSSG redox pair relative to spectra reduced 
by DTT. This Hill plot shows that 5 mM GSH is only able to reduce around 60% of W111F DEE¶[ relative 
to fully reduced spectra collected using 5mM DTTred. The DTTred peak is plotted as 4.999 mM GSH: 0.001 
mM GSSG for comparison with GSH: GSSG data points. Data points where it was deemed the reducing 
ability of GSH had been reached are circled in red.    




Attempts to fit the data to Hill plots when resonances were made relative to the 5 mM 
DTTred spectra showed that resonances in samples using >4.95 mM GSH seemed to 
plateau around 60% fraction reduced (see Figure 6.2). Higher total concentrations of 
reducing: oxidising agents were trialled (10 mM, 20 mM and 30 mM total concentrations), 
but the protein was not stable in such a great excess of redox agent. Instead, DTT was 
picked as an alternative red/ox agent, as it has a moderately stronger reducing ability (ܧ௢ᇱ  -
330 mV), and is also capable of fully reducing hPDI. Hence additional spectra were 
collected using differing ratios of the DTTred:DTTox redox pair (5 mM total concentration).  
Dithiothreitol is a moderately stronger reducing agent, and it was not possible to fully 
oxidise W111F DEE¶[ using DTTox. To enable data collected using both the glutathione 
and DTT data, the reduction potential of each individual experiment was calculated using 
the Keq of each experiment (see Equations 6.1 (a) and (b)) and the Nernst equation 
(Equation 6.2). Any glutathione collected data points that showed the reducing ability of 
GSH had been reached were removed from the fits (see two data points shown in red in 
Figure 6.2).  
An additional 11 data points were collected using the DTTred:DTTox pair, and example Hill 
plot fits of the data are shown in Figure 6.3. An average redox potential of ܧ௢ᇱ  -167.1 + 2.1 
mV was calculated for W111F DEE¶[. This value is moderately more reducing than the 
values calculated for both a domain (ܧ௢ᇱ  -145.3 + 1.0 mV) and ab fragment (ܧ௢ᇱ  -158 + 2.4 
mV), collected at 25¡C using the same method (Taylor et al., 2013). The value is however 
highly comparable to the value published by the Bulleid group for the a domain of full-
length hPDI (ܧ௢ᇱ  -162.7+ 2.9mV), that was determined using a chemical modification and 
mass spectrometry method as outlined in 6.1.2 (Chambers, Tavender et al. 2010).   





Figure 6.3: Redox potential graphs of W111F DEE¶[ as monitored by 15N,1H-HSQC, fit using the Hill 
Equation. Data points in black were collected using the DTTox:DTTred redox pair and data points in red were 
collected using the GSSG:GSH redox pair. The curves fit to give an average redox potential of -167.1 + 2.1 
mV. 




6.4 Discussion  
Overall this work shows the 15N,1H-HSQC method of determining redox potential is both 
reproducible and equally valid when different red/ox pairs are used. The redox potential of 
a domain as calculated here using W111F DEE¶[also closely agrees with the value of a 
domain as published by the Bulleid group for full-length hPDI (ܧ௢ᇱ  -162.7 + 2.9 mV). An 
interesting observation however is how the redox potential quoted here differs to values 
generated for other hPDI fragments containing a domain, as calculated within our 
laboratory using the same method. The raw data from fits of hPDI a and ab fragments (as 
published by Taylor et al. 2013) have been adapted to fit the same axis as the W111F 
DEE¶[ data given here, and an overlay of all averaged datapoints is shown in Figure 6.4. 
 
 
Figure 6.4: Redox potential graph of hPDI a (blue), hPDI ab (green) and hPDI W111F DEE¶[ (red) as 
monitored by 15N,1H-HSQC and fit using the Hill Equation. hPDI a and ab data was generated using the 
same method as published by Taylor et. al (2013).  




It appears that the redox potential of a domain becomes progressively more reducing upon 
addition of the extra domains. Note that the shape and gradient of each curve does not 
change for each of the hPDI fragments, but the curves merely shift towards a more 
reducing redox potential (read from the graph as 0.5 Fred). This suggests that additional 
domains are not destabilising the reduced or oxidised forms of the a domain, but the b 
domain and E¶ ligand binding domain are clearly having an effect on the redox potential.  
It was previously thought that like yPDI, the two active sites of hPDI must have differing 
redox potentials. ,Q \3', WKH (URĮ yeast homolog, Ero1p, preferentially oxidises the 
more reducing a domain of yPDI (yPDI active site of a: ܧ௢ᇱ  -194 mV, active site of D¶: ܧ௢ᇱ  -
164 mV), allowing the protein to exhibit oxidase activity with its a domain and isomerase 
activity with its D¶ domain (Vitu et al., 2010). This phenomena is reversed in humans, with 
(URĮ preferentially oxidising the D¶ domain over the active site in a (Baker et al., 
2008),(Wang et al., 2009). One might therefore infer that it is the D¶ domain of hPDI that 
has the more reduFLQJUHGR[SRWHQWLDODVLWLVSUHIHUHQWLDOO\WDUJHWHGE\(URĮ. However, 
the work by the Bulleid group suggests that the two active sites of hPDI are actually very 
similar in their reducing abilities (hPDI a active site : ܧ௢ᇱ  -162.7 + 2.9 mV, hPDI D¶  active 
site : ܧ௢ᇱ  -169.4 + 2.3 mV), and recent work by the Wang group also supports this. They 
instead believe the different abilites of the active sites are a result of asymetric recognition 
RI(URĮWRWKHE¶[D¶ fragment of hPDI, which causes specific oxidation of D¶ over the a 
domain active site (thereby allowing the a domain to primarily carry out isomerase 
activities, and the D¶ domain to carry out oxidase activity) (Zhang, Niu et al. 2014). They 
speculate that yPDI differs to hPDI in this manner, as yeast cells express far fewer 
disulphide-bonded proteins, thus regulated isomerase activity of yPDI is not as critical as it 
is for hPDI. However, this model of hPDI reduction/oxidation cannot explain why the 
redox potential of the active site in a domain might change upon additon of the b or E¶ 
domain, as has been published previously and reported in this thesis.  
In addition to the work shown here, preliminary studies carried out within our laboratory 
using hPDI DEE¶[D¶ show that the active sites of a and D¶ have significantly different redox 
potentials (active site of a: ܧ௢ᇱ  -180.7 + 12mV, active site of D¶: ܧ௢ᇱ  -219 + 8 mV, 
unpublished data). This could mean the yPDI and hPDI methods of redox control are much 
more analogous than is currently believed. Clearly, further work should be carried out to 
more accurately determine the redox potentials of the a and D¶ domains of full length hPDI, 




ideally together with calculations of D¶ as part of the E¶[D¶F and [D¶F fragments (individual 
D¶ domain would also be advantageous, but as a single domain gives exceedingly poor 





























Recombinant Fluoroindole Incorporation  
of W111F DEE¶[ 
 
 7.1 Introduction 
The work in Chapter 5 showed synthetic peptide fluorination is a technique well suited to 
study peptide ligand binding of hPDI fragments. The fluorination resulted in only modestly 
tighter Kd affinities, which were collected within a similar timescale to 15N, 1H-HSQC 
data, but with much faster analysis and greater data precision. The Kd values equated also 
had a greater degree of accuracy, so as a laboratory we were keen to further develop our 
use of fluorine probes to study hPDI.   
We recently published work that shows E¶[ protein is amenable to fluorination (Curtis-
Marof et al., 2014), using a simple and inexpensive recombinant labelling technique 
recently developed by Crowley et al. (Crowley et al., 2012). Recombinant fluorine 
labelling allowed the ligand binding evenWWREHREVHUYHGXVLQJµSURWHLQ-REVHUYHG¶'19F 
spectra and generated a Kd of 23 + ȝ0FDOFXODWHGDW& 
This chapter expands upon the published work, to further study the W111F DEE¶[ fragment 
of hPDI. It demonstrates the recombinant fluorine labelling of the protein fragment at its 




two key tryptophan residues; 35Trp,  that resides immediately adjacent to the active site of 
a domain, a reporter residue of protein redox state, and 3477US WKDW LV WKH µFDSSLQJ¶ DQG
ligand binding reporter of the x-linker region. Small preparative grows using 60 mg/L of 
each commercially available fluoroindole (4-F, 5-F, 6-F and 7-F) show that 6-F-indole 
gives greatest expression of W111F DEE¶[. This was in contrast to our work carried out 
using the E¶[ fragment of hPDI, where 5-F-indole gave greatest protein yields (and use of 
6-F-indole lead to some 10-fold poorer expression), suggesting that fluoroindole 
incorporation must be employed on a protein by protein basis.  
This chapter also demonstrates the use of 15N 6-F-Trp W111F DEE¶[ to further probe 
ligand binding and redox state, by both 15N,1H-HSQC and 19F 1D NMR spectra. In 
addition, a recent paper by Wang et al. suggested the active site of a domain may come 
much closer to the ligand binding site (when the protein is modelled in simulations) than 
any of their crystal structures suggest (Yang et al., 2014), and attempts to corroborate this 
idea by 1D and experimental 19F-19F NMR are also reported.  
7.1.1 Uses of Fluorine in Biochemistry 
Drug Development: Fluorine is extensively exploited by medicinal chemists for the 
unique properties and improved bioavailability or affinity it can confer to a compound. 
Despite its incredibly low uptake in nature, fluorine is now routinely incorporated into 
drugs, with over 20% of current pharmaceuticals containing at least one fluorine atom 
(Yamazaki et al., 2009). Fluorine can be used to modulate the basicity or lipophilicity of a 
compound, increasing membrane permeability or absorption. More commonly, substituents 
of fluorine are VSHFLILFDOO\ LQFRUSRUDWHG WR µEORFN¶ PHWDERlically labile sites of a drug, 
helping to increase its metabolic stability and half-life within the body (Bohm et al., 2004). 
Fluorines high electronegativity means it also has a powerful effect on the acidity or 
basicity of nearby functional groups, promoting tighter binding of a compound to its 
intended target, as well as increasing the overall stability and reactivity of it. The most 
historic use of fluorine in drug development is perhaps the development of 
fluoroquinolones, where addition of fluorine at carbon-6 increases the antibiotics potency 
more than 10-fold, and the minimum inhibitory concentration is reduced 100-fold 
(Andersson and MacGowan, 2003). 




Structure/Function-based Protein Studies: The incorporation of fluorinated amino acids 
into proteins to probe their structure and function is now heavily employed by scientists, 
with the topic well reviewed by Salwiczek et al. (Salwiczek et al., 2012). Fluorine makes 
for an attractive probe- it is not normally present in biological samples so has no 
competing background signal, and sterically the fluorine atom is a close mimic for 
hydrogen; fluorine is the next smallest atom after hydrogen, so a H-F or CH3- CH2F swap 
only occupies a 20% larger molecular volume (Yamazaki et al., 2009).  
The incorporation of fluorine has proven particularly useful in the study of hydrophobic 
protein cores, where initially fluorination works to increase hydrophobic interactions and 
therefore stabilises secondary structure, with successive fluorination causing 
destabilisation of the native secondary structure, either by steric hindrance or over-packing 
of the hydrophobic core (Horng and Raleigh, 2003), (Salwiczek and Koksch, 2009).  
There are a large number of fluorinated amino acids available for incorporation into 
peptides by solid-state synthesis or semi-synthetically into larger polypeptides by native 
chemical ligation. Cell free expression systems can also be used to produce fluorinated 
protein, a method that works by exploiting the anticodon-codon recognition between 
P51$ DQG W51$ FRXSOLQJ WKH FRUUHVSRQGLQJ ¶-terminus of a tRNA molecule to a 
fluorinated analogue results in the incorporation of fluorine into the polypeptide chain 
(Chapeville et al., 1962)). Site specific incorporation is also possible by use of orthogonal 
aminoacyl-tRNA synthetase-tRNA pairs that can incorporate non-canonical amino acids at 
DPEHUµVWRS¶FRGRQV(Noren et al., 1989)7KLVPHWKRGRIµH[SDQGLQJWKHJHQHWLFFRGH¶KDV
been intensively developed and it is now possible to incorporate non-canonical residues in 
bacterial (Neumann et al., 2008)), yeast (Hancock et al., 2010) and mammalian cell 
cultures (Mukai et al., 2008), and more recently has been made possible in multicellular 
organisms such as C. elegans (Greiss and Chin, 2011), (Parrish et al., 2012) and D. 
melanogaster (Bianco et al., 2012).  
7.1.2 Recombinant Protein Fluorination using E. coli 
Recombinant fluorine labelling of proteins is historically done in E. coli using auxotrophic 
strains that are not able to synthesise their own aromatic amino acids (Broos et al., 2003), 
or by using specific inhibitors of the aromatic synthesis pathway- indoleacrylic acid blocks 
tryptophan synthase (Matchett, 1972), and glyphosate blocks the Shikimate pathway 




(Hollnder and Amrhein, 1980). With these methods, supplementation with fluorinated 
aromatic amino acid analogues to the media consequently leads to their incorporation into 
the over-expressed protein. However, disruption of such an integral biosynthetic pathway 
can compromise the cells, leading to a build-up of metabolic intermediates, or more simply 
by causing secondary nutritional requirements (Whittaker, 2007). Equally, the fluorinated 
amino acid analogues and the inhibitors themselves can be costly to supplement.  
A recent method published by Crowley et al. (Crowley et al., 2012) is able to circumvent 
these problems, and works by a straightforward incorporation of fluoroindole into the 
growth media shortly before induction. To synthesise tryptophan, E. coli adds indole to a 
serine residue, in a condensation reaction catalysed by tryptophan synthase. This enzyme is 
DEOH WR DFFRPPRGDWH D ZLGH UDQJH RI LQGROH µPLPLFV¶ LQFOXGLQJ VHYHUDO IOXRULQDWHG
analogues (Ngo et al., 2007). Figure 7.1 demonstrates this reaction, showing the synthesis 




Figure 7.1: 6-F-Tryptophan synthesis from serine and 6-F-indole. The reaction is catalysed by tryptophan 
synthase in a condensation reaction.  
 
The developed method does not require special auxotrophic cell strains or inhibitors, and 
has the added benefit of being much more cost-effective; gram for gram 5-fluoroindole is 
fifty times cheaper than 5-fluorotryptophan. Previous work by our laboratory has shown 




incorporation of 5-fluoroindole into 5-F-Trp labelled E¶[ protein to be in excess of 80% 
(Curtis-Marof et al., 2014), proving the method as a simple and effective 19F labelling 
strategy for NMR studies. 
 
7.1.3 Fluorination of W111F DEE¶[ 
There are two sites in W111F DEE¶[ that should incorporate the fluoroindole into fluoro-
Trp:  35Trp, a conserved residue of unknown function, that lies immediately adjacent to the 
active site in a domain, and 3477US WKH µFDSSLQJ¶ reporter present in the x-linker region 
(see Figure 7.2).  
 
Figure 7.2: The DEE¶[ portion of the crystal model of reduced DEE¶[D¶ (4EKZ.pdb) highlighting the two 
Trp residues to be fluorinated (red), and the position of the W111F mutation. The ligand binding site is 









The W111F substitution is also highlighted in the Figure to demonstrate an additional 
advantage of using the W111F fluorescence mutant in place of WT DEE¶[. The 111Trp 
residue is buried within the protein core, and unpublished studies within the laboratory 
have shown that fluorination at this site may disrupt the stability of the protein 
(unpublished observation). 
 
7.2 Materials and Methods 
7.2.1 Recombinant Protein Expression 
The method of recombinant fluorine incorporation as outlined by Crowley et al. requires 
60 mg/L fluoroindole be added to the culture immediately prior to induction. Therefore, 
cells were grown initially as stated in 3.3.2 until an A600 of 0.7 AU was reached. Next, 
fluoroindole from a 200x stock (12 g/L stock, in 100% DMSO) was added to each flask to 
reach a final concentration of 60 mg/L, and incubated at 37¡C for 15 minutes with 200 rpm 
shaking. Cells were then induced as normal using 1 mM IPTG and incubated overnight at 
27¡C with 200 rpm shaking (as per standard protocol). Pelleted cells were then lysed and 
purified as outlined in 3.2.4.   
7.2.2 Mass Determination and Isotope Incorporation   
The molecular weight of 19F,15N isotopically enriched monomeric W111F DEE¶[ protein 
was determined using Electrospray Mass Spectrometry, performed by Mr Kevin Howland, 
Biomolecular Science Facility Manager, University of Kent. 
7.2.3 NMR Sample Preparation, Data Acquisition and Processing 
All 15N,1H-HSQC and 19F 1D NMR data was acquired and processed at the University of 
Kent as previously outlined in Chapter 5. 
7.2.4 NMR Data Analysis 
All subsequent data analysis of 1D spectra was carried out using Bruker Topspin software, 
and all 2D spectra analysis was carried out using CcpNmr Analysis software Version 2 
(Vranken, Boucher et al. 2005).  




7.2.4.1 19F Protein Assignment 
19F spectra of reduced 6-F-Trp DEE¶[ protein yielded two distinct fluorine resonances that 
overlaid well with previous spectra collected within the laboratory of other fluorinated 
hPDI fragments with 5-F-Trp incorporation. These previously assigned spectra permitted 
the straightforward assignment of 6-F-Trp resonances.        
7.2.4.2 Chemical Shift Perturbation Mapping 
All 15N,1H-HSQC and 19F 1D chemical shift perturbations were calculated as previously 
outlined in 5.2.3.2.  
7.2.4.3 Redox Potential of 6-F-Trp 15N W111F DEE¶[  
Using 15N data: Reduction potential by 15N was measured from peak volume intensities, 
and calculated as previously outlined in 6.2.3.1.  
Using 19F data: Reduction potential by 19F was plotted using the 35Trp integrated peak 
volume from each redox experiment, which was made relative to its corresponding peak in 
the fully reduced spectra and plot against the reduction potential as calculated by the 
Nernst Equation (Equation 6.2). Initial plots of the data from each redox pair (either 
glutathione or DTT) showed that in contrast to 15N collected data of DEE¶[, the points did 
not readily fit to the same curve. Therefore, each redox pair was fitted to individual Hill 
Plots to calculate a reduction potential for each separate glutathione or DTT redox pair.    
7.2.4.4 Graphical Fits 
All graphical fits were made as previously outlined in 6.2.3.2. 
 
7.3 Results 
7.3.1 Expression of 6-F-Trp 15N W111F DEE¶[ 
As previously reported in Chapter 3, E. coli BL21 (DE3) pLysS cells with the W111F 
DEE¶[ insert show normal growth times in minimal media, with a total cell increase upon 
standard overnight induction of around 170%. To assess the effect DMSO (the indole stock 
solvent), and each indole might have upon protein expression and cell growth, 100 mL test 




cultures were grown, with addition of the selected indole prior to induction. Pre and post 
induction A600 nm readings were recorded and pellets ran on reducing SDS-PAGE (see 
Table 7.1 and Figure 7.3).  
Table 7.1: Pre and post induction A600 nm readings of test indole cultures. 
Expression conditions Pre-Induction A600  Post-Induction A600        
(% cell increase) 
15N labelling 0.686 1.862 (171%) 
15N labelling + DMSO 0.695 1.831 (163%) 
15N labelling + indole 0.720 1.783 (148%) 
15N labelling + 4-F-indole 0.670 1.608 (140%) 
15N labelling + 5-F-indole 0.668 1.024 (53%) 
15N labelling + 6-F-indole 0.677 1.700 (151%) 
15N labelling + 7-F-indole 0.686 1.646 (140%) 
0.5% DMSO (the indole solvent) and 4, 6, or 7 F-indoles had minimal effect on % cell increase upon 
induction, whilst 5-F-indole appeared to have an inhibitory effect on cell growth after its addition, as shown 
by the markedly reduced % cell increase.    
 
With the exception of 5-F-indole, the cultures showed only a minor drop in total 
percentage cell increase (reduction of 8% upon addition of DMSO, and reduction of 23% 
upon addition of indole), thus the addition of these indoles did not appear to adversely 
affect cell growth. In contrast, 5-F-indole appeared to have an inhibitory effect upon cell 
growth, with an observed overnight cell increase of only 53%, one third of the cell growth 
observed when un-fluorinated indole was added to the culture (see Table 7.1). This is an 
interesting observation, as previous work by the laboratory using the same expression 
system has shown that incorporation of 5-F-indole actually has no effect on cell growth, 
and of the four fluoroindoles gives greatest expression of hPDI ab and E¶[ fragments.  




   
Figure 7.3: 10% reducing SDS-PAGE analysis of 19F W111F DEE¶[ expression in the presence of indole. 
Lane 1: Precision Plus protein marker, lanes 2 & 3: pre and post induction pellets (+ unfluorinated indole), 
lanes 4 & 5: pre and post induction pellets (+ 4-F-indole), lanes 6 & 7: pre and post induction pellets (+ 5-F-
indole), lanes 8 & 9: pre and post induction pellets (+ 6-F-indole), lanes 10 & 11: pre and post induction 
pellets (+ 7-F-indole). 
 
Figure 7.3 demonstrates the protein expression observed in pre and post induction pellets. 
It appears that only the 6-F-indole culture expressed an amount of W111F DEE¶[ protein 
comparable to the un-fluorinated indole control culture. The over-expressed protein band 
was noticeably lower in intensity for the 4-F-indole, 5-F-indole and 7-F-indole test 
cultures. As a result, 6-F-indole was chosen for incorporation into W111F DEE¶[ 
7.3.2 Mass Determination and Isotopic Incorporation 
The molecular weight of 15N W111F abb¶[ as determined by mass spectrometry (see 
Figure 3.8) is 41004.4 Da (98.9% 15N incorporation). There are two potential sites of 
fluorine incorporation within the protein, and the hydrogen to fluorine swap will result in a 
mass increase of +18 Da at each site.  Mass spectrometry analysis of 6-F-Trp 15N W111F 
DEE¶[ is shown in Figure 7.4 (a). It is clear from the spectra that the protein purifies as a 
heterogenous mixture of fluorinated and un-fluorinated protein. Deconvolution of the 
major peaks identified three different protein species (see Figure 7.4 (b)), the largest of 
which (41,020.5 Da) corresponds to a singly fluorinated species (~40% relative intensity). 
Unfortunately it is not possible from mass spectrometry alone to state which of the two 




sites has been fluorinated. The peak at 41,003.8 Da corresponds to un-fluorinated protein 
(~30% relative intensity), and the peak at 41,039.4 Da corresponds to double fluorinated 





Peak MW (Da) Mass Increase (Da) Sequence Identity Relative Intensity 
A 41003.1 N/A 15N W111F DEE¶[ (un-fluorinated) 30% 
B 41020.3 + 17.2 15N,19F W111F DEE¶[ (single fluorination) 40% 
C 41037.0 + 33.9 15N,19F W111F DEE¶[ (double fluorination) 30% 
 
Figure 7.4: Mass spectrometry analysis of 6-F-Trp 15N W111F DEE¶[ (a). Corresponding MW and 
relative intensities of each labelled peak (A, B and C from (a)) are shown in (b).   
 
To gain more information on the relative amounts of fluorination at each Trp residue, 19F 
1D spectra of the protein was also collected. The spectra was first overlaid with other 
spectra collected within the laboratory of two 5-F-Trp labelled hPDI fragments- ab and 




E¶[, to attempt identification of each fluorine peak of 6-F-Trp 15N W111F DEE¶[ (see 
Figure 7.5). The spectra of 5-F-Trp labelled fragments overlaid well with 6-F-Trp 15N 
W111F DEE¶[, and suggested the peak at -119.73 ppm corresponds to 35Trp of a domain, 
and the peak at -121.37 ppm corresponds to 347Trp of the x-linker region. The peak at -
119.23 ppm is a minor fluorine contaminant found in our water supply, and is present in all 




Figure 7.5: Overlaid 19F 1D spectrum of 5-F-Trp ab (blue), 5-F-Trp E¶[ (green) and 6-F-Trp W111F 
DEE¶[(red). 5-F-Trp ab and E¶[ 19F spectra collected by other laboratory members were used to assign 6-F-
Trp W111F DEE¶[. Note: 35Trp present in a domain, 111Trp present in a domain of WT ab only, 347Trp 
present in x-linker region. 347Trp as part of 5-F-Trp E¶[ is present in its µcapped¶ and µuncapped¶ species.  
 
Integration of the two fluorine peaks of 6-F-Trp 15N W111F DEE¶[ shown in Figure 7.6 
gives an estimated 40% fluorine incorporation at 35Trp, and 60% incorporation at 347Trp. 
Together with the mass spectrometry peak deconvolution, it can be estimated that their 
exists approximately 30% single 6-F-35Trp species and 10% single 6-F-347Trp species.  




Overall this level of incorporation is much lower than was achieved using 5-F-indole 





Figure 7.6: 19F 1D spectrum of 0.25 mM 6-F-Trp 15N W111F DEE¶[. Integration of the two peaks gives an 
approximate fluorine incorporation of 40% at 35Trp (a) :60% at 347Trp (x-linker).  
 
7.3.3 Effects of 19F Incorporation Observed by15N,1H-HSQC  
15N,1H-HSQC spectra collected from fluorinated protein samples overlays well with 
spectra of non-fluorinated protein (see Figure 7.7). This was to be expected; the spectra is 
displaying resonances of both the double and single fluorinated, and un-fluorinated protein 
species in the sample. As such, chemical shift perturbation maps of overlaid spectra with 
un-fluorinated protein reported no obvious perturbations, as each resonance was simply 
mapping to the non-fluorinated protein resonances.  
The 35Trp and 3477US LQGROH UHVRQDQFHV DUH VWLOO SURPLQHQW LQ WKH µIOXRULQDWHG¶ HSQC 
spectra; if fluorine is incorporated at these sites, they would not also be 15N labelled, and 
thus should disappear from the spectra. This observation is therefore consistent with a low 
rate of fluorine incorporation at the two sites. A closer inspection of the spectra showed 
there are extra peaks observable for both the 35Trp and 36Cys amide resonances, suggesting 
36&\VDOVR µVHQVHV¶DFKDQJHXSRQIOXRULQDWLRQRI 35Trp. The new peaks are an estimated 




two thirds the intensity of the non-fluorinated resonances, concurrent with the values 
estimated in 7.3.2 for fluorination at this Trp site (40%). Unfortunately 347Trp amide 
resonance is in a crowded region of the spectra, so any extra peak that may appear from the 
fluorinated protein is not readily visible. Unlike 35Trp and 36Cys, residues 38His and 39Cys 




Figure 7.7: 15N,1H- HSQC spectrum of 0.25 mM 15N DEE¶[(black) overlaid with 0.25 mM 6-F-Trp 15N 
W111F DEE¶[ (red). Resonances constituting the redox active site and the two fluorinated Trp residues are 
highlighted on the spectra by dashed boxes.  
   
7.3.4 Ligand Binding of 6-F-Trp 15N W111F DEE¶[  
As demonstrated by mass spectrometry, 15N,1H-HSQC and 19F 1D NMR, the total level of 
fluorine incorporation is relatively low when compared to uniform isotope labelling 
methods (98.9% incorporation of 15N was reported for W111F DEE¶[ in 3.3.5). Practically, 
WKLVOHYHORILQFRUSRUDWLRQOLPLWVWKHXVHRIµPL[HGIOXRULQDWHG¶SURWHLQIRUGHWDLOHGOLJDQG
binding analysis, where a homogenous, uniform protein species is paramount for 
quantitative studies. Ligand binding titrations carried out by 15N,1H-HSQC generated an 




average Kd of 90 + 65 ȝ0EXWLWPXVWEHDSSUHFLDWHGWKLVILJXUHLVUHSRUWLQJRQDPL[WXUH
of fluorinated and un-fluorinated protein within the sample (see Appendix 7.1 for graphical 
fits). As a result, the figure quoted may downplay the influence of fluorinated protein on 
peptide ligand binding. 
Preliminary 19F 1D spectra collected of exclusively fluorinated protein (whilst in a mixed 
fluorinated protein sample) showed the x-linker 347Trp residue is perturbed upon addition 
RI HLWKHU ¨-VRP RU ) ¨-som peptides, with chemical shift perturbation of a similar 
magnitude and direction to that observed as published with 5-F-Trp E¶[ protein (Curtis-
Marof et al., 2014). An interesting observation was the smaller perturbation of 35Trp 
resonance, that is found directly adjacent to active site in a domain. This resonance was 
seen to report shift changes upon addition of either fluorinated or un-fluorinated peptide 
(see Figure 7.8), suggesting that residues close to the catalytic active site in a are 
influenced by peptide ligand binding in E¶ domain. This phenomena had not previously 
been observed by traditional NMR methods. 
 
 
Figure 7.8: Overlaid 19F 1D spectrum of 0.25 mM 6-F-Trp 15N W111F DEE¶[ (blue) with addition of 
either 0.625 P0¨VRP (green) or 0.625 mM )¨VRPSHSWLGH (red). The spectra show that the 6-F-
Trp in the x-linker reports perturbation upon ligand binding with both fluorinated and un-fluorinated peptide. 
Interestingly, the 6-F-Trp in a domain is also perturbed by ligand binding of both peptides, with the greatest 
SHUWXUEDWLRQREVHUYHGXSRQDGGLWLRQRI)¨-som peptide.  




Close contact of the a domain active site and the ligand binding site have recently been 
suggested by the Wang group (Yang et al., 2014), so this was an exciting observation. The 
extent of perturbation was largest with the addition of fluorinated protein, therefore 
attempts were made by NOE difference and 19F-19F NOESY experiments (between 
fluorinated protein and fluorinated peptide) to confirm this occurrence, but unfortunately 
were not successful, resulting in blank spectra.   
7.3.5 Redox Potential of 6-F-Trp 15N W111F DEE¶[ 
19F 1D spectra were collected of reduced and oxidised 6-F-Trp 15N W111F DEE¶[, and 
showed that both fluorine resonances reported a perturbation upon change in redox state 
(see Figure 7.9). A clear shift was observed for 35Trp resonance upon change in redox 
state, with the oxidised peak appearing much broader and lower in intensity, consistent 
with the previous data collected of 15N labelled protein by 15N,1H-HSQC (see 4.3.1). The 
3477US UHVRQDQFH H[LVWV DV D PL[WXUH RI µFDSSHG¶ DQG µXQFDSSHG¶ SURWHLQ ZLWK UHGXFHG
SURWHLQ DGRSWLQJ D PRVWO\ µFDSSHG¶ IRUP DQG oxidised protein adopting a mostly 
µXQFDSSHG¶ IRUP ,W ZDV UHDVRQHG WKDW DV 3477US UHSRUWV WKLV G\QDPLF µFDSSLQJ¶ DQG
µXQFDSSLQJ¶HYHQWDnd appears as multiple resonances, it would not be an accurate reporter 
of protein redox state. Efforts were therefore directed to observation of 35Trp resonance to 
solely monitor protein redox state.             
 
Figure 7.9: Overlaid 19F 1D spectrum of 0.25 mM 6-F-Trp 15N W111F DEE¶[ reduced (red) and 
oxidised (blue).   
 




The redox potential of 6-F-Trp 15N W111F DEE¶[ was attempted from practical data, using 
the careful titration of differing ratios of the redox pairs GSH:GSSG (ܧ௢ᇱ  -240 mV) and 
DTTred:DTTox (ܧ௢ᇱ  -330 mV) to follow the 35Trp resonance. As per 15N,1H-HSQC redox 
potential data collection, control spectra using 5 mM GSSG (fully oxidised) and 5 mM 
DTTred (fully reduced) were collected. 35Trp peak heights and volumes were recorded from 
each spectra and made relative to the fully reduced spectra. In addition to the two control 
spectra, 4 data points were initially collected using differing ratios of GSH:GSSG, as 
shown in Figure 7.10. 
 
Figure 7.10: 19F 1D spectra of 6-F-Trp W111F DEE¶[ change in protein redox state, using the 
GSH:GSSG redox pair. The 35Trp resonance in a reports a gradual shift from a mixture of reduced/oxidised 
protein (at -176 mV), to a completely oxidised protein (at -108 mV). The 347Trp in x-linker also shows a 
JUDGXDOFKDQJHIURPPRVWO\µFDSSHG¶WRPRVWO\µXQFDSSHG¶IRUPVXSRQR[LGDWLRQ 
 




A similar threshold of the ability of GSH to reduce W111F DEE¶[ was also observed by 19F 
1D, hence an additional 5 data points were collected using differing ratios of 
DTTred:DTTox, to complete the reduced portion of the Hill plot. The spectra collected are 
shown in Figure 7.11.  
 
 
Figure 7.11: 19F 1D spectra of 6-F-Trp W111F DEE¶[ change in redox state, using the DTTred:DTTox 
redox pair. The 35Trp resonance in a reports a gradual change from reduced protein (at -330 mV) to a 
completely oxidised protein (at -176 mV). The 347Trp in x-linker shows a slight shift, IURPPRVWO\µFDSSHG¶
WRDPL[WXUHRIµFDSSHG¶DQGµXQFDSSHG¶IRUPV upon change in oxidation state.  
 
Similar experiments run using uniform 15N labelled W111F DEE¶[showed the DTT redox 
pair to be strongly reducing, capable of keeping the protein between 70-100% reduced (for 
a comparison see the black data points of Figure 6.3). In direct contrast, observation of the 
35Trp resonance in 19F 1D spectra here suggest the protein is more oxidised than 




anticipated by the redox potential equilibria used. An overlay of two experiments, both at 
equilibria of -176 mV (achieved with either 4.99 mM DTTox: 0.001 mM DTTred or 0.5 mM 
GSSG: 4.5mM GSH) show 35Trp reporting different protein redox states, depending on the 
redox pair used (see Figure 7.12).  
 
  
Figure 7.12: Overlaid 19F 1D spectra of 4.99 mM DTTox: 0.001 mM DTTred (red) and 0.5 mM 
GSSG:4.5 mM GSH (blue). Both experiments are conducted with the system at ܧ௢ᇱ : -176 mV.    
 
It is interesting to note that whilst the 35Trp appears in a mixed redox state with the 
glutathione redox pair, and subsequently an almost exclusively oxidised state with the DTT 
redox pair, that the 347Trp resonances report similar proportions of µFDSSHG¶ DQG
µXQFDSSHG¶ SURWHLQ LQ WKH RYHUODLG VSHFWUD 7KLV VXJJHVWV WKDW WKH x-linker Trp does not 
µVHQVH¶WKHFKDQJHLQUHGR[VWDWHLQWKHVDPHZD\WKH7USUHVLGXHLQa domain does.  
When the two datasets are fit independently to Hill plots (Figure 7.13), they give redox 
potentials of ܧ௢ᇱ  -187 + 5 mV for the glutathione pair, and ܧ௢ᇱ  -208 + 4 mV for the DTT 
pair. This stark difference was not observed when using 15N uniform labelled protein, 
where all data points fit to a single curve to give a redox potential of ܧ௢ᇱ  -167 + 2.1 mV. 
This suggests that either the fluorine is altering the local environment to such an extent as 
to modify the redox potential of the a domain active site, or alternatively, the presence of 
fluorine is causing an unexpected interaction between the DTT and the catalytic site. 





Figure 7.13: Redox potential graph of 6-F-Trp W111F DEE¶[ as monitored by 19F 1D spectra, fit using 
the Hill Equation. Data points in red were collected using the DTTox:DTTred redox pair and fit to give a 
redox potential of ܧ௢ᇱ  -208 + 4 mV. Data points in blue were collected using the GSSG:GSH redox pair and 
fit to give a redox potential of ܧ௢ᇱ  -187 + 5 mV. 
 
Indole is not thought to react with DTT, however spectra of 0.25 mM 6-F-indole in the 
presence of a 20 molar excess of either DTTred or DTTox are markedly different, with 
fluoroindole peaks in the presence of DTTox displaying peak broadening (see Figure 7.14), 
hinting there may be an interaction. 
It is apparent more work needs to be carried out to ascertain what effect the fluorination is 
having on the hPDI redox system, which unfortunately was not within the timescale of this 
thesis.        
 
 





Figure 7.14: Overlaid 19F 1D spectra of 0.25 mM 6-F-indole with 5 mM DTTred (red) or 5 mM DTTox 
(blue). Line broadening of the fluoroindole peaks suggests the DTTox could be interacting with 6-F-indole. 
 
7.4 Discussion 
7.4.1 Expression of 6-F-Trp 15N W111F DEE¶[ 
Incorporation of 60 mg/L unfluorinated indole into cells grown using standard minimal 
media for expression of 15N W111F DEE¶[ was successful, with the addition having no 
visible adverse effects to either cell growth or protein expression, and with comparable 
expression upon induction to standard minimal grows. Of the fluorinated indoles, addition 
of 4-F, 5-F or 7-F-indole to the growth medium were each found to have inhibitory effects- 
either by retarding cell growth (5-F), or with unaffected cell growth, but no visible W111F 
DEE¶[ expression bands by SDS-PAGE (4-F and 7-F). Protein expression using 6-F-indole 
gave a prominent protein band comparable to those observed in standard minimal grows. 
The protein was readily purified using metal affinity, anion exchange and size exclusion 
chromatography, resolving as a predominantly monomeric protein, with a small portion of 
well resolved dimer (as previously reported for W111F DEE¶[, Chapter 3). Final 
monomeric protein yields were also highly comparable to those previously described for 
W111F DEE¶[.       




Mass spectrometry of the monomeric protein indicated that several different forms of the 
monomer had been co-purified. Masses of 41,003.8 Da (corresponding to un-fluorinated 
protein: 30%), 41,020.5 Da (corresponding to singly fluorinated protein: 40%) and 
41,039.4 Da (corresponding to doubly fluorinated protein: 30%) were all identified. 
15N,1H-HSQC NMR spectra of the protein also demonstrated fluorine incorporation was 
not as high as had been anticipated- if fluoroindole is taken up by cells for synthesis of 
fluoro-tryptophan, then the indole of each Trp residue will not contain 15N labelling, (and 
should therefore disappear from the spectra). Both 35Trp and 347Trp indole resonances were 
still clearly visible in the spectra, suggesting a low proportion of protein was fluorinated at 
these sites. 
19F 1D NMR spectra of the protein showed two distinct peaks, that correlate well with 
corresponding 5-F-indole hPDI fragment spectra collected within the laboratory. Peak 
integration estimated 60% incorporation at residue 347Trp, and 40% at residue 35Trp. 
Together with the mass spectrometry analysis, this suggests 30% of protein was labelled at 
both Trp sites, 30% labelled at 347Trp (x-linker) only, 10% labelled at 35Trp (a domain) 
only, and the remaining 30% was expressed as un-fluorinated protein.  
This analysis suggested fluorine incorporation into W111F DEE¶[ by 6-F-indole was not as 
extensive or uniform as previously published for the E¶[ fragment (Curtis-Marof et al., 
2014), where greater than 80% incorporation of E¶[ was achieved using 5-F-indole. Work 
carried out within this thesis showed 5-F-indole had an inhibitory effect on the growth of 
cells encoding W111F DEE¶[. 5-F-indole has long been reported as being non-specifically 
cytotoxic to cells (Taub, 1977); indeed the method developed by Crowley et al. also 
reported a toxic effect on cells when used at concentrations of 300 mg/L (Crowley et al., 
2012). However, care was taken to use a final concentration of 60 mg/L 5-F-indole in the 
test expressions, so results from all fluoroindole grows could be directly compared. 
It is possible the new stock of 5-F-indole used within this thesis could have been 
contaminated with something else the cells find toxic, perhaps introduced at a stage of 
purification or synthesis. Unfortunately there was not time to probe this idea any further. It 
may be helpful to note that some of the fluorinated indoles have only been recently 
V\QWKHVLVHGE\6LJPD WKH\RIIHU µH[SHULPHQWDO¶JUDGHV WKDWGRQRWFRPHZLWKDQDO\WLFDO
identification or purity), with 7-F-indole only becoming available in 2015. It is also 




interesting to note that whilst 5-F-indole gave greatest protein expression for the E¶[ 
fragment, incorporation using 6-F-indole into E¶[ was also successful in the laboratory, 
with an estimated incorporation of 55%. This value is supportive of the incorporation 
observed here of 6-F-indole incorporation into W111F DEE¶[, where incorporation at 
347Trp (the same Trp residue fluorinated as in the E¶[ fragment) was estimated at 60%. 
In summary, the observed level of fluorine incorporation into W111F DEE¶[ complicated 
further quantitative analysis of fluorinated protein. 15N,1H NMR spectra report on all 15N 
labelled protein in the sample, whether fluorinated or not. It is clear to see from the 15N,1H-
HSQC in Figure 7.7 that some residues are shifting upon fluorination, but chemical shift 
perturbation maps will map to the nearest peak. In a mixed population this will likely be 
the unfluorinated peaks, FRQVHTXHQWO\µdownplayLQJ¶ WKHH[WHQW IOXRULQDWLRQ LVKDYLQJon 
the protein. Ideally, fluorinated protein needs to be isolated from unfluorinated protein 
prior to analysis by NMR. This was simply not possible by the purification techniques used 
within this thesis. Similarly, identification of either a +18 or +36 Da mass change to a 40.5 
kDa protein was only possible by mass spectrometry using sophisticated deconvolution 
software.  
It may be beneficial to trial fluoroindole expression using a fresh stock of 5-F-indole, to 
see if this fluoroindole can potentially be incorporated as successfully into W111F DEE¶[ 
as was reported for the E¶[ fragment.      
7.4.2 Protein-Observed Ligand Binding by 19F NMR 
Detailed ligand binding analysis of fluorinated protein was made more complex by the 
presence of a mixed protein sample, hence the dissociation constant calculated by 15N-1H-
HSQC (Kd: 90 + 65 ȝ0LVUHSRUWLQJ on both un-fluorinated and fluorinated protein in the 
sample. Whilst the measured Kd value suggests fluorination does not influence peptide 
binding affinity, it is difficult to conclusively say this is the case, due to mixed species 
being present. Nevertheless, the 19F peaks of 6-F-Trp W111F DEE¶[ were well resolved, 
and were also distinct from fluorinated peptide peaks, illustrating that ligand binding could 
be tracked for both peptide and protein simultaneously by 19F, especially if higher rates of 
protein fluorine incorporation can be achieved. Quantitative studies were not undertaken 
using 19F 1D spectra because work already carried out within the laboratory using the E¶[ 




fragment of hPDI determined a modest increase in binding affinity when 19F was 
incorporated (Curtis-Marof et al., 2014). 
It was an exciting observation that the fluorinated 35Trp resonance in a was perturbed upon 
ligand binding, suggesting that the active site of a domain is in a relatively close molecular 
proximity to the PDI binding site in E¶, as speculated by Wang et al. recent paper (Yang et 
al., 2014). Unfortunately work carried out to attempt collection of 19F-19F NOEs (between 
19F Trp in a domain, 19F Trp in x-linker DQG IOXRULQDWHG) ¨-som peptide) was not 
successful, giving blank spectra. In addition, NOE difference spectra, that work by 
selectively saturating ligand peaks to view changes to the protein peaks (or vice versa), did 
not yield any difference spectra. Consequently, all attempts to validate this occurrence 
were inconclusive.  However, work within the laboratory that was conducted after practical 
work for this thesis was concluded, has shown that at 14.1 tesla, 19F relaxation is severely 
influenced by chemical shift anisotropy. Although T1-based NOE transfer is possible, 
transverse relaxation would drive exceptionally fast signal decay and would hamper the 
detection of 19F-19F NOEs (personal communication with M.J.Howard).  
7.4.3 Redox Potential by 19F NMR 
It was anticipated that the incorporation of fluorine probes into the W111F DEE¶[protein 
might allow 19F 1D spectra to be used much like is reported in this thesis using traditional 
15N labelling approaches- to follow the protein through a change in redox state and equate 
a redox potential. 
Analysis of the redox state of fluorinated protein was complicated by several factors. 
Unfortunately, the 3477USUHVLGXHUHSRUWVDVDPL[WXUHRIµFDSSHG¶DQGµXQFDSSHG¶SURWHLQ
VR ZKLOVW D JHQHUDO WUHQG IURP µFDSSHG¶ LQ UHGXFHG VSHFWUD WR µXQFDSSHG¶ LQ R[LGLVHG
spectra) was observed, neither peak could be followed accurately through the redox 
titration to fit this residue, leaving the single reporter of 35Trp. Data collected by 19F using 
a titration of the glutathione redox pair, fit 35Trp to give a redox potential of ܧ௢ᇱ  -187 + 5 
mV, suggesting the redox potential may be made moderately more reducing by the 
fluorination. As per the 15N labelling strategy, collection of additional data points using the 
DTT redox pair were made, to improve the reduced section of the Hill plot. With 
experiments carried out to report between -176 mV to -300 mV, it was expected the Trp 
residue would report a predominantly reduced state. Instead, 35Trp reported a more 




oxidised state than expected; overlaid spectra at -176 mV (made using either 4.99 mM 
DTTox: 0.001mM DTTred or 0.5 mM GSSG: 4.5 mM GSH), should have resulted in 
comparible proportions of reduced and oxidised protein, but delivered a spectrum with an 
almost exclusively oxidised peak for 35Trp in the DTT spectra (see Figure 7.12). 
,QWHUHVWLQJO\WKHµFDSSHG¶DQGµXQFDSSHG¶IRUPVRI347Trp overlay extremely well in both 
spectra, suggesting the x-linker does not sense this change in redox state. This data 
indicates that fluorination of the protein has an effect on the system; either, 
fluorotryptophan modifies the redox active site, or interacts with DTT (a finding which is 
also inferred by Figure 7.14).     
It is possible that fluorine incorporation may change the local surface charge of the protein, 
to either repel reduced DTT or attract oxidised DTT. If either of these situations were to 
occur, then the local equilibria of DTTred:DTTox might not accurately reflect the actual 
equilibria of the experiment, thus the protein would not report an accurate redox state. It is 
also reasonable to assume that addition of fluorine so close to the active site could also 
result in other changes to the local environment (such as steric effects). Whilst the redox 
potential fit achieved by 19F using the glutathione pair reports only a modest increase in 
protein redox potential (see Figure 7.13), the curve fit is noticeably different to those 
generated using 15N labelled protein, with a much shallower gradient, suggesting lower 
cooperativity (see curve fits of Figure 6.3).  
Figure 7.15 illustrates the fluorine modification made at the 347Trp residue, and shows the 
fluorine atom is pointing directly towards the two sulphur atoms of 36Cys (within 7.45 ) 
and 39Cys (within 8.73 ). If this configuration is correct, a fluorine modification in close 
proximity to the active site sulphur atoms could impart some effect on the redox ability of 
the protein, or affect the stability of the protein.  
 
 





Figure 7.15: hPDI a domain active site (4EKZ.pdb) with 6-Fluoro-Trp incorporation: the fluorine 
atom of 35Trp points towards the two active site cysteines. The active site motif (CGHC) and 35Trp are 
shown as ball and stick models, the sulphur atoms of the cysteine residues are coloured green, and the 
fluorine atom is coloured orange. The aromatic ring carbons of 35Trp are also numbered. Molecular graphics 
created using Yasara (www.yasara.org).   
 
35Trp is a highly conserved residue among PDI in different species, but unfortunately there 
is little reported in the literature as to why it is conserved. It lies immediately adjacent to 
the active site in a domain, by which it is heavily quenched, and is therefore rarely targeted 
for mutation in protein fluorescence studies. A W35F/W111F/W379F/W390F mutant (all 
Trp residues of hPDI mutated to Phe) has been reported in the literature by Nguyen et al., 
with the mutations stated as having a destabilising effect on the protein, but it is not 
apparent which Trp residues cause this de-stabilisation (Nguyen et al., 2008). A recent 
paper by Gray et al. report how Tyr and Trp residues are present in close proximity to the 
redox active sites of a number of oxidoreductases. These residues may work to transport 
potentially damaging oxidising equivalents away from the active site of the protein (Gray 
and Winkler, 2015). It may be beneficial to explore this Trp conservation among PDI 
family members further, particularly if the residue plays a role in redox regulation. 




Alternatively, whilst DTT is known as a strong reducing agent (it is believed not to form 
mixed disulphides, due to a rapid rate of recylization), rare cases do occur where DTT 
adducts form. In a case published by Li et al. (Li et al., 1998), the two sulphur atoms of 
DTT form mixed disulphides with two different sulphur atoms of RNase A protein. A 
similar mode of action could be occurring for fluorinated W111F DEE¶[, and is 
demonstrated in Figure 7.16. 
 
  
Figure 7.16: Scheme showing the oxidation of reduced W111F DEE¶[ by DTTox (a) and the proposed 
mixed disulphide oxidation of 6-F-Trp W111F DEE¶[ by DTTox (b). In both cases, the initial interaction of 
reduced DEE¶[ with DTTox leads to a mixed disulphide. The DTT should then rapidly cyclize to yield DTTred 
and oxidised protein. If instead the mixed disulphide state is somehow stabilised, a subsequent DTTox could 
attack the free thiols of either the protein or the DTT molecule, resulting in an oxidised form of protein- 
where instead of an intramolecular disulphide bond as in (a), two intermolecular disulphides have formed 
instead with one DTT molecule.          




It is possible that the addition of fluorine into 35Trp works to stabilize a mixed disulphide 
state of DTT and protein. If this happens, DTT is no longer able to cyclize (and become 
DTTox), since it has no remaining free thiols. So, whilst each cysteine residue of the protein 
LV SULQFLSDOO\ LQ DQ µR[LGLVHG¶ VWDWH LQVWHDG RI EHLQJ LQWUD-molecularly bonded to one 
another, they are each bonded to a DTT molecule.  
The case described in Figure 7.16 relies upon subsequent interactions of reduced protein 
with DTTox, which could explain why datapoints collected between -189 to -208 mV 
(where there is a 9 to 39 times excess of DTTox compared to DTTred) report a more 
µR[LGLVHG¶IRUm of protein- the reaction conditions could work to promote formation of a 
µPL[HGGLVXOSKLGH¶VSHFLHV7KHGDWDSRLQWFROOHFWHGDW-224 mV (with a much lower excess 
of DTTox to DTTred) actually fits much more closely with the glutathione generated Hill 
plot (see -224 mV DTT datapoint in Figure 7.13). Unfortunately there was not time within 
the project to explore this idea any further, but if a mixed disulphide form of protein/DTT 
is present and stable for a suitable time period, it may be possible to identify the species 
using mass spectrometry (visble as a + 158 Da mass increase).     
It is also possible that DTTox may be interacting with the fluroinated indole- the overlaid 
spectra of 6-F-indole with either DTTred or DTTox (Figure 7.14) showed the 19F peaks of 6-
F-indole broaden out upon addition of the DTTox. Saturation Transfer Difference NMR 
(STD-NMR) could be used to determine if an interaction is occuring. The technique is 
largely used as a qualitative tool, WRVFUHHQIRUTXLFNµ\HVQR¶DQVZHUVWRELQGLQJ- in this 
type of experiment the protein is selectively saturated, and difference spectra (saturation 
on/off) will show perturbations of the ligand signals if binding occurs (Viegas et al., 2011). 
It has however been shown DTTox can interact with hPDI fragments at locations other than 
the catalytic active sites (the hPDI EE¶[D¶ crytal structure was published with a molecule 
of DTTox packed tightly into the ligand binding site in E¶ domain (Wang et al., 2012)). 
This is something that has not previously been observable in HSQC spectra of hPDI, but 
highlights that STD-NMR data should in this case still be treated with caution. 
It would be interesting to repeat the redox titration using another redox pair (for example 
XVLQJ ȕ-mercaptoethanol, which has a reducing ability intermediate of DTT and 
glutathione), to see how the protein reports its redox state in comparison to the data 
obtained. This data collection might also help to validate the idea of a mixed disulphide 




forming with DTTox LI WKH ȕ-mercaptoethanol titration reports more similarly to the 
glutathione redox titration.  
7.4.4 Overall Summary 
Work within this Chapter has reported some of the potential problems fluorine 
incorporation may impart. In this case it is possible the fluorination of 35Trp has modified 
the protein redox state in some way, or altered the biochemical properties local to the site 
of incorporation. Whilst the synthesis of fluorinated compounds in medicinal chemistry is 
now carried out on a routine basis, this work illustrates the continual requirement to 
explore the impact such a modification may make, and it is clear 19F protein labelling 
























Previously published research reports that hPDI is capable of binding a large range of 
unfolded or mis-folded proteins, as well as a variety of smaller unstructured peptide 
ligands. In addition, hPDI displays activity as a molecular chaperone, as incorrect 
disulphide bond formation or presence of cysteine residues are not prerequisite for binding.   
The primary substrate binding site was mapped to the E¶ domain and shows a large 
multivalent hydrophobic binding pocket that spans the domain (Byrne et al., 2009). More 
recent work has highlighted small hydrophobic patches present in a, b and D¶ domains that 
likely contribute to the binding of larger mis-folded proteins (Wang et al., 2013). 
hPDI is able to bind substrates at its primary E¶ binding site via reversible, hydrophobic 
interactions, but ultimately hPDI ligand specificity is still poorly understood. Early work 
showed hPDI bound two small peptides, somatostatin and mastoparan, but the peptides 
VKDUHQRGLVFHUQDEOHELQGLQJPRWLIK3',ZDVDOVRIRXQGWRELQGǻ-som, a double Cys-Ser 
form of somatostatin that lacks the WT 3Cys-14Cys disulphide bond, confirming binding of 
somatostatin was also not reliant on cysteine residues for recognition (Klappa et al., 1997). 
Work carried out at a similar time identified the binding specificity of the PDI family 
member PDIp to an hydroxyaryl group (Klappa et al., 2001). It was suggested that hPDI 
ligand specificity may work in a similar manner, in that ligands may be recognised by their 





However, as the binding could not be attributed to a specific motif like PDIp, recognition 
by hPDI was anticipated to be somewhat more complex. 
Obtaining more detailed information of the substrate specificity of hPDI is of significant 
importance, as hPDI is implicated in many different disease states. Chronic up-regulation 
of hPDI can eventually lead to cell apoptosis, and additionally a major loss of 
physiological hPDI function can occur as a result of aberrant post-translational S-
nitrosylation. hPDI is also industrially relevant, owing to its ability to fold recombinant 
therapeutics, many of which require correct disulphide bond formation to be biologically 
active.  
To summarise, hPDI displays great potential as both a therapeutic treatment but also a 
druggable target in vivo. Unfortunately many of the small molecule inhibitors of hPDI are 
targeted to the catalytically active CGHC redox sites, and are plagued by cytotoxic effects 
and broad specificity. The main aims of this thesis were to characterise the E¶[ and 
previously unassigned DEE¶[ fragments of hPDI, and use them to accurately determine the 
ELQGLQJDIILQLW\RIK3',WRLWVPRGHO OLJDQGSHSWLGHǻ-som. In addition, we aimed to use 
VSHFLILFUHVLGXHVXEVWLWXWLRQVRIǻ-som to ascertain hPDI binding specificity. 
Two fragments of hPDI were used: E¶[, the smallest monomeric fragment capable of 
peptide ligand binding, and DEE¶[, a larger fragment of hPDI that also includes a redox 
active site. Studies of E¶[D¶F hPDI fragment within the laboratory show in solution the D¶ 
domain is on the verge of unfolding, even in the absence of denaturant (unpublished 
observations). As such, it gives exceedingly poor NMR spectra. It was anticipated the 
W111F DEE¶[ fragment of hPDI would be more stable and hence give better NMR spectra. 
Studies of hPDI by NMR spectroscopy typically report the use of different protein 
fragments. Increased molecular weight introduces a greater number of resonances to the 
NMR spectra, complicating both resonance assignment and spectral analysis. In addition, 
larger molecules have slower tumbling rates in solution, which will also negatively impact 
spectral quality. The current size limit of protein NMR is ~35 kDa, so studies of the 40.5 
kDa W111F DEE¶[ IUDJPHQWRIK3',KDGDSSURDFKHGWKHµXVHIXO¶OLPLWRIVWDQGDUG105
techniques. Larger proteins can be studied using deuteration, but this option is not always 





In Chapter 3, expression of E¶[ and DEE¶[ in minimal media produced proteins that 
purified as mixed monomer: dimer species, as previously published for the E¶[ fragment. 
Dimer formation occurs at the E¶ substrate binding site, so DEE¶[ dimer had also been 
anticipated. Average yields of 21 mg/L monomeric 15N E¶[ and 38 mg/L monomeric 15N 
W111F DEE¶[ were purified by size exclusion chromatography for subsequent NMR 
studies.  
Monomeric W111F DEE¶[ displayed a hydrodynamic volume 7% smaller than expected 
for a protein of its size, which suggests the monomer may exist in a more compact state 
compared to full length hPDI, which has an anomalously large elution profile. This finding 
LV DOVR FRQVLVWHQW ZLWK SUREDEOH µFDSSLQJ¶ RI WKH E¶ binding site by the x-linker region, 
ZKLFKLIIUHHLQVROXWLRQPLJKWEHH[SHFWHGWRDGGWRWKHSURWHLQ¶VK\GURG\QDPLFYROXPH 
Capping was evident additionally in Chapter 4, by observation of two distinct resonances 
of 347Trp indole in 15N,1H-HSQC spectra of both E¶[ and W111F DEE¶[. Upon titration of 
a binding ligand into both proteins in Chapter 5, the Trp resonance corresponding to 
µFDSSHG¶ SURWHLQ VKLIWV WR RYHUOD\ ZLWK WKH µXQFDSSHG¶ UHVRQDQFH LQGLFDWLYH RI DQ XQ-
FDSSHGµOLJDQGERXQG¶SURWHLQVSHFLHV7KLVHYHQWZDVDOVRREVHUYHGE\19F 1D spectra of 
6-F-Trp W111F DEE¶[ in Chapter 7.    
Despite the relatively large size of W111F DEE¶[, 68% of backbone resonances were 
assigned by NMR spectroscopy. In addition, secondary structure prediction by DANGLE 
closely agreed with the equivalent portion of the recently published DEE¶[D¶ crystal 
structure (Wang et al., 2013a).  
Like many PDI fragments, W111F DEE¶[ gave optimal spectra as a reduced protein, with a 
significant number of peaks in oxidised spectra appearing much broader or absent from the 
spectra. Minimal chemical shift maps of the protein show that all domains of W111F 
DEE¶[ are perturbed upon a change in redox state. The redox potential of W111F DEE¶[ 
was determined in Chapter 6 as ܧ௢ᇱ  -167.1 + 2.1 mV, a value in close agreement with the 
published a domain redox potential of full length hPDI (Chambers et al., 2010). 
Interestingly work carried out in this thesis, along with previously published work by the 
laboratory have shown that the redox potential of a domain becomes progressively more 
reducing upon addition of extra domains, to such an extent that GSH is no longer able to 





This observation of changing redox potential helps to demonstrate cross-talk among the 
four domains of hPDI. It is clear more work needs to be carried out to explore this notion, 
especially as preliminary work in our laboratory suggests a and D¶ as part of DEE¶[D¶ have 
markedly different redox potentials. Current literature states the two active sites of hPDI 
have redox potentials within 7 mV of one another, however we estimate much greater 
difference, similar to yPDI where a 30 mV difference is reported (Vitu et al., 2010).  
 
The spectra of E¶[ and W111F DEE¶[ assigned in Chapter 4 were used to confirm hPDI 
ligand binding RIǻ-som, with each fragment reporting Kd of 103 + ȝ0DQG+ ȝ0
respectively, values that are moderately tighter than the estimated binding affinity of 0.1-1 
mM (Klappa et al., 1997). Furthermore, the binding affinity was shown to be unaffected by 
protein redox state or the presence of neighbouring domains to the primary ligand binding 
site in E¶ domain, with the magnitude of shifts observed in the ab portion of W111F DEE¶[ 
XSRQ ELQGLQJ ǻ-som minimal in comparison to those observed in the E¶[ fragment.  In 
light of this, subsequent peptide titrations were carried out using the smaller E¶[ fragment, 
expressed and purified immediately prior to NMR time to ensure only stable, monomeric 
protein was analysed. 
Previously published word has demonstrated that the presence of a single Tyr of Trp 
residue in the peptide sequence is sufficient to promote binding of a peptide to the PDI 
family member PDIp. In Chapter 5 wKHQ WKHVH UHVLGXHVRIǻ-som were mutated to Phe, 
PDIp lost its ability to bind the peptide ligand, suggesting that PDIp ligand recognition was 
not mediated by Phe residues (Ruddock et al., 2000). Contrastingly, the three Phe residues 
RI ǻ-som have proven crucial for binding recognition by hPDI in this study, with the 
VXEVWLWXWLRQ RI D VLQJOH 3KH UHVLGXH RI ǻ-som weakening binding ~two-fold, the 
substitution of two Phe residues weakening binding still, and substitution of all three Phe 
residues resulting in a complete loss of binding affinity as measurable by NMR 
spectroscopy. This is despite there still being a Trp residue present in the peptide, proving 
that ligand specificity between hPDI and PDIp is clearly distinct.  
An interesting observation was the C-terminal Phe residue (11Phe) of the peptide, which of 
the three Phe residues seemed most imperative to binding. Of the three Phe, it was the 





fluorinated peptides, and additionally its substitution to alanine had the greatest negative 
HIIHFWWRELQGLQJRIDOOWKHVLQJOHVXEVWLWXWLRQV7KHVLQJOH3KHĺ$ODVXEVWLWXWHGSHSWLGH
UHSRUWHG D GURS LQ DIILQLW\ FRPSDUDEOH WR WKDW REVHUYHG IRU WKH GRXEOH 3KH ĺ $OD
peptide.    
In summary, ligand titrations by NMR spectroscopy have allowed the binding affinity of 
K3', WR ǻ-som to be accurately quantified, and the 19F ligand-observed data closely 
supported the data collected by 15N,1H-HSQC protein-observed methods. Generally the 
curve fits published in this thesis do not reach 100% occupancy, due to a requirement of 
0.25 mM minimum protein concentration for collection of adequate spectra. The titration 
HQGSRLQWZDV DOVR OLPLWHG WR D[PRODU H[FHVVRISHSWLGH DV VHYHUDOǻ-som peptides 
hydrolysed within hours of storage at >0.7 mM in aqueous solutions. Hence, graphical fits 
were limited by practical working concentrations of protein and peptide, and it is not 
surprising the Kd fits quoted in this thesis have relatively large error ranges associated with 
them.  
Overall the collection methods undertaken in this thesis were straightforward and 
reproducible, but additionally the 19F data collected in Chapters 5 and 7 also gave greater 
precision and was less labour intensive to analyse when compared to 15N,1H-HSQC 
spectra. In this instance, use of fluorinated peptides has provided a suitable method by 
which to probe ligand binding of hPDI, when traditional recombinant labelling techniques 
were met with limited success. The work described in this thesis could readily be extended 
WR LQFOXGH VXEVWLWXWLRQ RI WKH 7US UHVLGXH RI ǻ-som, or even a total alanine scan of the 
peptide. Indeed, if recombinant peptide production had been more straightforward it is 
likely several mutant peptides would have been expressed for study in NMR titrations.  
The results obtained relating to the C-WHUPLQDO 3KH UHVLGXH RI ǻ-som may also explain 
observations made upon hPDI binding Pep20, a synthetic peptide used within our 
laboratory that binds to E¶[ with a marginally increased affinity. Interestingly Pep20 
contains two Phe residues in its C-terminal region; further work could be carried out using 
fluoro-Phe incorporation into the peptide or alanine substitutions, to further develop the 
ideas proposed in this thesis.  
If recombinant isotoSLF ODEHOOLQJRI ǻ-som had been more straightforward, an additional 





Indeed, preliminary NOESY experiments were collected to gain structural restraint 
information upon binding, but collection of useful data was hindered by a running 
temperature incompatibility between peptide and protein. Owing to its large size, hPDI 
W111F DEE¶[ gave best spectra at 37϶C, however peptide was only visible by 2D NMR 
methods at temperatures lower than 10϶C. 
At the point of submission of this thesis, project students had demonstrated successful and 
VWUDLJKWIRUZDUGSXULILFDWLRQRILQWDFWǻ-som peptide, from GB1-FXa-ǻ-som fusion protein 
expressed in LB media. The next step would be to try purification of isotopically labelled 
peptide from a minimal media growth, where overall expression (and therefore total fusion 
yields) will be lower. The final protein yield of intact peptide reported in this thesis is still 
lower than is routinely reported with GB1 fusions, however this could be due in part to the 
K\GURSKRELFDQGXQVWDEOHSURSHUWLHVRIWKHXQVWUXFWXUHGǻ-som peptide. 
 
Finally, owing to the relative ease with which 19F data was collected from fluorine 
containing peptides (Chapter 5), in Chapter 7 recombinant fluorination of the protein was 
trialled, to determine if ligand binding by 19F could also be collected from a protein-
observed perspective, and additionally, if a fluorine probe at 35Trp of a domain could be 
used to calculate protein redox state, as was determined in this thesis using 15N,1H-HSQC 
titration (Chapter 6). 
Fluorine incorporation into W111F DEE¶[ was not as uniform as recently published for the 
E¶[ fragment (Curtis-Marof et al., 2014), and the presence of two potential fluorination 
sites complicated attempts to ascertain overall fluorine incorporation. A combination of 
mass spectrometry and 19F NMR were only able to give estimations: NMR could provide a 
relative ratio of fluorination at each site but could not report on un-fluorinated protein, 
whereas mass spectrometry could only report on relative amounts of non, single and 
double fluorinated protein. Together the data could estimate 30% un-fluorinated protein, 
30% singly fluorinated at 35Trp, 10% singly fluorinated at 347Trp, and 30% double 
fluorinated protein. Such a heterogeneous population limited the application of 6-fluoro-
Trp W111F DEE¶[ in redox and ligand binding studies. In addition, analysis of the 347Trp 
fluorine peak in 19F 1D spectra was complicated by the x-linker¶V ability to exist in 





:KLOVW D JHQHUDO WUHQG IURP PRVWO\ µFDSSHG¶ VSHFLHV LQ UHGXFHG VSHFWUD WR D PRVWO\
µXQFDSSHG¶VSHFLHVLQR[LGLVHGVSHFWUDFRXOGEHREVHUYHGWKH x-linker could not be used to 
probe redox state or accurately report on ligand binding.  
Interestingly, the 35Trp present in a domain reported perturbation upon ligand binding- this 
residue and both of the active site cysteines of W111F DEE¶[ were all assignable by triple 
resonance, yet reported no significant perturbation upon ligand binding when observed by 
15N,1H-HSQC. Hence, this observation by 19F is particularly relevant given the Wang 
groups recent publication of hPDI modelling simulations, which indicates the a domain of 
hPDI comes into much closer contact with E¶ in solution than is shown by their DEE¶[D¶ 
crystal structures (Yang et al., 2014). 
Finally, 19F spectra revealed the 35Trp residue could not be used as a reporter of protein 
redox, as this resonance reported markedly different redox states depending on the redox 
buffer used. This was not something observed by 15N,1H-HSQC titration when using non-
fluorinated protein, collected using both glutathione and dithiothreitol redox buffers.  
It is not apparent if this observation was an effect of fluorine modifying the redox ability of 
W111F DEE¶[, or if 19F Trp is able to promote formation of a mixed disulphide state 
between DTT and the catalytic site of a domain. This work further suggests that the highly 
conserved 35Trp residue of PDI family members may be integral to protein redox control, 
and clearly warrants further investigation.   
 
,Q FORVLQJ WKLV WKHVLV KDV FRQILUPHG SHSWLGH OLJDQG ELQGLQJ RI ǻ-som by hPDI occurs 
independently of protein redox state and neighbouring domains, unlike binding of larger 
mis-folded proteins, where additional hydrophobic patches in a, b and E¶ are thought to 
contribute to binding. Site specific fluorination and alanine substitutions of the ǻ-som 
SHSWLGHKDYHLQGLFDWHGWKDWWKHWKUHH3KHUHVLGXHVRIǻ-som are together crucial for binding 
recognition by hPDI, and suggest the C-terminal region of the peptide is most important 
for binding affinity. It is hoped future work will be carried out to more ascertain any 
potential binding motif of hPDI, with the ultimate goal of designing specific peptide 
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2.3 Expression Region of modified pET-23a(+) expressing N-terminal His6-tag (x2) 
GB1 fusion proteins 
 
Black script is original pET-23a(+) vector  
Blue script is sequence added to original pET-23a(+) vector 
Red script (cat) is sequence removed from original pET-23a(+) vector 
Uppercase script is translated  
Lowercase script is not translated 
rbs is in bold 
restriction sites are highlighted  














2.4 Translated Fusion Protein Sequences:  
All fusion protein sequencing was carried out by Beckman Coulter Genomics, using their 
T7 promotor Primer (forward primer) and their T7 terminator primer (reverse primer).  
Sequencing files were submitted to Expasy Translate (http://web.expasy.org/translate), and 
the translated region submitted to Expasy ProtParam (http://web.expasy.org/protparam) 
for calculation of protein parameters. 
 
2.4.1 KSI-¨-som  
Met H T P E H I T A V V Q R F V A A L N A G D L D G I V A L F A D D A T V E D P 
V G S E P R S G T A A I R E F Y A N S L K L P L A V E L T Q E V R A V A N E A A 
F A F T V S F E Y Q G R K T V V A P I D H F R F N G A G K V V S I R A L F G E K 
N I H A C Q Met A G S K N F F W K T F T S S Stop  
Fusion MW: 15193.2 Da 
Cleaved Peptide: 1607.7 Da  
 




Fusion MW: 10280.0 Da 
Cleaved Peptide: 1607.7 Da  
 




Fusion MW: 10147.0 Da 











































































3.1 Expression region of modified pET-23a(+) expressing N-terminal His6-tag hPDI 
fragments 
 
                              
 
Black script is original pET-23a(+) vector  
Purple script is Met-protein of interest-Stop sequence added  
Uppercase script is translated polypeptide  
Lowercase script is not translated 
rbs is in red 
restriction sites are highlighted  
Translated polypeptide is underlined 
 
3.2 Amino acid sequences and Expasy analysis of expressed hPDI fragments 
3.2.1 His6-tag-E¶[: 
        10         20         30         40         50         60  
MHHHHHHMKH NQLPLVIEFT EQTAPKIFGG EIKTHILLFL PKSVSDYDGK LSNFKTAAES  
 
        70         80         90        100        110        120  
FKGKILFAFI DSDHTDNQRI LEFFGLKKEE CPAVRLITLE EEMTKYKPES EELTAERITE  
 
       130        140  
FCHRFLEGKI KPHLMSQELP EDWDKQP 
 
 
Number of amino acids: 147 
 
Molecular weight: 17240.7 Da 
 




Carbon      C        781 
Hydrogen    H       1203 
Nitrogen    N        205 
Oxygen      O        224 
Sulfur      S          6 
 
 
Extinction coefficients: Extinction coefficients are in units of M-1 cm-1, 
at 280 nm measured in water. 
 





3.2.2 His6-tag W111F DEE¶[: 
 
        10         20         30         40         50         60  
MHHHHHHMDA PEEEDHVLVL RKSNFAEALA AHKYLLVEFY APWCGHCKAL APEYAKAAGK  
 
        70         80         90        100        110        120  
LKAEGSEIRL AKVDATEESD LAQQYGVRGY PTIKFFRNGD TASPKEYTAG READDIVNFL  
 
       130        140        150        160        170        180  
KKRTGPAATT LPDGAAAESL VESSEVAVIG FFKDVESDSA KQFLQAAEAI DDIPFGITSN  
 
       190        200        210        220        230        240  
SDVFSKYQLD KDGVVLFKKF DEGRNNFEGE VTKENLLDFI KHNQLPLVIE FTEQTAPKIF  
 
       250        260        270        280        290        300  
GGEIKTHILL FLPKSVSDYD GKLSNFKTAA ESFKGKILFI FIDSDHTDNQ RILEFFGLKK  
 
       310        320        330        340        350  
EECPAVRLIT LEEEMTKYKP ESEELTAERI TEFCHRFLEG KIKPHLMSQE LPEDWDKQP  
 
 
The W111F mutation is underlined (note the numbering is different owing to His6-tag) 
 
 
Number of amino acids: 359 
 
Molecular weight: 40534.7 Da 
 




Carbon      C       1828 
Hydrogen    H       2815 
Nitrogen    N        475 
Oxygen      O        552 
Sulfur      S          8 
 
Extinction coefficients: Extinction coefficients are in units of M-1 cm-1, 
at 280 nm measured in water. 
 














4.1 W111F DEE¶[ (37¡C) Backbone Resonance Assignment Table 
                                Resonance not present in amino acid  
 






1 Asp - - - 
 
40 Lys 8.66 123.39 60.09 
2 Ala - - - 
 





42 Leu 7.42 116.49 55.99 
4 Glu - - - 
 
43 Ala 7.36 120.98 57.18 





6 Glu - - - 
 
45 Glu 6.98 118.13 58.18 
7 Asp - - - 
 
46 Tyr 8.54 124.05 62.59 
8 His - - 58.41 
 
47 Ala 7.74 117.59 54.78 
9 Val 7.82 123.43 61.54 
 
48 Lys 7.84 120.74 59.67 
10 Leu 8.94 128.18 55.72 
 
49 Ala 8.08 122.93 55.20 
11 Val 8.28 124.34 62.76 
 
50 Ala 7.75 119.27 54.85 
12 Leu 8.36 125.97 52.72 
 
51 Gly 8.49 106.72 47.08 
13 Arg 8.83 118.06 53.77 
 
52 Lys 8.03 124.67 59.58 
14 Lys 8.88 122.54 60.98 
 
53 Leu 7.72 119.08 57.77 
15 Ser 7.97 108.61 60.21 
 
54 Lys - - 58.72 
16 Asn 7.54 117.46 52.43 
 
55 Ala 7.85 122.41 54.67 
17 Phe 7.86 123.23 63.36 
 
56 Glu 7.38 114.14 56.21 
18 Ala 8.67 118.78 55.09 
 
57 Gly 7.86 109.09 45.82 
19 Glu 8.04 118.77 59.30 
 
58 Ser 7.68 112.33 58.61 
20 Ala 7.69 123.18 55.01 
 
59 Glu 8.99 125.43 56.84 
21 Leu 7.43 117.61 57.02 
 
60 Ile 8.34 122.58 62.97 
22 Ala 7.03 116.00 53.10 
 
61 Arg 7.82 123.06 52.19 
23 Ala 7.30 118.88 53.00 
 
62 Leu 9.07 124.17 54.98 
24 His 7.13 116.19 55.00 
 
63 Ala 9.36 120.65 49.59 
25 Lys - - - 
 
64 Lys 9.43 121.21 54.37 
26 Tyr - - 55.06 
 
65 Val 8.73 119.46 60.25 
27 Leu 8.40 125.67 53.46 
 
66 Asp 8.85 127.14 52.42 
28 Leu 8.96 131.01 53.64 
 
67 Ala 8.78 130.46 53.22 
29 Val 9.58 126.43 61.73 
 
68 Thr 8.54 109.23 63.24 
30 Glu 8.38 128.01 53.97 
 
69 Glu 6.81 122.30 57.19 
31 Phe 9.83 128.88 57.18 
 
70 Glu 8.31 120.19 52.72 
32 Tyr 8.91 121.35 54.80 
 
71 Ser 7.40 115.41 61.31 
33 Ala 7.08 119.94 47.62 
 





73 Leu - - - 
35 Trp 5.89 109.79 53.81 
 
74 Ala - - - 
36 Cys 6.63 126.31 60.04 
 
75 Gln - - - 
37 Gly - - 47.61 
 
76 Gln - - - 
38 His 9.46 127.72 59.21 
 
77 Tyr - - 58.91 
39 Cys 9.64 127.79 64.40 
 
















80 Arg - - 55.23 
 
125 Asp 7.02 111.92 52.50 
81 Gly 7.09 107.39 43.70 
 
126 Gly 8.99 106.38 47.32 
82 Tyr 8.09 117.18 53.75 
 





128 Ala 8.46 120.26 53.23 
84 Thr 8.65 117.47 63.53 
 
129 Ala 7.71 112.19 55.44 
85 Ile 9.59 130.46 60.22 
 
130 Glu 8.32 116.89 59.40 
86 Lys 9.23 125.27 53.79 
 
131 Ser 7.82 112.64 61.42 
87 Phe 9.49 123.21 55.06 
 
132 Leu 7.36 122.80 58.39 
88 Phe 9.20 128.91 57.01 
 
133 Val 7.87 119.26 66.81 
89 Arg 8.75 121.01 53.52 
 
134 Glu 8.10 115.01 58.03 
90 Asn 9.69 121.27 54.40 
 
135 Ser 7.46 112.68 59.88 
91 Gly 9.17 107.74 46.28 
 
136 Ser 7.00 115.30 57.24 
92 Asp 7.60 119.05 54.04 
 
137 Glu 8.57 124.53 59.93 
93 Thr 8.98 123.93 60.92 
 
138 Val 7.22 113.46 60.52 
94 Ala - - - 
 
139 Ala 9.02 126.88 51.29 
95 Ser - - - 
 





141 Ile 8.98 124.34 60.11 
97  Lys - - - 
 
142 Gly 8.51 115.63 44.43 
98 Glu - - - 
 
143 Phe 8.36 127.82 54.98 
99 Tyr - - - 
 
144 Phe 8.10 116.88 55.64 
100 Thr - - - 
 
145 Lys 9.33 124.63 58.99 
101 Ala - - 50.79 
 
146 Asp 8.76 117.09 51.87 
102 Gly 7.91 104.37 45.34 
 
147 Val 8.43 120.71 63.96 
103 Arg 8.42 118.78 55.67 
 





149 Ser 7.43 115.80 58.14 
105 Ala 9.73 125.17 56.39 
 
150 Asp 8.77 121.24 58.21 
106 Asp 8.70 113.86 57.61 
 
151 Ser 8.35 113.93 61.58 
107 Asp 7.27 119.49 57.39 
 
152 Ala 6.87 125.36 54.54 
108 Ile 7.40 121.58 65.03 
 
153 Lys 7.94 115.86 60.01 
109 Val 8.01 117.64 67.73 
 
154 Gln - - - 
110 Asn - - - 
 
155 Phe - - - 
111 Phe - - - 
 
156 Leu - - - 
112 Leu - - - 
 
157 Gln - - - 
113 Lys - - - 
 
158 Ala - - - 
114 Lys - - - 
 
159 Ala - - - 
115 Arg - - 56.12 
 
160 Glu - - 57.48 
116 Thr 7.02 106.64 61.33 
 
161 Ala 7.16 119.34 52.80 
117 Gly 7.23 110.28 44.26 
 





163 Asp 8.29 122.91 54.78 
119 Ala - - - 
 
164 Asp 8.42 115.64 54.89 
120 Ala - - - 
 
165 Ile 7.05 118.91 57.72 





122 Thr - - - 
 
167 Phe 8.65 119.80 55.72 
123 Leu - - - 
 










169 Ile 8.83 120.69 58.54 
 
214 His 7.77 113.93 58.47 
170 Thr 8.55 121.05 60.15 
 
215 Asn 7.19 113.69 54.46 
171 Ser 8.58 119.70 56.72 
 
216 Gln 7.56 114.94 57.41 
172 Asn 8.14 120.58 55.08 
 
217 Leu 7.33 119.47 51.90 





174 Asp 8.53 122.07 57.42 
 
219 Leu 8.24 120.53 57.88 
175 Val 7.92 122.10 65.87 
 
220 Val 7.40 111.39 59.42 
176 Phe 7.88 120.24 61.81 
 
221 Ile 8.75 125.41 59.91 
177 Ser 7.99 111.97 61.65 
 
222 Glu 8.26 127.73 54.86 
178 Lys 7.56 123.83 - 
 
223 Phe 8.59 128.92 59.41 
179 Tyr - - - 
 
224 Thr 7.19 119.32 59.14 
180 Gln - - - 
 
225 Glu 8.86 120.07 59.41 
181 Leu - - - 
 
226 Gln 7.95 114.53 58.20 
182 Asp - - 53.27 
 
227 Thr 7.48 108.74 61.90 
183 Lys 7.62 117.08 54.43 
 
228 Ala 7.60 125.67 56.86 





185 Gly 8.57 107.17 45.55 
 
230 Lys 7.13 115.65 57.62 
186 Val - - - 
 
231 Ile 7.54 119.01 64.35 
187 Val - - - 
 
232 Phe 7.93 115.23 59.04 
188 Leu - - 54.24 
 
233 Gly 7.64 106.75 45.35 
189 Phe 9.48 126.43 56.95 
 
234 Gly 7.38 108.00 44.79 
190 Lys 8.33 115.83 53.51 
 
235 Glu 8.46 117.69 57.98 
191 Lys - - 55.89 
 
236 Ile - - - 
192 Phe 6.53 113.34 54.44 
 
237 Lys - - 55.57 
193 Asp 8.83 117.54 56.02 
 
238 Thr 6.74 115.86 62.12 
194 Glu 10.15 123.61 58.30 
 
239 His 8.86 125.64 53.79 
195 Gly 7.69 108.97 46.59 
 
240 Ile 9.12 122.45 58.99 
196 Arg 7.13 120.99 54.96 
 
241 Leu 8.95 128.48 53.52 
197 Asn 9.15 121.60 53.79 
 
242 Leu 8.73 123.36 52.81 
198 Asn 9.01 123.13 52.47 
 
243 Phe 9.18 128.07 56.76 
199 Phe 8.29 124.81 58.94 
 
244 Leu 8.90 126.90 50.95 





201 Gly 6.89 108.35 43.50 
 
246 Lys 8.18 123.88 58.83 
202 Glu 8.31 120.32 56.21 
 
247 Ser 7.61 107.91 58.28 
203 Val 9.00 126.39 64.45 
 
248 Val 7.55 123.19 62.06 
204 Thr 7.13 117.73 58.06 
 
249 Ser - - - 
205 Lys 9.24 123.99 60.74 
 
250 Asp - - - 
206 Glu 9.03 116.55 60.88 
 
251 Tyr - - 62.87 
207 Asn 7.90 117.92 55.34 
 
252 Asp 8.55 115.04 57.34 
208 Leu 8.44 121.38 57.61 
 
253 Gly 7.77 110.12 47.07 
209 Leu 8.39 120.00 58.98 
 
254 Lys 7.94 123.02 59.78 
210 Asp 7.56 118.79 57.83 
 
255 Leu 8.12 119.97 57.55 
211 Phe 7.79 120.64 60.41 
 
256 Ser 8.36 114.70 62.05 
212 Ile 8.66 121.14 65.51 
 
257 Asn 7.90 121.56 56.60 
213 Lys 8.10 117.91 59.39 
 










259 Lys - - - 
 
304 Glu 7.47 123.16 56.52 
260 Thr - - - 
 
305 Glu 8.41 122.09 59.30 
261 Ala - - - 
 
306 Glu - - - 
262 Ala - - - 
 
307 Met - - - 
263 Glu - - - 
 
308 Thr - - 62.52 
264 Ser - - - 
 
309 Lys 8.79 123.72 54.92 
265 Phe 7.17 115.85 57.19 
 
310 Tyr 9.62 120.00 57.66 
266 Lys 7.32 123.27 58.58 
 
311 Lys - - - 





268 Lys 8.30 118.62 57.19 
 
313 Glu - - - 
269 Ile 7.86 116.45 60.42 
 
314 Ser - - - 
270 Leu 8.32 130.66 54.64 
 
315 Glu - - - 
271 Phe 9.17 129.72 56.84 
 
316 Glu - - 57.40 
272 Ile - - - 
 
317 Leu 8.54 125.32 53.14 
273 Phe - - - 
 
318 Thr 6.74 108.18 59.46 
274 Ile - - - 
 
319 Ala 9.20 125.22 56.06 
275 Asp - - - 
 
320 Glu 9.27 118.19 60.32 
276 Ser - - - 
 
321 Arg 7.59 119.44 57.94 
277 Asp - - - 
 
322 Ile 8.52 121.75 65.52 
278 His - - - 
 
323 Thr 8.57 116.99 67.93 
279 Thr 8.86 127.69 66.09 
 
324 Glu 8.12 121.75 - 
280 Asp 10.72 124.47 56.86 
 
325 Phe - - - 
281 Asn 7.98 115.02 52.74 
 
326 Cys - - - 
282 Gln - - - 
 
327 His - - - 
283 Arg - - - 
 
328 Arg - - - 
284 Ile - - 63.56 
 
329 Phe - - 60.67 
285 Leu 7.36 121.57 60.56 
 
330 Leu 8.14 123.44 57.48 
286 Glu 7.89 117.21 59.37 
 
331 Glu 7.72 116.37 56.29 
287 Phe 8.03 121.76 60.86 
 
332 Gly 7.73 108.43 46.34 
288 Phe 7.46 113.11 59.45 
 
333 Lys 7.99 116.56 56.18 
289 Gly 7.94 110.74 46.62 
 
334 Ile 7.98 120.03 59.25 
290 Leu 7.66 120.77 53.53 
 
335 Lys 8.91 128.04 54.29 





292 Lys - - 60.98 
 
337 His - - - 
293 Glu 9.36 116.52 58.86 
 
338 Leu - - - 
294 Glu 7.57 118.05 55.82 
 
339 Met - - - 
295 Cys 6.99 117.61 58.35 
 





341 Gln - - - 
297 Ala 8.45 123.18 51.57 
 
342 Glu - - - 
298 Val 8.56 117.88 59.38 
 
343Leu - - - 





300 Leu 8.76 125.58 54.33 
 
345 Glu 8.39 120.46 57.29 
301 Ile 9.64 122.39 58.46 
 
346 Asp 8.19 119.13 54.07 
302 Thr 8.66 114.19 59.13 
 
347 Trp 7.70 120.59 57.93 
303 Leu 8.52 125.19 54.49 
 







349 Lys 7.51 120.51 55.83 
350 Gln 8.06 122.93 53.53 




























4.2 E¶[ (37¡C) Backbone Resonance Assignment Tables  
Residue HN N
H Cɲ Cɴ 
213 Lys - - - - 
214 His - - - - 
215 Asn - - - - 
216 Gln - - - - 




219 Leu - - 57.09 42.92 
220 Val 7.24 111.15 59.71 - 
221 Ile - - 59.95 41.49 
222 Glu 8.24 127.45 54.78 29.86 
223 Phe 8.59 128.79 59.41 40.63 
224 Thr 7.11 118.55 - - 
225 Glu 8.89 120.42 59.43 29.03 
226 Gln 7.83 114.48 58.15 28.87 
227 Thr 7.39 108.93 61.98 69.53 




230 Lys 7.18 115.27 57.40 32.27 
231 Ile 7.52 119.10 64.24 38.74 
232 Phe 7.82 115.59 58.88 38.30 
233 Gly 7.58 106.66 45.38 
 234 Gly 7.41 107.81 44.79 
 235 Glu 8.38 117.54 58.26 30.44 
236 Ile 7.72 119.41 61.85 37.90 
237 Lys - - 55.63 33.03 
238 Thr 6.73 115.87 62.19 69.94 
239 His 8.77 125.57 54.01 35.31 
240 Ile 9.14 122.39 58.97 40.15 
241 Leu 8.97 128.57 53.66 43.54 
242 Leu - - 52.87 41.81 
243 Phe 9.04 127.54 56.80 39.29 




246 Lys 8.18 123.62 58.74 32.17 
247 Ser 7.53 108.16 58.27 63.60 
248 Val 7.41 122.31 62.02 32.64 
249 Ser 8.30 120.50 59.75 63.25 
250 Asp 8.88 122.43 52.90 35.62 
251 Tyr 7.54 121.15 62.97 39.22 
252 Asp 8.57 115.11 57.40 40.55 
253 Gly 7.71 110.09 47.10 
 254 Lys 7.94 122.98 59.99 32.97 
255 Leu 8.06 119.84 57.56 40.60 






H Cɲ Cɴ 
257 Asn 7.92 121.60 56.57 38.66 
258 Phe 7.64 121.71 61.63 40.59 
259 Lys 8.43 117.10 59.79 32.52 
260 Thr 8.18 116.34 66.70 68.62 
261 Ala 7.53 124.08 54.87 18.66 
262 Ala 7.20 118.99 53.98 19.52 
263 Glu 6.93 114.04 58.82 29.71 
264 Ser 7.39 111.93 60.71 63.51 
265 Phe 7.11 115.85 57.28 41.16 
266 Lys 7.22 123.03 58.50 31.85 
267 Gly 9.47 114.75 45.60 
 268 Lys 8.25 118.60 57.16 35.67 
269 Ile 7.75 116.28 60.39 43.34 
270 Leu 8.27 129.80 54.59 43.15 
271 Phe 9.11 129.71 56.68 39.37 
272 Ile 9.05 123.95 58.95 42.12 
273 Phe 8.81 122.55 54.65 42.64 
274 Ile 8.70 121.43 59.94 42.39 
275 Asp 8.36 123.86 52.69 40.33 
276 Ser 7.40 123.69 60.53 64.81 
277 Asp 8.29 119.32 55.55 41.65 
278 His 7.16 121.28 58.34 31.88 
279 Thr - - 65.99 68.77 
280 Asp 10.75 124.49 56.80 40.01 
281 Asn 7.89 114.93 52.75 38.55 
282 Gln 7.56 120.72 59.50 28.19 
283 Arg 8.41 118.07 59.79 32.59 
284 Ile 8.49 120.66 55.82 37.12 
285 Leu 7.39 121.87 60.43 40.92 
286 Glu 7.91 117.31 59.36 29.29 
287 Phe 7.79 120.43 63.65 37.31 
288 Phe - - 59.56 39.87 
289 Gly 7.95 110.73 46.71 
 290 Leu 7.68 120.93 53.48 45.80 
291 Lys 8.08 119.04 54.12 34.19 
292 Lys 8.99 123.95 60.95 32.11 
293 Glu 9.38 116.54 58.83 28.33 
294 Glu 7.58 118.09 55.87 30.67 




297 Ala 8.34 122.97 51.58 23.50 
298 Val 8.59 118.11 59.47 35.23 
299 Arg 8.66 123.10 53.03 35.54 







H Cɲ Cɴ 
301 Ile 9.53 121.72 58.42 42.69 
302 Thr 8.72 114.19 59.33 71.03 
303 Leu 8.55 125.12 54.48 42.47 
304 Glu 7.48 123.28 56.55 29.85 
305 Glu 8.43 122.15 59.27 29.13 
306 Glu 7.87 116.20 54.90 31.42 
307 Met 8.83 123.87 56.10 33.90 
308 Thr 8.35 121.55 62.45 70.37 
309 Lys 8.55 123.31 54.87 35.92 
310 Tyr 9.50 119.26 57.63 41.59 




313 Glu 8.89 119.35 57.65 30.21 
314 Ser 7.45 111.72 56.48 65.22 
315 Glu - - - - 
316 Glu - - - - 
317 Leu - - 53.10 41.25 
318 Thr 6.75 108.17 59.67 70.57 
319 Ala 9.22 125.27 56.14 18.03 
320 Glu 9.30 118.23 60.31 29.21 
321 Arg 7.61 119.58 58.04 29.94 
322 Ile 8.44 121.74 65.50 38.22 
323 Thr 8.50 116.83 - 67.87 
324 Glu 7.99 121.52 59.94 30.35 
325 Phe 7.84 119.66 59.33 38.89 
326 Cys 7.62 115.90 64.41 27.46 
327 His 8.54 118.17 60.43 30.45 
328 Arg 8.66 118.84 59.93 30.21 
329 Phe 8.24 120.62 60.47 37.83 
330 Leu 8.13 123.59 57.50 41.35 
331 Glu 7.68 116.28 56.33 30.64 
332 Gly 7.66 108.45 46.36 
 333 Lys 7.92 116.52 56.22 33.62 
334 Ile 7.82 118.61 59.22 38.73 




337 His - - - - 
338 Leu - - - - 
339 Met - - - - 
340 Ser - - - - 
341 Gln - - - - 
342 Glu - - - - 










H Cɲ Cɴ 
345 Glu 8.40 120.39 57.31 29.94 
346 Asp 8.20 119.12 54.14 40.60 
347 Trp 7.71 120.57 57.95 29.14 
348 Asp 7.97 120.30 54.10 40.21 
349 Lys 7.52 120.38 55.87 32.88 
350 Gln 8.06 122.91 53.55 28.80 




4.3 0.3 mM E¶[ (37¡C) Methyl Sidechain Resonance Assignment Tables  
 
Residue 221 Ile 227 Thr 228 Ala 231 Ile 236Ile 238 Thr 240 Ile 241 Leu 
Cɲ 59.95 62.03 56.83 64.24 61.85 61.94 58.97 53.66 
Hɲ 4.30 4.93 3.69 3.43 4.07 4.15 4.87 4.96 
Cɴ 41.49 69.84 16.20 38.71 37.90 69.54 40.15 43.55 
Hɴa 1.67 4.01 1.06 1.32 1.79 4.10 0.90 0.52 
Hɴb               1.10 
Cɶ1 28.01 23.56   28.26 27.99   30.02 28.90 
Hɶ1a 1.04 0.90   0.64 1.02   0.79 1.15 
Hɶ1b 1.51     1.32 1.54   1.34   
Cɶ2 17.77     16.61 18.59 22.43 14.86   
Hɶ2 0.78     -0.03 0.87 1.13 -0.25   
Cɷ1 14.51     14.20 13.30   14.60 26.43 
Hɷ1 0.82     0.51 0.76   0.58 0.29 
Cɷ2               26.03 













Residue 242 Leu 244 Leu 248 Val 255 Leu 260 Thr 261 Ala 262 Ala 269 Ile 
Cɲ 52.87 50.89 61.95 57.55 66.64 54.83 53.92 60.39 
Hɲ 4.21 5.01 4.19 3.72 3.84 4.02 1.84 4.27 
Cɴ 41.81 44.72 32.66 40.60 68.60 18.60 19.54 43.33 
Hɴa 1.31 0.98 2.25 0.77 4.23 1.61 0.61 1.59 
Hɴb 1.44 1.95   1.47         
Cɶ1 26.82 25.04 21.31 26.38 21.42     27.61 
Hɶ1a 1.50 0.70 1.06 1.10 1.12     1.52 
Hɶ1b               1.52 
Cɶ2     21.77         17.40 
Hɶ2     1.19         0.39 
Cɷ1 23.99 26.41   21.77       13.31 
Hɷ1 0.62 0.21   0.05       0.35 
Cɷ2 25.21 26.46   24.43         
HɷϮ 0.67 1.48   0.34         
 
 
Residue 270 Leu 272 Ile 274 Ile 279 Thr 285 Leu 290 Leu 297 Ala 298 Val 
Cɲ 54.57 58.97 59.94 65.98 60.43 53.47 51.63 59.38 
Hɲ 4.84 5.43 4.29 4.02 3.75 4.46 4.79 5.69 
Cɴ 43.16 42.51 42.39 68.75 40.73 45.80 23.50 35.46 
Hɴa 1.58 1.70 1.16 4.15 1.77 0.82 1.37 1.73 
Hɴb 1.94       1.77 0.95     
Cɶ1 27.07 27.60 28.82   29.08 26.84   21.95 
Hɶ1a 1.50 0.89 0.47   1.48 0.95   0.72 
Hɶ1b   1.41 1.07           
Cɶ2   19.02 18.20 21.54       21.95 
Hɶ2   0.74 0.47 1.28       0.82 
Cɷ1 24.39 15.70 14.99   25.53 24.21     
Hɷ1 0.85 0.63 -0.12   0.62 -0.14     
Cɷ2 25.28       25.92 25.28     











Residue 300 Leu 302 Thr 303 Leu 308 Thr 317 Leu 318 Thr 319 Ala 322 Ile 
Cɲ 54.40 59.39 54.48 62.43 53.10 59.15 56.03 65.51 
Hɲ 5.43 4.36 4.74 4.58 4.55 5.39 3.98 3.91 
Cɴ 47.25 70.50 42.46 70.37 41.25 70.92 18.05 38.22 
Hɴa 1.18 4.67 1.71 4.09 1.50 4.31 1.53 1.93 
Hɴb 1.36   1.88   1.67       
Cɶ1 27.19 22.56 27.60 22.20 26.06 21.98   28.81 
Hɶ1a 1.18 1.25 1.63 1.04 1.67 1.41   1.16 
Hɶ1b               - 
Cɶ2               18.60 
Hɶ2               1.10 
Cɷ1 24.29   25.95   24.00     12.90 
Hɷ1 -0.27   0.92   0.65     0.90 
Cɷ2 26.15   25.15   26.13       
HɷϮ -0.47   0.95   0.73       
 
 
Residue 330 Leu 334 Ile 
Cɲ 57.69 59.22 
Hɲ 3.42 4.54 
Cɴ 41.35 38.73 
Hɴa 1.43 2.07 
Hɴb 2.09   
Cɶ1 26.64 26.40 
Hɶ1a 1.91 1.18 
Hɶ1b   1.41 
Cɶ2   18.60 
Hɶ2   1.37 
Cɷ1 26.36 12.12 
Hɷ1 0.90 1.02 
Cɷ2 22.35   








5.1 Derivation of Dissociation Constant (Kd) 
 
During a titration we know the total concentrations of ligand [L] and protein [P]:- 
[L]total =  [L] + [PL] Complex 
[P]total =  [P] + [PL] Complex 
:HDOVRNQRZWKHFKHPLFDOVKLIWVREVHUYHGǻobs in fast exchange state are a weighted 
DYHUDJHRIWKHVKLIWVRIIUHHįfree DQGERXQGįbound states:- 
ǻobs = ǻfree¦free ǻbound¦bound 
ZKHUH¦free DQG¦bound are the fractions of free and bound respectively. Because:- 
¦free ¦bound = 1 
The fraction of ligand bound can be expressed as:- 
¦bound ǻobs - ǻfreeǻbound - ǻfree) 
And Kd can be derived as follows:- 
















5.2 0.3 mM E¶[ P0ǻ-som (37¡C) Methyl Sidechain Resonance Assignment 
Tables  
 
Residue 221 Ile 227 Thr 228 Ala 231 Ile 236Ile 238 Thr 240 Ile 241 Leu 
Cɲ 59.97 62.09 56.79 64.31 61.97 61.91 58.96 53.66 
Hɲ 4.30 4.92 3.77 3.42 4.07 4.15 4.87 4.98 
Cɴ 41.49 69.84 16.20 38.71 37.50 69.55 40.32 43.55 
Hɴa 1.65 4.00 1.12 1.30 1.79 4.10 0.90 0.49 
Hɴb               1.04 
Cɶ1 28.00 23.56   - 28.00   - 28.60 
Hɶ1a 1.03 0.89   - 1.01   - 1.17 
Hɶ1b 1.54     - 1.54   -   
Cɶ2 17.80     17.01 18.60 22.42 14.86   
Hɶ2 0.81     0.00 0.87 1.15 -0.25   
Cɷ1 14.91     14.20 13.30   14.65 25.77 
Hɷ1 0.84     0.57 0.76   0.57 0.33 
Cɷ2               26.18 
HɷϮ               0.54 
 
 
Residue 242 Leu 244 Leu 248 Val 255 Leu 260 Thr 261 Ala 262 Ala 269 Ile 
Cɲ - 50.86 61.91 57.42 66.40 54.77 53.95 60.78 
Hɲ - 5.00 4.20 3.73 3.83 4.02 1.86 4.29 
Cɴ - 44.72 32.64 40.65 68.55 18.60 19.54 43.72 
Hɴa - 0.98 2.25 0.81 4.23 1.62 0.61 1.59 
Hɴb - 1.95   1.48         
Cɶ1 - 25.29 21.30 27.17 21.43     27.26 
Hɶ1a - 0.67 1.06 1.12 1.12     0.80 
Hɶ1b               1.52 
Cɶ2     21.71         16.99 
Hɶ2     1.19         0.40 
Cɷ1 - 26.40   21.85       13.36 
Hɷ1 - 0.17   0.06       0.35 
Cɷ2 - 26.40   24.50         









Residue 270 Leu 272 Ile 274 Ile 279 Thr 285 Leu 290 Leu 297 Ala 298 Val 
Cɲ 54.19 58.95 59.54 65.91 60.46 53.88 51.58 59.66 
Hɲ 4.86 5.47 4.30 4.03 3.68 4.43 4.79 5.70 
Cɴ 43.16 42.46 42.40 68.77 40.76 45.84 23.23 35.49 
Hɴa 1.62 1.73 1.18 4.15 1.76 0.81 1.38 1.72 
Hɴb 1.82       - 1.00     
Cɶ1 27.47 27.59 28.57   28.82 26.70   - 
Hɶ1a 1.50 - 0.54   1.45 1.00   - 
Hɶ1b   0.92 1.10           
Cɶ2   19.10 17.79 21.55       21.95 
Hɶ2   0.79 0.48 1.28       0.80 
Cɷ1 24.80 15.66 15.00   25.50 24.20     
Hɷ1 0.84 0.66 -0.01   0.58 -0.15     
Cɷ2 24.80       25.10 25.28     
HɷϮ 0.97       0.84 0.36     
 
 
Residue 300 Leu 302 Thr 303 Leu 308 Thr 317 Leu 318 Thr 319 Ala 322 Ile 
Cɲ 54.40 59.41 - 62.42 52.68 59.09 55.98 65.11 
Hɲ 5.40 4.35 - 4.47 4.46 5.38 3.99 3.91 
Cɴ 47.65 70.53 - 70.37 41.63 70.81 18.06 38.30 
Hɴa 1.17 4.67 - 4.08 1.34 4.27 1.53 1.92 
Hɴb 1.36   -   1.49       
Cɶ1 27.15 22.56 - 21.79 26.94 21.98   28.81 
Hɶ1a 1.17 1.25 - 1.06 1.50 1.41   1.14 
Hɶ1b               1.95 
Cɶ2               18.60 
Hɶ2               1.10 
Cɷ1 24.34   -   23.72     12.53 
Hɷ1 -0.27   -   0.65     0.89 
Cɷ2 26.04   -   26.14       











Residue 330 Leu 334 Ile 
Cɲ 57.39 59.22 
Hɲ 3.46 4.54 
Cɴ 41.31 38.93 
Hɴa 1.45 2.03 
Hɴb 2.10   
Cɶ1 26.64 26.34 
Hɶ1a 1.94 1.16 
Hɶ1b   1.41 
Cɶ2   18.36 
Hɶ2   1.30 
Cɷ1 22.39 12.48 
Hɷ1 0.91 1.00 
Cɷ2 26.24   




















5.3 Representative fits of 0.25 mM 15N W111F DEE¶[ (reduced) + 19)ǻ-som: 
D)ǻ-som (protein observed)  
Peptide concentration is shown along the x-axis (mM), delta chemical shift is shown along the y-axis (Hz). 
Kd is given as m3 value (mM).   


















































































































































































































































































6.1 Table of Redox Potential Samples 
All peak intensities were made relative to the fully reduced control spectra (highlighted in 
green). 
 




























-190 4.8 0.2 






-179 4.6 0.4 
  -176 
  
0.001 4.999 
-161 3.9 1.1 
  -156 3.75 1.25 
  -146 3 2 
  -138 2.5 2.5 
  -126 1.8 3.2 
  -108 1 4 
  -103 0.85 4.15 
  -97 0.7 4.3 
  -68 0.25 4.75 
  -44 0.1 4.9 










6.2 15N W111F DEE¶[ Redox Potential Raw Data (Fred) 
Redox Potentials in red collected using DTTred:DTTox, in black using GSH:GSSG  




Redox Potential (mV) 14 Lys 21 Leu 31 Phe 32 Tyr 33 Ala 35 Trp  40 Lys 
-299 1.000 1.000 1.000 1.000 1.000 1.000 1.000 
-256 1.005 0.999 0.918 1.098 1.082 0.991 1.060 
-238 1.019 0.935 0.929 0.958 0.936 1.094 1.028 
-232 1.036 1.004 0.928 1.000 0.982 0.974 1.040 
-229 1.006 0.963 0.913 1.127 0.944 1.062 1.077 
-224 1.034 1.012 0.880 0.901 0.918 0.998 1.009 
-219 0.997 1.041 0.858 1.126 1.007 1.024 1.071 
-208 1.012 1.028 0.873 0.965 1.065 1.031 1.030 
-198 1.024 0.995 0.904 1.100 1.094 1.081 1.090 
-189 0.950 0.962 0.989 1.050 1.002 1.072 1.047 
-182 0.831 0.819 0.766 0.719 0.887 0.867 0.903 
-176 0.640 0.629 0.626 0.550 0.656 0.646 0.666 
  
      
  
-190 0.623 0.759 0.663 0.506 0.299 0.557 0.553 
-179 0.583 0.765 0.659 0.587 0.643 0.520 0.549 
-161 0.342 0.548 0.366 0.284 0.336 0.293 0.298 
-156 0.356 0.468 0.345 0.356 0.192 0.235 0.351 
-146 0.212 0.374 
  
0.712 0.254 0.173 
-138 0.178 0.263 0.418 0.275 0.197 0.000 0.000 
-126 0.153 0.000 0.000 0.000 0.664 0.000 0.000 
-108 0.000 0.000 0.000 0.000 0.452 0.000 0.000 
-103 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
-97 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
-68 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
-44 0.000 0.000 0.000 0.000 0.000 0.000 0.000 











Redox Potential (mV) 41 Ala 42 Leu 43 Ala 65 Val 66 Asp 67 Ala 70 Glu 
-299 1.000 1.000 1.000 1.000 1.000 1.000 1.000 
-256 1.110 1.016 1.056 0.848 1.022 1.052 0.973 
-238 1.056 1.027 0.995 0.913 1.036 1.047 0.995 
-232 1.079 1.039 1.052 0.872 0.957 0.981 0.992 
-229 0.983 1.044 0.962 0.970 1.120 1.057 0.988 
-224 1.065 1.038 1.041 0.835 1.024 0.954 0.988 
-219 1.070 1.083 1.082 0.939 1.013 0.973 1.043 
-208 1.063 1.072 1.072 0.950 0.981 0.943 1.035 
-198 1.027 0.992 1.060 0.824 0.997 0.959 1.003 
-189 0.990 0.974 1.047 0.905 0.917 0.921 0.957 
-182 0.887 0.904 0.871 0.706 0.876 0.744 0.893 
-176 0.665 0.634 0.675 0.524 0.665 0.564 0.758 
  
      
  
-190 0.566 0.539 0.554 0.613 0.669 0.537 0.900 
-179 0.522 0.445 0.550 0.678 0.570 0.504 0.863 
-161 0.340 0.288 0.339 0.303 0.338 0.398 0.746 
-156 0.257 0.257 0.339 0.469 0.166 0.277 0.731 
-146 0.208 0.166 0.240 0.371 0.000 0.376 0.650 
-138 0.168 0.175 0.269 0.265 0.000 0.000 0.663 
-126 0.000 0.000 0.000 0.000 0.000 0.000 0.604 
-108 0.000 0.000 0.000 0.000 0.000 0.000 0.134 
-103 0.000 0.000 0.000 0.000 0.000 0.000 0.043 
-97 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
-68 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
-44 0.000 0.000 0.000 0.000 0.000 0.000 0.000 















Redox Potential (mV) 78 Gly 81 Gly 84 Thr 90 Asn 
-299 1.000 1.000 1.000 1.000 
-256 1.097 1.017 0.925 0.886 
-238 1.118 1.056 0.940 1.013 
-232 1.131 1.010 0.988 0.913 
-229 1.096 1.039 0.979 0.989 
-224 1.157 1.015 0.966 0.989 
-219 1.200 1.037 0.871 1.056 
-208 1.129 1.040 1.031 0.978 
-198 1.025 0.983 1.041 1.025 
-189 1.059 1.036 0.920 1.023 
-182 0.917 0.859 0.739 0.847 
-176 0.808 0.690 0.565 0.622 
  
   
  
-190 0.649 0.680 0.648 0.498 
-179 0.611 0.615 0.492 0.452 
-161 0.328 0.332 0.243 0.276 
-156 0.370 0.325 0.325 0.257 
-146 0.235 0.112 0.369 0.313 
-138 0.203 0.164 0.217 0.000 
-126 0.000 0.136 0.487 0.000 
-108 0.000 0.000 0.388 0.000 
-103 0.000 0.000 0.000 0.000 
-97 0.000 0.000 0.000 0.000 
-68 0.000 0.000 0.000 0.000 
-44 0.000 0.000 0.000 0.000 














7.1 Fits of 0.25 mM 15N 6-F-Trp W111F DEE¶[ UHGXFHGǻ-som: 
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